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ABSTRACT 
The Influence of Pharmaceutical Company Sponsored Educational Programs, 
Promotions and Gifts on the Self-Reported Prescribing Beliefs and Practices of Certified 
Nurse Practitioners in Three States 
Elizabeth Muncey Blunt 
Dr. Fredricka Reisman 
 
 
 
 
The influence of pharmaceutical industry sponsored education, promotions and 
gifts on the prescribing practices of physicians and medical students has been well 
documented in the literature (Avorn et al., 1982; Curcura, 1999; Gonul et al., 2001; 
Stolberg & Gerth, 2000; Wazana, 2000).  Nurse practitioners also prescribe 
pharmaceutical products for their patients.  However, the effect of corporate promotions 
on the prescribing practices of nurse practitioners has not been assessed.   This 
quantitative, descriptive study investigated the relationship between pharmaceutical 
company sponsored educational programs, promotions and gifts and the self-reported 
prescribing beliefs and practices of certified nurse practitioners.   
This study utilized a survey type questionnaire to ascertain the self-reported 
prescribing beliefs and practices of NPs after encountering pharmaceutical company 
sponsored educational programs, sales visits, promotional products, or gifts.  A survey 
was developed, piloted, and sent to nationally certified nurse practitioners in three states.  
A 56% response rate was obtained.  
Data demonstrate that nurse practitioners practice is influenced by their 
interactions with pharmaceutical companies (p< 0.05) yet, like their physician 
counterparts, some NPs do not recognize the influence pharmaceutical companies have 
on their prescribing practice.   NPs value pharmaceutical interactions and recognize the 
xii 
benefits accrued including: increased access to medications for patients, education 
opportunities for NPs, educational resources for patients and potentially, increasing 
opportunities for NP-pharmaceutical company cooperation in education and research.   
However, the practicing nurse practitioner needs to be able to recognize and acknowledge 
the influence of pharmaceutical company promotions in order to utilize the information 
appropriately.  Nurse practitioners need to become critical users of pharmaceutical 
company services.   They need to be aware and understand the influence pharmaceutical 
companies may exert on their prescribing practices.  Professional nursing organizations 
need to develop position statements on NP-pharmaceutical company interaction, and 
educators need to integrate pharmaceutical marketing and influence issues into the 
curriculum.  
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CHAPTER 1: INTRODUCTION 
Introduction 
Pharmaceutical companies spend more than $15 billion dollars each year in the 
promotion and marketing of their products (National Institute for Health Care 
Management, 2001; IMS Health, 2002).  Estimates are that 5 to 8 billion dollars annually 
goes to sales representatives to promote their products (Greene, 2000; Wolfe, 2002).   
United States (U.S.) drug spending increased 17.1% to $154.5 billion dollars in 2001.  
One-quarter of this increase was due to a shift to the use of more expensive drugs 
(National Institute for Health Care Management, 2002).  By 2003, U.S. prescription drug 
sales had risen to $216.4 billon, up by 11.5% from the previous year (IMS Health, 2004).   
Meanwhile, global sales of generic drugs are expected to grow by more than 20 percent 
annually to reach an estimated $80 billion by 2008 ( IMS Insights, 2004).   The 
proportion of the gross domestic product (GDP) spent on healthcare varies around the 
world from a low of 7.4% in the UK to a high of 14.7% in the U.S.  (IMS Health, 2004).  
This high GDP is reflective of the billions of dollars spent each year on pharmaceutical 
and other healthcare products.  
Pharmaceutical companies vie for the favor of healthcare providers in order to 
increase sales of their company’s product.   They use a number of tactics including 
providing educational programs, sales visits to practice sites, free drug samples and gifts 
to providers (Murray, 2002; Wazana, 2000; Wolf, 1998).   They also market directly to 
patients through the media and the popular press using print advertisements and 
television commercials.  These direct-to-consumer advertising methods are another 
attempt to influence the prescriber by having the patient request specific pharmaceutical 
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products they have seen advertised through a variety of media or recommended by family 
or friends. (Calfee, 2001; Chin, 2001; Wang, Ausiello & Stafford, 1999).  Since 1995, 
research and development staff the U.S. brand name drug companies have decreased by 
2%, while marketing staff have increased by 59%.  Currently, 22% of pharmaceutical 
staff are employed in research and development, while 39% are in marketing  (Socolar & 
Sager, 2001). 
The influence of pharmaceutical company sponsored educational programs and 
gifts on the prescribing practices of medical doctors (MD’s), medical students, and 
residents has been well documented in the literature (Avorn, Chen & Hartley, 1982; 
Curcura, 1999; Gonul, Carter, Petrova, & Srinivasan, 2001; Stolberg & Gerth, 2000; 
Wazana, 2000).    Nurse Practitioners (NPs) also serve as prescribing providers to a large 
variety of patient populations, and prescribe pharmaceutical products for their patients.  
NPs also are recipients of pharmaceutical company sponsored education, sales visits, 
promotions and gifts (Scott-Levin, 2000a).  Greene (2000) reported that pharmaceutical 
sales representatives had begun to target NPs and Physician’s Assistants for 
informational sales visits. While NP’s decision making process for the selection of 
medications for their patients has been found to be similar to those of MDs, studies have 
shown differences in prescribing patterns including an increased use of non-
pharmacologic treatment modalities, selection of lower priced prescription alternatives 
and an increased use of educational materials  by NPs (Mahoney, 1994; Munroe, Pohl, 
Gardner, & Bell, 1982; Wright & Neill, 2001).  Although there is much data in the 
literature about MD prescribing beliefs and practices, the results of the MD studies 
cannot be assumed to be reflective of NP practice. Despite this, to date there has only 
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been one published study addressing the influence of pharmaceutical company sponsored 
education programs, sales visits, promotions or gifts on NP prescribing beliefs and 
practices.  The NP study (Kessenich, 1999) was a qualitative design with a very small NP 
population.  After the initial investigation, no further research was conducted (C.R. 
Kessenich, personal communication, February 18, 2002).  The purpose of this study is to 
investigate the relationship between pharmaceutical company sponsored education, 
promotions and gifts and the self reported prescribing beliefs and practices of certified 
NPs.   
Physicians and Pharmaceutical Company Influence 
Several studies have found that medical students and residents significantly 
underestimate the influence pharmaceutical company sponsored education has on their 
prescribing practices (Steinman, Shlipak & McPhee, 2001; Wazana, 2000; Waud, 1992).   
These findings have raised the issue of the ethics surrounding the influence 
pharmaceutical company educational programs and gifts have on physician’s prescribing 
practices (Avorn, et al., 1982; Curcura, 1999; Gonul et al., 2001; Wazana, 2000).  The 
American College of Physicians is so concerned about this influence that they issued two 
Position Statements, one in 1990 and one in 2002 (appendix A), on physician-
pharmaceutical company interaction, educational programs, and gifts (Coyle, 2002a; 
2002b).   The American Medical Association (AMA) has also issued ethical guidelines 
for gifts to physicians from industry, first in 1991 and updated in July 2002 (AMA, 1991; 
1995-2002), [appendix B].    Concurrent with the development of the second set of 
American College of Physicians guidelines, the Pharmaceutical Research and 
Manufacturers of America (PhRMA) developed and approved a new Code of Interactions 
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with  Healthcare Professionals (PhRMA, 2002a), [Appendix C].   The Code is a set of 
voluntary guidelines for pharmaceutical representatives and others involved in marketing 
pharmaceuticals.  The guidelines address the interaction of pharmaceutical 
representatives and health care professionals, including the following categories: (a) 
general interaction, (b) entertainment, (c) continuing education, (d) consultants, and (e) 
educational and healthcare practice-related items.  The Code, July 1, 2002, placed clear 
parameters on acceptable and unacceptable interaction between the pharmaceutical sales 
representative and the health care provider (PhRMA, 2002b). 
Nurse Practitioners and Pharmaceutical Companies 
Today, there are over 102,000 nurse practitioners working in urban, rural, and 
suburban communities providing care to a variety of patient populations from primary 
care to specialty practice  (National Center for Workforce Analysis, 2004; National 
Sample Survey of Registered Nurses, 2001).  Nurse practitioners in all 50 states and the 
District of Columbia have some level of prescriptive authority, with 26 states allowing 
nurse practitioners to prescribe independently (Greene, 1999; Scott-Levin, 2000b).   
According to a Scott-Levin survey (2000a), in 1999 nurse practitioners wrote 29 million 
prescriptions.  That number was 55% from 1998 and up 75% over the last five years 
(Greene, 2000).  This increase in the number of prescriptions written by NPs is attributed 
to two major factors.  First, there are increasing numbers of NP in practice each year 
(McGiven, 1993; National Center for Workforce Analysis, 2004; Spratley, Johnson, 
Sochalski, Fritz, Spenser, 2001; Scott-Levin, 2000b) and second; more states are granting 
NPs the right to prescribe under their own name rather than the name of their 
collaborating physician (Pearson, 2002).    Whatever the causes of the increase in NPs 
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prescribing, the result remains the same; more NPs are writing prescriptions each year.  
Despite this increase, there is a dearth of published studies that address the influence of 
pharmaceutical company education, sales visits and promotions on NP prescribing beliefs 
or practices.    
Purpose of the Study 
This study seeks to answer the question does the receipt of pharmaceutical 
company sponsored education, sales visits, promotional products and gifts influence the 
prescribing beliefs and practices of NPs?   The logical follow-up to this question is if  
NPs prescribing beliefs and practices are influenced, what are the implications for NP  
educators and curricula, practicing NPs, and for nursing professional organizations?   
Additional questions include; 1) does the geographic location of the NPs practice (urban, 
suburban or rural) influence the number of self-reported interactions with pharmaceutical  
company programs, promotions and gifts?, 2) do NPs change or modify their prescribing  
after pharmaceutical company interaction?, 3) do NPs recognize the influence  
pharmaceutical company interactions have on their prescribing practice and how does 
that relate to their perception of the influence? 4) what is the importance of sample  
availability to the NPs practice? 5) Do NPs believe it is appropriate to accept sample  
drugs for their patients?, 6) how useful do NPs believe pharmaceutical company  
information is to their practice? 7) Do NPs believe pharmaceutical company information  
is unbiased?, 8) Do NPs believe pharmaceutical companies play an important role in  
patient and NP education?, 9) Would NPs continue to see pharmaceutical company 
representatives if they provided items or information the NP viewed as useful to their  
practice?, and 10) are NPs behaviors congruent with their beliefs about accepting  
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pharmaceutical company promotions, products and gifts?, and finally, 11) what, if any,  
influence does direct-to consumer marketing have on NPs prescribing practice?   
Persuasion Theory (Bar-On & Parker, 2000; Reardon, 1981; Story, 1997) will be used as 
the framework for this study. 
Stakeholder Groups 
This study will provide important information for three groups involved in 
nursing practice issues.  First, information related to the effect of NP-pharmaceutical 
company interaction will be important to faculty who teach NP students about critical 
decision making related to prescribing medications.   If NPs are influenced by 
pharmaceutical company interactions in a similar manner as physicians and medical 
students, the issue of influence can then be addressed in the NP curriculum.  This will 
begin to prepare NP students to critically assess the information they receive from 
pharmaceutical sources while in training and allow them to begin making their 
prescriptive decisions accordingly.  This has clear implications for NP education at both 
the preparatory and post-graduate continuing education levels. 
Second, this information may be important to NPs who currently practice and 
interact with pharmaceutical companies.  If the findings indicate that NPs, like MDs, are 
influenced by pharmaceutical company marketing techniques, this potential influence on 
practice will be important to identify in order to make appropriate judgments about the 
information and gifts they receive from the pharmaceutical companies.  The third 
stakeholder group will be professional nursing organizations and State Boards of 
Nursing.  These organizations develop and disseminate standards of care, professional 
guidelines and scopes of practice, therefore the findings of this study will be important to 
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all groups of stakeholders.  If NPs are influenced by pharmaceutical company 
interactions in a similar manner as physicians and medical students, nursing professional 
organizations may choose to develop guidelines related to NP-pharmaceutical company 
interactions. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
Introduction 
 This chapter will present a review of the literature on the historical development 
of the NP role, compare the roles of the NP and the physician, identify several persuasion 
theories and models, and review the literature on the influence of pharmaceutical 
company sponsored education, promotions and gifts on physician prescribing practices.  
The chapter will also review the single article in the literature about pharmaceutical 
company influence and NP prescribing practices, address the direct-to-consumer 
marketing issue and finally, identify existing professional guidelines related to 
pharmaceutical company interaction with physicians, NPs and other healthcare providers. 
Historical Development of the Nurse Practitioner Role 
The early 1960’s saw a period of social upheaval and change in the United States 
that paved the way for the growth of the NP role (Hickey, Ouimette, & Venegoni, 2000; 
Marchione & Garland, 1980; McGivern, 1993; Thompson, Kershbaumer & Krisman-
Scott, 2001).  John F. Kennedy was president, civil rights were becoming a topic of 
discussion throughout the nation, social welfare movements were growing, and the needs 
of many underserved communities were beginning to be recognized (Kane et al., 1989; 
Sheehy & McCarthy, 1998).  Lack of even basic healthcare services in rural and urban 
underserved communities pointed to a lack of primary care providers especially in the 
pediatric and family care arenas (Marchione & Garland, 1980).   An inadequate 
distribution of available physicians, identification of women and children as underserved 
populations, and escalating healthcare costs led to a 1963 Surgeon General report 
recommending that nurses be educated to provide primary care in collaboration with 
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physicians (Elder & Bullough, 1990; Hickey et al., 2000; Thompson et al., 2001).  This 
report, in conjunction with the desire of nurses to achieve professional autonomy, led to 
the development of the nurse practitioner role (Marchione & Garland, 1980). 
The first reported nurse practitioner training program was established at the 
University of Colorado in 1965 by Loretta Ford, Ph.D., a nurse educator, and Henry 
Silver, M.D., a pediatrician (Ford & Silver, 1967; Hickey et al., 2000; Larson, 1996; 
Marchione & Garland, 1980; Thompson et al., 2001).  Dr. Ford identified a medically 
underserved pediatric population in rural Colorado.  At the time, registered nurses and 
nurse midwives were providing women’s healthcare independently, without a physician, 
in these same communities.  Dr. Ford believed that baccalaureate prepared nurses with 
advanced practice and skills training could provide primary care services to pediatric 
populations in these underserved areas (Ford & Silver, 1967).  Working with Dr. Silver in 
1965, she established the first nurse practitioner program.  This program was 24-months 
in length and was designed to train post-baccalaureate nurses to provide pediatric primary 
care in rural Colorado (Ford & Silver, 1967; Hickey et al., 2000; Thompson et al., 2001; 
Marchione & Garland, 1980).  Ford and Silvers’ NP program was based on a nursing 
model, which focused on the promotion of health, and growth and development in 
children as well as the prevention of disease and disability (Ford, 1982, 1986).  Their 
model “afforded the nurse an opportunity to assess autonomously, innovate and work 
collaboratively with physicians and families in providing care” (Sheehy & McCarthy, 
1998, p. 32).    Over the next twenty years, the NP role continued to flourish in a society 
that expressed concern for affordable, accessible primary care for all (Marchione, 1980; 
Sheehy & McCarthy, 1998).  This environment permitted a growing nurse practitioner 
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community to autonomously serve not only children but also adults, the elderly and 
families (Hickey et al., 2000; McGiven, 1993).    
The number of nurses prepared as NPs over the last fifteen years has grown from 
approximately 23,500 NPs in 1988 (McGiven, 1993) to an estimated 53,753 in 1996, to 
over 102,829 in March 2000 (Spratley, Johnson, Sochalski, Fritz, Spenser, 2001).  
However, it was not until the1980’s that one saw the nurse practitioner role begin to 
expand beyond the primary care setting (Hickey et al., 2000).  Increasing patient acuity 
(the complexity of illness and intensity of nursing care required by the patient), shortened 
length of hospital stays, fragmentation of care and the intricacy of healthcare systems led 
the way for the development of the acute care nurse practitioner role.  Acute care NPs 
function primarily in hospitals or acute care centers or but may also be found in 
comprehensive management clinics for the chronically ill, practicing with specialty 
physician groups such as orthopedists, urologists and cardiologists as well as 
collaborating with their primary care nurse practitioner counterparts on management of 
complex patients (Hickey et al., 2000; National Center for Workforce Analysis, 2001; 
Thompson et al., 2001).  This role has expanded the scope of NP practice beyond primary 
care and into acute care hospitals, long-term care facilities and a variety of other patient 
care arenas.  This increase in the scope of NPs practice, and consequently the prescribing 
function has caught the attention of pharmaceutical companies who have begun to 
specifically target NPs with their educational programs, promotional products and gifts 
(Greene, 2000). 
There were over 102, 000 NPs in the United States in 2000.   This is an increase 
of 44.8% between March 1996 and March 2000.  An estimated 76,650 (74%) of these 
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NPs have national certification.   The majority (62%) have completed a Masters degree 
program, compared with 46% who were Masters prepared in 1996 (Spratley, Johnson, 
Sochalski, Fritz, Spenser, 2001).    
Currently, NP entry-into-practice education requirements vary from state to state 
and NPs come from a variety of educational backgrounds including certificate, Masters 
or Post-masters level preparation.   For example, an NP may have a Master of Science in 
Nursing (MSN), which he or she obtained in a Nursing Administration track.  While 
prepared as an administrator, the nurse may decide to return to direct patient care and 
then to enter a nurse practitioner program.  Depending on where the nurse lives, there 
may not be a Master’s level NP program in their area while, perhaps, there is a certificate 
NP program available close by.   At that time, they may choose to complete a certificate 
NP program, thus have an MSN in Nursing Administration but be NP prepared at the 
certificate level.    Still other NPs programs were completed at the MSN level.  These 
discrepancies will begin to decline over the next few years as many states are now 
requiring NP entry-into-practice at the MSN level.  NP certifying bodies also have moved 
to the MSN for entry into practice, or will be doing so by 2007 (NCC, 2003). 
NPs work in a variety of geographic settings from urban to rural, working in 
independent practices, small office groups and for large hospitals and medical centers.  
They serve a variety of patient populations, from newborn to geriatric, and care for their 
patients in offices, hospitals, nursing and geriatric centers, private homes, public clinics 
and clinical trials practices (Pearson, 2002).  Today NPs may be certified in the care of 
families, children, acute care or hospitalized patients, geriatrics, women’s health care, 
family or adult psychiatric mental health care, neonatal care, and adult primary care 
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(American Nurses Credentialing Center, 2002a; National Certification Corporation, 
2002a).  Some NPs are certified in more than one specialty area.  Forty-one states require 
that NPs be both licensed in the state of practice and certified by a national certifying 
body in order to practice. There are four U.S. organizations, which offer certifying exams 
for Nurse Practitioners.  These are the American Nurses Credentialing Center (ANCC), 
American Academy of Nurse Practitioners (AANP), National Certification Board of 
Pediatric Nurse Practitioners and Nurses (NCBPNP/N), and the National Certification 
Corporation (NCC).   ANCC offers certifying exams for a variety of NP specialties.  
AANP offers only Family and Adult NP certification exams.    NCC offers only 
Women’s Health Care NP and Neonatal NP certification which neither ANCC nor AANP 
offer.  NCBPNP/N offers only pediatric NP certification. 
  These certifying bodies administer certification examinations that measure entry-
into-practice NP competencies.  Each certifying exam content is specific to the role for 
which the NP is requesting certification.  The largest of the certifying organizations is 
ANCC with 58,000 advanced practice nurses certified under their auspices (ANCC, 
2002a).   ANCC administers NP certifying exams in the following areas: Family, Adult 
Primary Care, Adult Acute Care, Pediatrics, Psychiatric Mental Health, Pediatric Acute 
Care, and Geriatrics (ANCC, 2002b)..   AANP offers Family and Adult NP certification 
and has available an Academy membership list which includes NPs and other certified 
nurses.  NCC is the only certifier of Women’s Health Care and Neonatal NPs in the 
United States.  By the end of 2001, NCC had certified 10,707 NPs  (NCC, 2002a).  The 
National Certification Board of Pediatric Nurse Practitioners and Nurses (NCBPNP/N) 
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certifies Pediatric Nurse Practitioners (CPNP).   Since 1977 the NCBPNP/N has certified 
more than 8000 CPNPs (NCBPNP/N, 2002).  
ANCC and NCC are the two largest certifiers of NPs in the United States with a 
combined population of approximately 72,500 certified Nurse Practitioners. Of note, the 
combined number of 72,500 NPs identified as being certified by ANCC and NCC is 
significantly less than the estimated 102,000 NPs currently licensed in the U.S.  There are 
several possible reasons for this discrepancy;  (1) some states do not require NP 
certification in order to be licensed or to practice in the state, one such example is 
Florida, which requires state licensure but does not require national certification in order 
to practice; (2) NPs who became certified in the past may have let their certification lapse 
because of retirement or death, (3) some NPs choose to be certified by more than one 
certifying body; for example ANCC and AANP, (4) NPs certified by AANP and 
NCBPN/N are not included in the combined ANCC and NCC numbers,  (5) some NPs 
are certified in more than one specialty area, for example Adult Primary Care and 
Women’s Health care.  Some or all of these factors may affect the reported number of 
certified NPs. 
NP licensure is regulated by the states.  In most states, re-licensure occurs every 
two years following initial license issuance. Some states require continuing education 
credits for re-licensure.  Other states simply renew the license with payment of a renewal 
fee.  National re-certification must occur every five years (7 years for CPNPs who are 
certified by NCBPNP/NP0).  Re-certification requires both a documented clinical 
practice component of 1000 hours (NCC) or 1500 (ANCC) hours in five years (or an 
average of 3.7 to 5.5 hours per week) plus a minimum of 75 hours (NCC) to 125 hours 
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(ANCC) of continuing education credits within the same five-year period (ANCC, 2002b; 
NCC, 2002b).  NCBPNP/N has slightly different recertification regulations, requiring   
re-certification every 7 years.  CPNPs certified by NCBPNP/N may recertify by one of 
five options, several of which do not require a clinical practice component (NCBPNP/N, 
2002).   
NPs and Prescriptive Authority 
Nurse practitioners in all 50 states and the District of Columbia have some level 
of prescriptive authority, with 26 states allowing nurse practitioners to prescribe 
independently (Greene, 1999; Scott-Levin, 2000b).   According to a Scott-Levin survey, 
in 1999 nurse practitioners wrote 29 million prescriptions.  That number is up 55% from 
1998 and up 75% over the last five years (Scott-Levin, 2000a). During the first quarter of 
2000, NPs reported writing an average of 68 prescriptions per week (Scott-Levin, 2002b).  
During the same quarter, 10% of all pharmaceutical sales calls went to NPs and 
Physicians Assistants (PAs), an estimated 1.2 million calls in the quarter.  Of that total, 
NPs accounted for 728,000 and PAs for 501,000 of the sales calls (Scott-Levin, 2000b).  
Despite the documented number of sales calls to NPs, there has been only one small 
published study that addressed the influence of pharmaceutical company education, sales 
visits and promotions on NP prescribing beliefs or practices (Kessenich & Westbrook, 
1999). 
Nurse Practitioners and Physicians: Role Comparison 
Over the last thirty years, many studies have been conducted comparing  
physician and nurse practitioner roles, specifically outcomes and effectiveness across a 
wide array of issues including patient management, length of visit, decision-making, 
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prescribing practices and patient satisfaction (Bryant & Graham, 2002; Pulcini & 
Vampola, 2000; Mundinger et al., 2000; Sox, 2000; Wright & Neill, 2001).  Many have 
found the quality of care provided by NP’s to be to equal that of MD’s, especially in the 
management of primary care populations (Brown & Grimes, 1995; DeNoon, 2002; 
Spitzer, Sackettt & Sibley, 1974; U.S. Congress, 1986). 
  Patient satisfaction with their health care is one of many indicators of quality 
health care (Bryant & Graham, 2002). A number of studies have addressed satisfaction of 
patients cared for by NPs in a variety of settings (Brown & Grimes, 1995; Bryant & 
Graham, 2002; Perry, 1995).   Other studies have compared the levels of patient 
satisfaction of patients managed by MDs verses those managed by NPs (DeNoon, 2002; 
Pinkerton & Bush, 2000).  Patient satisfaction of those cared for by NPs in independent 
practice has also been found to be positive at nurse-managed clinics across the United 
States (Bagwell, 1987; Haq, 1993; Pulliam, 1991). 
Using a large-scale randomized design in the same clinical practice group, 
Mundinger, et al. (2000) conducted the first study comparing the practice outcomes of 
physician and NP providers with comparable patient populations.  This study found no 
significant difference in overall patient outcomes between the patients cared for by NP’s 
and those cared for by physicians.    The study concluded "In an ambulatory care 
situation in which patients were randomly assigned to either nurse practitioners or 
physicians, and where nurse practitioners had the same authority, responsibilities, 
productivity and administrative requirements, and patient population as primary care 
physicians, patients' outcomes were comparable"  (Mundinger, et al, 2000, pg. 65).    
17 
The advent of Nurse Managed Health Centers (NMHC) in the U.S. has also 
generated much data on the efficacy of the NP in managing primary care patient 
populations.  NMHC are primary care facilities, most often found in urban or rural 
underserved communities. These centers provide care to high concentrations of minority 
or disadvantaged populations who have historically experienced woefully inadequate 
access to health care services (Anderko & Uscain, 2001; Edwards, Kaplan, Barnett & 
Logan, 1998; Helvie, 1999).   The centers are usually established with federal funding 
and NPs, nurse educators and other non-physicians provide healthcare to the population.  
Research has shown that primary care patients who receive health care at these centers 
are at least as satisfied with their medical care as those cared for by physicians in primary 
care settings, have less emergency department visits, require less hospitalizations, are 
managed more cost effectively and have equal health outcomes as those cared for by 
physicians (Erikson, 2000; Mundinger et al., 2000; Safriet, 1992).  A study by Erikson  
(2000) showed that both Pediatric NPs (PNPs) and Family NPs (FNPs) prescribed lower 
cost antibiotics than physicians in three clinical practice sites over a 2-year period.  
Patient outcome data was similar for all patients regardless of whether their primary care 
provider was a physician or an NP (Erikson, 2000).   
 A study by Safriet (1992) reviewed over 20 years of research in NP patient 
management.   The study reported that NPs provided care at a lower cost than physicians, 
prescribed fewer drugs, used less expensive tests and selected lower cost treatment 
options than physicians, while providing a comparable level of care.  The study 
concluded that  NPs provide cost effective care and recommended that barriers to NP 
practice, such as prescriptive authority limitations, be eliminated.  The study further 
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concluded that there are advantages to joint physician-NP practice.  These occur not 
because the NPs cost less to hire, but rather that the NPs tend to select treatment options 
that are less costly than, but as effective as, the treatment plans implemented by 
physicians (Safriet, 1992). 
Horrocks, Anderson, & Salisbury (2002) performed a Meta analysis of the 
literature on NP patient satisfaction and outcomes in the United Kingdom (UK).   Their 
findings are similar to U.S. data that patient satisfaction and outcomes are comparable for 
patients receiving care in primary care settings.  Their review demonstrated that NPs tend 
to provide longer consultations with their patients and carry out more investigations than 
MDs.  Additionally, no differences were found in return visits, referrals or prescriptions 
written.  They note in their discussion: 
Nurse Practitioners can provide care that leads to increased patient satisfaction    
and similar health outcomes when compared with care from a doctor.  Nurse 
practitioners seemed to provide a quality of care that is at least as good, and in 
some ways better, than doctors (Horrocks et al., 2002, pg. 821).    
They conclude that increasing the availability of NPs in primary care in the UK is likely 
to lead to high levels of patient satisfaction and a high quality of care. 
 Another large UK study by Sakr, et al. al (n=700) looked at the care provided to 
emergency department patients presenting with minor injuries.  The study showed the 
care provided by the NPs was clinically equal in outcomes to the care provided by junior 
doctors.  Further, the NPs were identified as documenting more complete medical 
histories.  Fewer patients seen by the NPs required unscheduled follow-up visits.  There 
were no significant differences between the adequacy of physical examination, adequacy 
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of treatment or request for x-rays, between the NP and MD groups (Sakr, Angus, Perrin, 
Nixon, Nicholl, Wardrope, 1999).    
           Studies of Acute Care NPs (ACNPs) have shown similar results when their 
practice was evaluated.  Dahle, Smith, Ingersol & Wilson (1998) found ACNPs 
management of uncomplicated, hospitalized, congestive heart failure patients to be more 
cost effective than physician management.  This was evidenced by a significant decrease 
in total hospital costs, a trend towards decreased length of stay and no significant 
difference in the 30-day readmission rates of the patients (Dahle et al., 1998).  Overall, 
patient satisfaction with the care provided by NP’s has been found to be equal to that of 
physicians in similar settings and practice populations (Mundinger et al., 2000; Rhee & 
Dermyer, 1995).    
Lambling, Adams, Fox, and Divine investigated geriatric patient management in a 
2004 study.   This study used a convenience sample of 100 geriatric patients and 17 care 
providers (5 NPs and 12 MDs) and compared the care delivered in an inpatient geriatric 
unit.  Their results show that NPs deliver effective care to hospitalized geriatric patients.  
“Overall, the NPs met expectations, sometimes surpassing their counterparts in selected 
areas, such as identifying the need for and initiating physical and occupational therapy 
consultation, nutrition consultation, and advanced directive discussion” (Lambling, 
Adams, Fox, & Divine, 2004).  
     Despite these findings, the American Medical Association continues to oppose 
independent NP practice, although it suggests that MDs work in close collaboration with 
NPs.  Yank Coble, president-elect of the AMA in 2002, stated that most primary care 
patients are not very sick and that with adequate rest, 98% of them would get better 
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without medical intervention.  He believes NPs do not have the scientific background to 
keep up with the rapidly changing world of medicine and expressed concern that NPs will 
miss subtle or complex illnesses in their patients (DeNoon, 2002).  He is countered by 
Lucy Marion, PhD, president of the National Organization of Nurse Practitioner Faculties 
(NONPF) who states: 
Not every doctor is trained to treat every kind of medical issue that is out                                        
there…Doctors who work with us realize there is a whole domain of practice in 
which nurse practitioners are highly qualified and need no supervision to perform 
(DeNoon, 2002, p. 2). 
Given the similarity in care provided by NPs and MDs, influences on their 
practice, and outcomes for their patients, it is possible that NPs are influenced in a similar 
manner as MDs when exposed to pharmaceutical company influence. 
Persuasion Theory 
Persuasion affects everyone, every day (Aylesworth & Goodstein, 1999; Dillard 
& Peck, 2000; Jacobs, 1995).  Every time we look at a television commercial, negotiate a 
meeting time with a business associate or try to convince a friend to stop smoking, we are 
engaging in persuasion.  Pharmaceutical companies use these same techniques in an 
attempt to influence healthcare providers’ prescriptive decisions.  Advertising in medical 
journals, educational visits to practice sites, sample medications for distribution to 
patients, and gifts to healthcare providers, are all intended to influence the MD or NPs 
choice of prescription drugs.    
Persuasion is closely linked to emotion and whether we recognize it or not, 
persuasion is based on an emotional response to the situation in which we find ourselves 
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(Dillard, & Peck, 2000; Nabi, 1999; O’Donnell & Kable, 1982).   Persuasion also 
involves cognition (Bar-On & Parker, 2000).  It is the interaction of emotion and 
cognition that may lead to a change of attitude or belief (O’Donnell & Kable, 1982).   
Many people confuse the term persuasion with similar terms such as 
communication, coercion or propaganda.  However, there are significant differences in 
the words.  Communication is defined as an information exchange between two 
individuals by a system of symbols, signs or behaviors, an exchange of information 
(Websters, 1985).  Propaganda is defined as dissemination or promotion of popular ideas; 
information or rumor.  Coercion is defined as enforcing or bring about by force (Jowett & 
O’Donnell, 1999).  Persuasion does not include aspects of force, coercion or rumor.  
Rather, it is a complex, continuing, interactive process in which sender and receiver are 
linked by symbols, verbal and non-verbal, through which the persuader attempts to 
influence the listener to adopt a change in a given attitude or behavior because the 
listener has had his or her perceptions enlarged or changed (Jowett & O’Donnell, 1999; 
O’Donnell & Kable, 1982).  Persuasion necessitates that an individual change attitude, 
beliefs or behavior voluntarily because they have experienced a specific, mind changing 
interaction.  Most often, this change of mind is related to the individuals’ own needs, 
wants or desires.  These changes can come about instantaneously or they may take days, 
months or years (Storey, 1997).  
 There are four specific elements of persuasion: both a sender and receiver of 
information are required, the exchange is interactive or dynamic, the change in behavior 
or belief must be voluntary and there is some amount of time required for this transaction 
to occur (Bettinghaus, 1980).   
22 
There are many theories about how persuasion occurs.  Most rely on a model of 
interpersonal communication to influence another individual.  One theory relies on 
identifying how to resist persuasion (Nabi, 1999; O’Donnell & Kable, 1982;  Storey, 
1997). 
Early Studies in Persuasion Theory 
Yale Studies 
 Research into the nature of persuasion began at Yale University in the mid 1940’s 
and early 1950’s (Reardon, 1981).  During and after World War II Carl Hovland and 
associates were concerned with influencing the morale of soldiers on the battlefield and 
changing the attitudes of civilians towards the war effort.  They believed “that attitude is 
an implicit approach or avoidance response to some object.  As such, it is an emotional 
reaction (Reardon, 1981, pg.65).  The Yale group focused on belief as the change agent 
of attitude and they defined beliefs as the cognitive or knowledge component of attitude 
(Bettinghaus, 1980).  Much of the work of the Yale Group focused on stimulus-response, 
source credibility, personality traits and susceptibility to persuasion as well as extensive 
work on fear as a persuader (Bettinghaus, 1980; Jowett & O’Donnell, 1999; Reardon, 
1981).  The Yale Group established the relationship between emotion and cognition as 
the intrinsic elements of change in beliefs or attitudes, one definition of persuasion.  
Cognitive Dissonance 
 Festinger’s Theory of Cognitive Dissonance asserts that persuasion occurs when 
an individual learns new information or experiences a new event which is different from 
their ingrained set of ideas and beliefs (Bettinghaus, 1980; Reardon, 1981; Storey, 1997). 
Festinger proposes, as do many other social theorists, that change and growth occur only  
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when the individual is in a state of conflict.  Humans are always striving for a sense of 
equilibrium or homeostasis and new information causes tension or disequilibrium.  This 
results in the individual seeking to change in order to reestablish homeostasis (Festinger, 
1968).   
 According to Festinger (1968) people seek to reduce dissonance in one of four 
ways; revoking their decision, increasing the attractiveness of the alternative, decreasing 
the attractiveness of the unchosen alternative, or creating cognitive overlap between the 
items in question (Storey, 1997).  Others hypothesize that we attempt to resolve 
dissonance in one of three ways; the individual may change, in this case, be persuaded; 
they may lash out and fight the new information in the hope of reestablishing their own 
reality or they may flee and simply avoid the conflict of information by removing 
themselves from the environment (O’Donnell & Kable, 1982; Bettinghaus, 1980).  An 
example of attempted resolution of cognitive dissonance is found in the current attitudes 
towards smoking cigarettes.  We have information that smoking is harmful (information), 
we do not want to die (fear) but we want to smoke (dissonance between the known 
information that smoking is harmful and our desire to smoke).  In order to   resolve the 
dissonance we can try to refute the scientific data (revoke the information), choose to 
stop smoking (creative cognitive overlap), smoke only reduced tar cigarettes (increasing 
the attractiveness of the alternative), or stop smoking and say, “I didn’t really like 
smoking anyway” (increasing the attractiveness of the alternative).  All these approaches 
attempt to resolve the conflict and return the individual to homeostasis.   
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Exposure Learning Theory 
 Zajonc’s Exposure Learning Theory asserts that the more frequently individuals 
are exposed to an idea or concept, the more likely they are to adopt that belief 
(Bettinghaus, 1980).  In other words, increased exposure leads to increased familiarity, 
which leads to increased acceptance.  There is comfort in familiarity and like Festinger’s 
Cognitive Dissonance Theory; Exposure Learning Theory focuses on the need of the 
individual to feel comfortable, or familiar with an idea or concept.   Zajonc also found 
that frequent exposure actually reinforced low positive or negative beliefs.  Therefore, 
beliefs about an idea or concept were slightly negative prior to exposure, rather than 
convincing the individual to change their belief to the positive, frequent exposure 
reinforced negative attitude, thereby persuading a shift to the negative realm. 
Diffusion of Innovations Theory 
 Coleman’s Diffusion of Innovations Theory (1968) looks at the influence and 
persuasion inherent in peer networks.  His late 1960’s work identified the impact of mass 
interpersonal communication networks (peer networks) on individual members attitudes 
and beliefs.  His research identified the strength of peer network communication when he 
discovered that a group of physicians continued to use less than appropriate prescribing 
practices even after receiving hard data and scientific reports identifying specific 
antibiotics as the best treatment for a disease entity (Bettinghaus, 1980; Coleman, Katz, 
Menzel, 1968).   Coleman theorized that the influence of peer opinion and experience 
outweighed the impact of scientific data for this group.  Peer persuasion was more  
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influential than medical journal articles.  He acknowledged that peer influence networks 
might take years to have an impact but that the impact, when achieved, could be 
significant.    
Elaboration Likelihood Model 
 Petty and Cacioppo clearly labeled emotion and cognition in their Elaboration 
Likelihood Model (ELM), one of the most frequently cited theories of persuasion (Jowett 
& O’Donnell, 1999; O’Donnell & Kable, 1982; Weiss, 2000).  ELM addresses the 
individuals’ effort to process new information based on their motivation and ability to 
engage in message and issue-related thinking (Jowett & O’Donnell. 1999).  ELM asserts 
that individuals use both cognitive abilities and   emotional response to the information to 
interpret the data and make a decision.  They describe motivation as 1) the individuals’ 
personal involvement or interest in the issue, 2) the ability to process persuasive 
arguments and attentional factors, and 3) the determination that there is sufficient time or 
inclination to focus on the issue.  Petty and Cacioppo (1985) found that the less 
individuals are interested in the issue, the less attention they paid to the information 
presented and the less motivated they were to cognitively process the argument.  When 
motivation for the issue was low, peripheral cues became more important (Jowett & 
O’Donnell, 1999).  For example, in advertising, when an individual is not hungry (basic 
need) a hamburger commercial becomes essentially unimportant.  Watchers then tend to 
notice the peripheral cues more, such as the attractiveness or credibility of the presenter, 
the background music or visual displays.  When they are hungry, the food itself becomes 
the focus of interest.  In this scenario, cognition and emotions interplay to focus attention 
on the area of most importance to the individual at the time of exposure.    
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Spiral of Silence Theory 
  This theory asserts community of peers as the most influential aspect of 
persuasion.  A sense of belonging to a community is a basic human need (Maslow, 1969).   
Noelle-Neumann (1991) proposes that when individuals exhibit unacceptable behavior, 
ideas or beliefs the community of peers shuns them resulting in isolation and forcing the 
individual to resolve the need for belonging.  Such a state of affairs causes individuals to 
reassess opinions, beliefs and attitudes.  If they are persuaded to change their ways and 
conform to the peer group, they are accepted into the community.  If they do not 
conform, they are isolated (Jowett & O’Donnell, 1999; Noelle-Neumann, 1991).  Thus, 
individuals constantly reassess community and personal opinion and, based on cognitive 
assessment and emotional response to that assessment, make decisions to conform or be 
isolated. 
Persuasion and Emotion 
 Emotion is a patterned collection of chemical and neural responses processed   
consciously or unconsciously (Weiss, 2000).  The site of emotional response is the body 
and brain.  Physiologic responses of emotion are experienced primarily through the 
viscera and the musculoskelatal system.  The same emotional responses are also 
transmitted to the brain where specific areas such as the monoaminergic nuclei in the 
brainstem, the amygdala, ventro-medial prefrontal cortices and hypothalamus convert the 
information into cognitive responses (Bechara, Trane, & Damasio, 2000; Lane, 2000). 
The emotion is expressed physiologically as sweating palms, a pounding heart, flushed 
skin or an increased pulse and cognitively as a changes in foci of attention.  Once the 
information reaches the brain and viscera, the brain focuses its attention on the stimulus 
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and begins its cognitive, decision-making.  In this way the emotions are organizers, 
prioritizers and motivators of behavior (Lane, 2000; Machleit & Eroglu, 2000).  Each 
individual has inherent adaptive functions that are based on personally relevant events.  A 
person who fears heights may not be fazed by spiders.  Each emotion also has a distinct 
goal or purpose for the individual.  The purpose may be direction of cognitive processing, 
arousal, sustaining of action, or physical activity.  We are all “hardwired” for fight or 
flight.  It is inherent in every human.    That fight or flight response is the joint product of 
situational cues and physiologic arousal.  Our need to fight or flee is usually based on our 
needs, wants or desires and is why we spend so much time persuading.  
Persuasion and Culture 
 Persuasion is a transactional event involving both cognition or thought and an 
emotional component.  It is human nature to look to others to fulfill our needs and 
reinforce our perceptions and self-esteem.  Individuals are forever trying to shape the 
world to meet our needs which requires persuading others to do what we want or need 
them to do.  Persuasion theories have shown us that persuasion is response shaping, 
response reinforcing and response changing.   
Persuasion is also culturally bound.  Aaker and Williams (1998) have shown that 
ego-focused emotional appeals lead to more favorable attitude changes for members of an 
individualist culture, while non-egocentric appeals lead to more favorable attitude 
changes in collectivist cultures. Egocentric communities, such as the Western world of 
the United States and Western Europe, tend to focus on the needs of self.   Collectivist 
cultures, such as the Eastern cultures of China and Japan, tend to repress the needs of self 
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in order to promote the betterment of the community.  This research demonstrates the 
impact of cultural orientation on emotional appeals response.  
Persuasion Techniques 
Persuasion is a transaction involving verbal and non-verbal communication.  Rush 
Limbaugh, a popular radio talk show host, has been identified by many as a persuasive 
speaker.    Jacobs (1995) identifies some of the persuasion techniques used by Limbaugh 
and other successful marketers wishing to persuade the consumer to purchase a product 
or change their behavior.  Persuasion techniques include:  
• Stories, anecdotes and metaphors.  Stories are used to persuade because they are 
familiar and comforting so the storyteller can control the ending and make the 
outcome what we want.  Metaphors are also used to invoke universal meaning.  
“You’re throwing your money away”, “Don’t get burned on that deal”. 
• Double Bind.  The speaker provides the listener with two alternatives both of 
which lead to the result the persuader is trying to obtain.  “Do you want to go 
shopping on Monday or Tuesday”? gives the listener a choice but both outcomes 
will have them going shopping.  It is much harder to say no when choices are 
given.  Double binds are most effective when using two positives. 
• Contingency.  The persuader links ideas or two choices together so the listener 
must accept or reject both together.  “Perhaps you are not courageous enough to 
do what I asked”. 
• Rapport.  The speaker creates an affinity with the listener by establishing a bond 
or sameness.  It instills a sense of confidence or togetherness.   “My friends…”, “I 
know how you feel…”, I am an American, just like you”. 
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• Authority.  The persuader utilizes rank or role to influence decisions.  The 
authority does not have to be real to be effective.  Assumptions of authority or 
people in authority roles such as health care providers or military leaders can be 
very persuasive.  “This medicine will make you better”, “we can win this war”.  
• Humor.  Humor often bonds the listener to the speaker, especially if the brunt of 
the joke is the speaker her/himself.   
• Emotional words and language.  Certain words, phrases or descriptions can 
trigger positive or negative emotions in a group.   These words or phrases may be 
culturally or often socio-economically bound.  Words like patriotism, proud, 
winning, truth and excellence are all viewed as positive.  Negative words in our 
culture include communism, enslave, liar, manipulate and tyranny. 
Persuasion Theory Summary 
Persuasion is a combination of cognitive processing and affective response.  
Persuasion occurs when someone pushes the “right buttons” in another individual to 
trigger the meshing of emotions and cognition.  Some emotional responses, such as fight 
or flight, are instinctively inherent in us as humans.  Others are learned.   Emotional 
responses are cued by the situation in which individuals find themselves.   The 
individuals’ responses, both physiologic and emotional, are based on prior experience 
and motivation.  What terrifies one person will barely ruffle the hair of another.  Pushing 
those emotional and cognitive buttons is persuasion.     From large corporations, like the 
pharmaceutical companies who are trying to sell a product, to the charitable organization 
pulling at your heartstrings for a donation, to mothers “guilting” their children into 
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coming for dinner each is searching for the right combination of cognition and emotion 
that will make you do what they want.   This is persuasion. 
Buyer Behavior Marketing Model 
 Pharmaceutical companies market their products to health care providers, 
patients, and health care facilities in order to increase sales their products and strengthen 
sales revenues.   There are many marketing models in the literature, which address the 
influences affecting how, and why individuals and organizations choose which products 
they will purchase (Aaker & Williams; 1998, Bar-On & Parker; 2000, Curcura, 1999;  
Gonul et al., 2001;  Mintzes, 1998;  Tutor2u, 2004; Wolfe, 2002).  This study will focus 
on the buyer behavior-stimulus response model of marketing (Tutor2u, 2004). 
The Buyer Behavior - Stimulus-Response Model (S-R) illustrates the many 
factors that go into marking choices and decisions by pharmaceutical companies and 
others who wish to sell a product or service.  One can assume the purpose of most 
pharmaceutical company incentives such as samples and education programs is to 
influence or persuade healthcare providers to change prescribing behavior and prescribe a 
drug from the sponsor company’s array of products.  Generally, S-R models assume that 
an incentive of some type, with appropriate modification for specific groups and 
populations, will result in a response that could be predicted by the marketer; that is, the 
marketer’s offer to take a health care provider to a high priced restaurant for dinner and 
an educational program about a new drug, or a new use for an existing drug, will result in 
the healthcare provider prescribing more of the pharmaceutical company’s product 
presented at the dinner.  Figure 1 summarizes this well-developed and tested model of 
buyer behavior (tutor2u, 2004).   
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Figure 1 – Stimulus-response model of buyer behavior 
 
 
In this model, marketing questions and other factors enter the “black box” known 
as the customer and produce certain responses.   The marketing personnel must try to 
decide how the customer thinks and emotionally responds to the event, represented in the 
chart by the black box.  This could be termed both a cognitive and an emotional response 
to the event.    The buyer characteristics will influence how they understand, interpret and 
perceive the stimuli.  Then, a decision-making process occurs which ultimately 
determines what, if any, buying behavior is occurs. 
The first stage of understanding buyer behavior is to focus on the factors that 
determine the buyer characteristics found in the black box area of figure 2 (tutor2u, 
2004).  
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Once the buyer characteristics have been identified for the target population, 
marketing strategies appropriate to the specific buyer group can be developed and a 
marketing plan implemented. 
 
 
 
 
 
Figure 2 – Buyer characteristics  
 
 
Influence of Pharmaceutical Company Sponsored Education, Promotions, and Gifts on 
Physicians Prescribing Practices 
 
The influence of pharmaceutical company sponsored education and gifts on the 
prescribing practices of MD’s, medical students and residents have been well 
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documented in the literature (Avorn et al., 1982; Curcura, 1999; Gonul et al., 2001; 
Stolberg & Gerth, 2000; Wazana, 2000).  More than $11 billion dollars are spent each 
year by pharmaceutical companies in promotion and marketing of their products.  It has 
been estimated that 5 to 8 billion dollars goes to sales representatives to promote their 
products (Greene, 2000).  This is an estimated $8,000 to $13,000 per year spent on each 
physician in the United States (Gibbons et al., 1998; Greene, 2000; Wazana, 2000; 
Westfall, McCabe, & Nicholas, 1997).  MD’s, medical students and residents have all 
admitted that attendance at educational conferences would be significantly less if 
promotional gifts and free meals were not included (Steiman, Shlipak & McPhee, 2001; 
Wazana, 2000).    
A recent New York Times article (Harris, 2004) describes the current federal 
investigation of several large, multinational, pharmaceutical companies.   The 
investigation involves companies such as Schering-Plough, Bristol-Myers Squibb, 
Johnson and Johnson, and Wyeth.  Through a review of securities filings and interviews 
with physicians and pharmaceutical company executives, the government has identified 
inappropriate and illegal marketing tactics including direct monetary incentives and 
encouraging physicians to bill third party payers for drugs given to the physician free of 
charge.    
 
The check for $10,000.00 arrived in the mail unsolicited.   
The doctor who received it from the drug maker Schering- 
Plough said it was made out to him personally in exchange 
for an attached “consulting” agreement that required nothing  
other than his commitment to prescribe the company’s  
medicines.  Two other physicians said in separate  
interviews that they, too, received checks unbidden  
from Schering-Plough (Harris, 2004). 
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 Other pharmaceutical companies have paid fines and/or pled guilty to criminal 
charges involving the marketing of their products in recent years.  In 2003 Astra Zeneca 
paid $355 million in fines, TAP Pharmaceuticals paid $875 million in 2001, and in May 
2004, Pfizer Pharmaceuticals agreed to pay $430 million in fines.   
All of these companies plead guilty to criminal charges of fraud for encouraging 
physicians to bill the federal government for drugs the company gave the physicians 
without cost.  Prosecutors in Philadelphia are currently investigating whether or not 
Schering-Plough overcharged Medicaid for pharmaceuticals given to patients (Harris, 
2004). 
These issues have raised a question about the unethical influence such programs 
may have on physician’s prescribing practices (Avorn et al., 1982; Curcura, 1999; Gonul 
et al., 2001; Wazana, 2000, Wolfe, 2002).   Several studies have found that medical 
students and residents significantly underestimate the influence pharmaceutical company 
sponsored education has on their prescribing practices (Steinman et al., 2001; Wazana, 
2000; Waud, 1992).  In a 1982 study (Avorn et al., 1982) 46% of physicians reported that 
pharmaceutical representatives were moderately to very important in influencing their 
prescribing habits.   Steinman et al. (2000) reported that 61% of medical residents stated 
that industry promotions did not influence their own prescribing, however only 16% 
believed other physicians to be similarly uninfluenced.  A 2002 ethics survey conducted 
by the journal Medical Economics found that 71% of physician respondents did not think 
that accepting gifts, trips or hospitality diminished their objectivity (Murray, 2002).  
Murray reports, “Indeed, many physicians found the suggestion [that they may be 
influenced] insulting” (Murray, 2002, pg. 119).  Chew and colleagues (2000) found that 
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in the treatment of hypertension, over 90% of physicians would dispense a sample that 
differed from their preferred drug choice if the sample was available in the office to 
dispense to a patient.  According to industry estimates, $7.2 billion dollars worth of free 
pharmaceutical samples were distributed in 2000 (IMS Health, 2002).   Westfall et al. 
(1997) found that 96% of physicians and their staff had taken medication samples for 
personal or family use during the preceding year.  Only 2 of the 53 respondents reported 
taking no sample medications in the previous year.  The authors estimated the retail 
worth of these drugs at nearly $10,000 in 1997 Westfall, et al. also point to the issue of 
physicians in training learning to prescribe medications based on whatever samples are 
available in the office rather than on what is the most effective medication indicated for 
the patient’s problem.  They state:  “The use of whatever medication is available on the 
sample shelf (usually the more expensive of several options) is contrary to the 
development of good prescribing habits that will be necessary for success in practice” 
(pg. 142). 
Hodges (2002) examined interactions between pharmaceutical company 
representatives and psychiatry residents and interns in seven Canadian teaching hospitals.  
Results   showed a correlation between the receipt of promotional items and a belief that 
discussion with the pharmaceutical representatives did not influence physician 
prescribing.  The more gifts or promotional items the resident or intern had received, the 
less likely he or she was to believe the pharmaceutical representative influenced his or 
here prescribing (Hodges, 1995).  A University of Chicago (1997) team studies 
advertising directed towards medical students and the students’ attitude towards 
pharmaceutical representatives.  The study found that 90% of the students had received 
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one or more books from pharmaceutical representatives.  The students believed the 
pharmaceutical representatives to be helpful and informative and also stated that they felt 
obligated to listen to the pharmaceutical company representatives informational sales 
pitch after they had received a free meal or a gift (Sandberg, Carlos, Sandberg & Roizen, 
1997). 
Bowman and Pearle (1988) studied the impact of commercial company funding of 
continuing medical education (CME) courses and found that “while the rates for 
prescribing some of the related drugs increased after the courses, overall the sponsoring 
drug companies products were favored” (pg.17).  They further state that although 
physicians attending CME conferences should be aware of this potential influence, the 
final evaluation of drugs to be prescribed remains the responsibility of the physician 
prescriber (Bowman & Pearle, 1998).  Lurie, Rich and Simpson (1990) found that 33% of 
medical residents reported that they had changed their prescribing practice based on 
information provided by pharmaceutical representatives.   Studies have shown medical 
students thought it inappropriate to accept certain gifts, yet when asked about their own 
behavior, indicated that they had accepted those same items (Steinman, Shlipak & 
McPhee, 2001; Wazana, 2000) .  Wang et al. (1999) found that there was a significant 
increase in MD’s requests for specific drugs to be placed on their hospital’s drug 
formulary or pharmacy after attending an educational program sponsored by the parent 
pharmaceutical company.  These requests for formulary and hospital pharmacy additions 
were despite a lack of clear scientific data supporting the advantage of the requested drug 
over the existing formulary product.  Similar findings were reported by Wazana (2000) in 
a meta analysis of 29 articles found in the peer-reviewed literature related to the extent of, 
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and attitudes towards, the relationship between physicians and the pharmaceutical 
industry and its impact on the knowledge, attitudes and behaviors of physicians.  
 Wolf (1998) conducted a study in his allergy and asthma office practice in 
Nashville, Tennessee and found that the office practice received approximately 
$262,662.00 worth of pharmaceutical sample products in one year.  The practice is 
comprised of only two health care providers, Wolf and one NP, who together practice in 
3 offices sites for a total of only 10 days of patient office visits per week.  Wolf itemized 
the classifications of drug samples received and the pharmaceutical companies who 
provided them. He commented, “There may not always be as large a pipeline of samples 
at our disposal.  We need to avail ourselves of the opportunity and options at hand” 
(Wolf, 1998, pg. 1699).  In a response to Dr. Wolf’s study, Westfall et al. (1998) 
challenge Wolfs’ belief that the availability of drug samples is a positive thing.  “Wolf 
seems to support physicians’ partnerships with the pharmaceutical industry.  We hope 
that a physicians’ partnership with his or her patients will always take precedence” 
(Westfall, McCabe & Nicholas, 1998, pg. 1699).  
 Haxby (1995) examined drug samples distributed by pharmaceutical companies 
to the Oregon Health Sciences family medical clinic over a 14-month period of time and 
found that the clinic received a total of 1,117 separate deliveries or visits, resulting in 331 
different drug samples from 43 different pharmaceutical companies.  Most of the clinic’s 
health care providers admitted they did not know what was actually delivered when they 
signed for samples.  Many of the samples delivered were found to be drugs not stocked 
by the clinic’s pharmacy and not on formulary (not an approved drug) at the institution 
(Haxby, Rodriguez, Zenchnich, Schuff, & Tanigawa, 1995). 
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Studies have also looked at the reliability or accuracy of information provided by 
pharmaceutical company representatives through office visits and educational 
programming.  Zeigler, Lew, & Singer (1995) surveyed 27 physicians who attended 13 
conferences at which lunch was provided by a pharmaceutical company.  Twelve 
pharmaceutical representatives from nine different drug companies gave presentations 
ranging from 30 seconds to 12 minutes in length, with an average length of 2.4 minutes. 
The authors concluded that pharmaceutical representatives statements about their 
products were inaccurate 11% of the time and that the inaccurate information directly 
contradicted information readily available to them.   They also found that statements 
about the representatives’ drug products were more favorable than statements referring to 
their competitors’ drugs.  Eighty five percent of the physicians in the study felt 
pharmaceutical representatives provided useful information while only 26% said they 
recalled false statements in the presentations.   Thirty seven percent of the physicians said 
information from pharmaceutical representatives influenced the way they prescribe drugs 
(Ziegler, Lew, & Singer, 1995). 
These findings have led to the development of several non-profit organizations 
focused on highlighting the physician-pharmaceutical company representative interaction 
and on any inappropriate marketing and promotional activities.   Goodman, an internal 
medicine physician from New York founded one such organization, No Free Lunch.  The 
organizations’ message is “Our quarrel is not with the pharmaceutical industry, but with 
pharmaceutical industry promotion.  The time has come to eliminate its influence from 
our practices” (No Free Lunch, 2002a).  The membership and supporters of No Free 
Lunch are listed as “physicians, pharmacists, dentists, nurses, physician assistants, 
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medical ethicists and others” (No Free Lunch, 2002a).  The organization provides 
reference lists from key pharmaceutical-physician studies, a forum for concerned health 
care professionals and a downloadable slide presentation on the subject of pharmaceutical 
company influence, promotions and gifts.  The site sells paraphernalia such as coffee 
mugs and tee shirts to raise money to continue the effort.  The web site also contains a 
pledge that health care providers may take if they are committed to being free of 
pharmaceutical company influence.  The pledge states: 
 
I, __________________, am committed to practicing medicine in the                  
best interest of my patients and on the basis of the best available evidence, rather 
than on the basis of advertising or promotion.   I therefore pledge to accept no 
money, gifts, or hospitality from the pharmaceutical industry; to seek unbiased 
sources of information and not rely on information disseminated by drug 
companies; and to avoid conflicts of interest in my practice, teaching, and/or 
research (No Free Lunch, 2002b). 
The Medical Lobby for Appropriate Marketing (MaLAM) was founded in 1983.  
MaLAM is an international non-profit organization for health professionals whose aim 
“is to defend health care from misleading and harmful marketing” (Healthy Skepticism, 
2002).  The organization goals are to provide a forum for (a) dialogue between health 
professionals and pharmaceutical companies, (b) support of high quality compassionate 
health care, (c) reliable drug information services, and (d) empowered health 
professionals who improve their critical appraisal skills (Healthy Skepticism, 2002).  The 
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organization changed its name from MaLAM to Healthy Skepticism in 2001 when it 
adjusted its focus from “misleading promotion in developing countries where the  
consequences may be worse because of lack of regulatory controls and lack of 
independent information” to “misleading promotion in any country” (Healthy Skepticism, 
2002).  
The literature has demonstrated that physicians are influenced by their 
interactions with pharmaceutical companies and are frequently unaware of the extent of 
the influence.   As NPs practice in a manner similar to MDs, it may be that NPs are also 
influenced by interaction with pharmaceutical companies and their marketing 
promotions. 
Nurse Practitioners Interactions with Pharmaceutical Company Representatives 
In 1999, Kessenich and Westbrook reported the results of a small study in which 
the researcher interviewed 6 NPs in the New England area about their interactions with 
pharmaceutical company representatives and other factors that may have influenced their 
prescribing practices.  The NPs were asked about 1) acceptance of drug samples, 2) 
dispensing free (sample) medications, 3) the perceived influence of the sample 
medications on the NPs prescription choices, 4) drug information from pharmaceutical 
company representatives, 5) sources of new drug information, 6) attendance at 
pharmaceutical company sponsored events, 7) acceptance of gifts and 8) attention to 
pharmaceutical company advertisements (Kessenich & Westbrook, 1999).     
Of the sample population, 100% of the NPs had attended pharmaceutical 
company sponsored educational programs and all (100%) had accepted free sample 
medications for their patients.  Four of the NPs (67%) had received written or verbal 
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communication about drug products during pharmaceutical company encounters such as 
office lunches.   Four of the NPs (67%) believed the availability of sample medications 
might have influenced their prescribing choices.    All 6 NPs had read drug 
advertisements in professional journals and 100% of the NPs believed that 
pharmaceutical companies influenced their prescribing behaviors, “even in a subliminal 
manner” (Kessenich & Westbrook, 1999, pg. 537).   
It is difficult to compare the results of this study to studies involving MDs 
because of the small size of the sample.  However, the issues addressed in the research 
questions are reflective of issues identified in the physician literature.  The findings of 
this study were 1) NPs appear to have a realistic view of the influence marketing may 
have on their prescribing behavior and 2) pharmaceutical companies may have some 
influence on NPs prescribing behaviors and practices.  The researchers concluded that 
further studies need to be undertaken to identify factors that may influence NPs 
prescriptive decisions (Kessenich & Westbrook, 1999).   
Direct to Consumer Marketing. 
 A more recent method of pharmaceutical marketing is to target the patient 
consumer rather than the MD, NP, or PA.  Since the early 1990’s, pharmaceutical 
companies have been advertising directly to the consumer (DTC) through television 
advertisements, mass market publications, billboards and gifts that entice the patient to 
ask about, and ask for, specific products when they see their healthcare provider 
(Manning & Masia, 2001).  Many of the advertisements use familiar or famous people to 
pitch their products including Olympic gold medal ice skater Dorothy Hamil advertising 
for the arthritis medication Celebrex and Senator Bob Dole extolling the virtues of 
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Viagra.  These advertisements tend to present the products as the best, newest or most 
effective product for the complaint.  Many infer that if the patients’ healthcare provider is 
not prescribing this medication for them, they are not getting the best possible 
management of their illness or problem (Ingelfinger, 1972; Mintzes, 1998; Mixed 
Reaction to Consumer Advertising, 2003).  These tactics compel the patient to ask the 
MD or NP about the drug, and sometimes, to directly request the advertised drug in place 
of, or in addition to, their current medications (Mintzes, 1998; Wolfe, 2002).   Patient 
requests for specific products have been documented to affect the MD’s choice of 
prescription for the patient  (Mixed Reaction to Consumer Advertising, 2003; Steinman 
et al., 2001).  Wolfe notes  “There is evidence that many drug advertisements are not 
balanced or accurate and duped gatekeepers may not adequately resist patients’ 
exhortations to write a prescription” (2002, p.525). These concerns are mirrored by a 
2002 study published in the British Journal of Medicine which looked at U.S. and 
Canadian primary care practice sites to ascertain whether or not MDs were influenced by 
their patients’ requests for prescription drugs. The authors reported that patients requested 
prescription drugs in 12% of the visits.   Of the requested prescription drugs, 42% were 
products advertised directly to consumers.  After controlling for many of the variables in 
the study, the authors concluded that the patient’s request for a prescription medication 
significantly influenced the physicians’ choice of drugs prescribed.  “In most cases 
physicians prescribed requested medications but were often ambivalent about the choice 
of treatment” (Mintzes, et al., 2002, pg. 279).   
 Several studies have looked at the accuracy of information provided by 
pharmaceutical sales representatives about their products.  Westfall et al. (1998, pg. 
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1699), state that physician prescription biases “are often generated by information 
supplied by pharmaceutical representatives and the sample medications they dispense, 
not necessarily on the best scientific evidence available in the medical literature”.  Ziegler 
et al. (1995) found that a significant number of pharmaceutical representatives’ 
comments and claims were inaccurate. 
Overall, promotional spending on prescription drugs rose to $15.7 billion in 2000, 
up from $13.9 billion in 1999 and only $9.2 billion in 1996 (National Institute for Health 
Care Management, 2001).   An estimated two and one-half billion dollars were spent on 
direct-to-consumer advertising in 2000 up from $1.8 billion in 1999 and $791 million in 
1996 (National Institute for Health Care Management, 2002).  Increases in the sales of 
the 50 drugs most heavily advertised to consumers were responsible for almost half 
(47.8%) of the $20.8 billion increase in spending in 2000.  (National Institute for Health 
Care Management, 2002).  In 2000, Merck spent $161 million on advertising for Vioxx, a 
new drug for relief of arthritis pain.   That is more than Anheuser-Busch spent advertising 
Budweiser beer ($146 million) or Pepsico spent advertising its soft drink, Pepsi Cola 
($125 million).  The increase in Vioxx sales in 2000 accounted for 5.7% of the 1-year 
increase in drug spending in the U.S. (National Institute for Health Care Management, 
2001). 
A 2001 publication by Pfizer Pharmaceuticals addressed the issue of direct-to-
consumer marketing and took a position that the trend is good for the patient (Manning & 
Masia, 2001).  The authors stated that direct-to-consumer advertising empowers the 
consumer-patient by “encouraging them to explore and discuss with a physician health 
concerns that might otherwise have been ignored” (pg. 3).  They disputed the claim that 
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direct-to-consumer advertising drives up the cost of healthcare saying “undiagnosed, 
untreated and under-treated diseases often get attention and appropriate treatment as a 
result of DTC ads” (pg. 2).  Others have voiced similar beliefs, agreeing that patients who 
see “their” problem addressed in a television commercial, magazine advertisement or on 
a billboard are more likely to ask their healthcare provider about the condition and 
therefore receive earlier intervention for the problem (Calfee, 2001; Holmer, 1999).  A 
recent FDA survey of 500 physicians reported that 37% said DTC advertising had 
affected their practice “somewhat positively”, while 27% said DTC advertising’s impact 
was negative (Mixed Reaction to Consumer Advertising, 2003, pg. 13).  Manning and 
Keith (2001) stated that the increased advertising costs associated with DTC marketing 
are generally recovered by the increase in volume of sales, resulting in increased profits 
for the pharmaceutical company, not in an increased cost to the patient.  
Professional Guidelines: The Medical Community 
 As early as 1990 the American College of Physicians voiced its concern about the 
influence of pharmaceutical company sponsored educational programs and gifts on 
physicians’ and medical students’ prescribing practices with the release of its position 
paper Physicians and the Pharmaceutical Industry (American College of Physicians, 
1990; American Medical Association, 1991; Wazana, 2000).  This position paper 
addressed the potential influence that pharmaceutical companies could have on physician 
prescribing practices.  Despite the existence of the position statement for over a decade, 
and the American College of Physicians and American Medical Associations’ 
recommendation that it be discussed with all students and residents, studies showed that 
only 23% to 50% of residents knew the position statement existed.  Additionally, only 
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62% of practicing physicians knew of a least one of the guidelines (Gibbons et al., 1998).  
This lack of knowledge about the influence that pharmaceutical company sponsored 
education has on the prescribing practices of medical students and residents has resulted 
in a recent American College of Physicians position statement released on March 5, 2002 
(Coyle, 2002a; 2002b).  This new statement reiterated the need for awareness of the 
implications of pharmaceutical company sponsored education and its influence on 
prescribing practices and recommended that all medical students, residents and 
physicians receive training on this issue (Coyle, 2002b).  The 2002 position statement 
specifically addressed the responsibility of graduate and continuing medical education 
providers to ensure that unbiased educational content is provided and organizational 
policies are in place to identify acceptable and unacceptable interactions with the 
pharmaceutical industry both for medical students and for practicing physicians (Coyle, 
2002a; 2002b).  Other professional medical associations have similar guidelines 
concerning pharmaceutical sales representatives interactions with physicians.  These 
associations include the American Medical Association, Canadian Medical Association, 
the Royal College of Physicians and Surgeons of Canada, the Academy of Medicine and 
the American College of Physicians (Wazana, 2000).  Notwithstanding their stand on 
pharmaceutical company influence, the American Medical Association continues to 
generate $20 million annually by selling detailed personal and professional information 
on all doctors practicing in the United States to the pharmaceutical industry for use in the 
pharmaceutical company’s physician prescribing databases (Stolberg & Gerth, 2000). 
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Professional Guidelines: The Nursing Community 
Despite the extensive literature addressing the influence of pharmaceutical 
company sponsored educational programs, promotions, and gifts on physician prescribing 
practices, to date, none of the fifty State Boards of Nursing, none of the myriad of 
professional nursing organizations, and only one NP professional organization have 
addressed this issue in their licensure, accreditation regulations, or professional 
guidelines.  The American College of Nurse Practitioners (ACNP) has both a policy 
guideline regarding industry sponsorship at the ACNP annual clinical conference 
(ACNPa, 2004) and a policy statement on NPs and direct to consumer 
prescription/nonprescription drug advertising (ACNPb, 2004).  The clinical conference 
guidelines state:  
 The ACNP recognizes industry as a partner by accepting 
 sponsorship and support funding as one of its revenue 
sources for ACNP programs.  The ACNP also recognizes  
the potential for commercial bias, perceived or otherwise,  
as well as members concerns about industry involvement.  
 
We value the partnership the ACNP has established with 
Industry, however, ACNP will never compromise the  
Independence of its programs through relationships with  
its corporate partners.  Appropriate guidelines and input 
from attendees are essential components of managing 
our relationship with industry if we are to maintain our 
integrity as an organization and the confidence of the  
medical profession (ACNPa, 2004). 
 
 The ACNP policy statement about NPs and direct to consumer marketing  
 
addresses the need for accurate and complete information disclosure to consumers.  The  
 
statement incorporates the  United States Food and Drug Administration's  
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"Guidance to the Industry - Consumer Directed Broadcast Advertisements"  
 
document, which reminds pharmaceutical advertisers not to limit their promotions to  
 
physicians.    
 
 
To this end, it is the position of ACNP and the more than 88,000 nurse 
practitioners in the United States (HRSA 2000) that patients and families 
must be given correct consumer information regarding the profession and 
the care delivery, which can be affected and expected by Americans. One 
area of consumer information is contained in pharmaceutical advertising 
of prescription and nonprescription (OTC) drugs and immunizing agents. 
 
This has been addressed by the United States Food and Drug 
Administration's "Guidance to the Industry - Consumer Directed 
Broadcast Advertisements" (August 1999) which states: "FDA also 
reminds sponsors of prescription drug advertisements to be careful not to 
imply that only physicians can prescribe their products." It is enormously 
important that consumers be directed to all qualified health care 
professionals who are able to diagnose, treat and prescribe these agents. If 
the consumer is directed to only one group of licensed prescribers, in 
effect, consumers are misdirected and denied the correct and complete 
information by which they base their health care decisions (ACNP - Policy 
Statement: Nurse Practitioners and Direct to Consumer Prescription/ 
Nonprescription Drug Advertising, 2004). 
  This recognition of the interaction between the pharmaceutical industry and  
the practicing NP is an important first step in the acknowledgment that pharmaceutical  
influence extends beyond the currently identified physician population. 
In light of the dearth of information about NP-pharmaceutical company 
interaction, the purpose of this study is to answer the question, does the receipt of 
pharmaceutical company sponsored education, sales visits, promotional products and 
gifts influence the prescribing beliefs and practices of NPs? 
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CHAPTER 3: METHODOLOGY 
Introduction 
This quantitative correlational study used a survey type questionnaire designed to 
ascertain the self-reported prescribing beliefs and practices of NPs after encountering 
pharmaceutical company sponsored educational programs, sales visits, promotional 
products, or gifts.   
Survey Tool 
The study instrument (appendix D), a 22-question survey, was developed by the 
researcher from a review of the literature, review of the survey tool developed by Berger-
Evans and colleagues, personal experiences and content expert review. 
Bergman-Evans’ survey asked final clinical year physician, pharmacy and NP 
students about their knowledge of pharmaceutical company education programs and gifts, 
their faith in the pharmaceutical company representatives’ knowledge and information 
and how they selected which drugs to prescribe for their patients.  Reliability and validity 
data were run for the Bergman-Evans survey (Bergman-Evans, 2002).  Dr. Bergman-
Evans and her colleagues gave permission for the adaptation of their survey for this 
study, if necessary.  
The survey questionnaire from Bergman-Evans and colleagues was significantly 
modified in order to reduce the number of survey items and eliminate questions which 
were not applicable to this study.  The questions eliminated included participant’s general 
knowledge of pharmaceutical spending and budgets and student knowledge about 
professional nursing organizations’ stance on pharmaceutical company – NP interactions.    
Some items were revised to be more appropriate for practicing NPs and additional items,  
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such as the NPs predominant patient practice population and whether the NP has ever 
accepted any of the listed promotional or gift items, were added.  Additionally, the 
demographic information to be collected was expanded in order to more fully describe 
the respondent population.  This refinement of the Bergman-Evans survey reduced the 
total number of survey items from 58 to 44, resulting in a 22 question Blunt survey.    
Furthermore, the Blunt Survey emerged as a very different tool than the Bergman-Evans’ 
as item construction and analysis proceed. 
  The survey was designed to collect demographic data related to the survey 
population including, number and type of pharmaceutical company-NP interactions, and 
issues related to direct-to-consumer marketing.  Questions related to NPs personal 
practices and beliefs included: whether or not the NPs felt their prescribing practices 
were influenced by pharmaceutical company sponsored gifts such as pens, note pads, 
textbooks; promotions such as drug samples, or by education programs at conferences, 
dinners or in their practice site; whether the NP’s felt other NPs were influenced by these 
interactions; and whether or not NPs had ever changed their prescribing practices after a 
pharmaceutical company interaction such as an educational program, promotion or 
receipt of a gift.  Respondents were then asked their reasons for changing their 
prescribing practice after the encounter, if they had made changes.   Additionally, NPs 
were asked to rate the appropriateness of accepting pharmaceutical company promotional 
products or gifts, or attending a pharmaceutical company presentation at a conference, 
dinner or office luncheon. They were also asked what, if any, promotional products, 
educational programs or gifts they might have accepted and their beliefs about the  
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appropriateness of accepting such items.  Respondents were also asked how important a 
patient request for a specific drug would be to their prescribing practice and how 
important sample drugs available in the office would be to their prescriptive decisions.   
Next, NPs were asked several questions related to pharmaceutical company 
representative interactions.  First, they were asked to rate the likelihood that they would 
see a pharmaceutical representative again if they received an item useful in their practice 
such as an educational monograph, product information, drug samples, note pads or pens, 
or educational materials.  Second, they were asked to indicate strength of agreement or 
disagreement about statements related to the usefulness, accuracy, and importance of 
pharmaceutical company representative information.  Finally the respondents were asked 
to rate the adequacy of information they received during their nurse practitioner 
education program regarding how a nurse practitioner should interact with 
pharmaceutical representatives so that they could make informed prescribing decisions 
Survey items were nominal or scaled.  A panel of NP experts, NP educators and 
practicing NPs was used to test the survey for content validity. The final pilot survey 
(appendix E) was tested for reliability and external validity once Institutional Review  
Board (IRB) approval for the study was obtained.   Cronbach's Alpha was run to 
determine test reliability.  The questionnaire was revised based on the results of pilot 
testing.       
   Demographic data collection include (a) age, (b) sex, (c) race, (d) educational 
preparation: diploma, associate degree, bachelors degree, masters degree, PhD or EdD, 
(e) years of nursing experience, (f) years of NP experience, (g) number of encounters per  
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month with pharmaceutical companies through sales visits and educational programs, (h) 
whether the respondent has ever received drug samples, gifts, promotional products and  
(i) educational programs or information, (j) belief in the reliability of information 
provided by pharmaceutical companies, (k) self-assessment as to whether pharmaceutical 
company interaction affects their prescribing practice and (l) their perception of the 
prescribing practice of their peers.   
Independent variables were defined as (a) number of encounters with 
pharmaceutical company representatives, (b) receipt of pharmaceutical samples, gifts or 
educational materials, (c) NP beliefs about the validity of information provided by 
pharmaceutical company representatives.  Dependent variables were defined as (a) NPs 
self-reported change in prescribing practice and (b) NPs self-reported belief in the 
accuracy and usefulness of product information received through educational programs, 
promotions and gifts.     
Pilot Data Analysis 
The pilot survey was used to assess the internal reliability of the Blunt Nurse 
Practitioner Prescribing Survey tool.   Two pilot tests were performed.  The first pilot 
survey was sent to a total of 99 nurse practitioners in October 2003.   The names selected 
were the first 23 names on the purchased ANNC national certification mailing list for 
New York, Pennsylvania and Florida  (name numbers 1 – 23) and the first 10 names from 
each of the three states on the NCC mailing lists (name numbers 1 – 10).   A total of 54 
surveys were returned completed, with 47 usable surveys and 7 NPs stating that they had 
not prescribed medications or practiced within the last 5 years.   The returned surveys 
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were reviewed by a statistician who identified several problems with the survey 
construction that would result in unusable survey data if the survey were  
implemented as constructed.  After consultation with the statistician and revision of the 
survey, including changes in scaling and survey layout, a second pilot survey was mailed 
out in November 2003 to 51 nurse practitioners.  The names selected were 12 names on 
the purchased ANCC national certification mailing lists for New York, Pennsylvania and 
Florida (name numbers 24-35) and 5 names from each of the three states on the NCC 
mailing lists (name numbers 11-16).  A total of 19 surveys were returned with 14 surveys 
meting inclusion criteria.  The five surveys excluded were NPs who had not prescribed 
medications or practiced within the last 5 years.  Cronbach Alpha, a correlation 
coefficient used to test the internal consistency of a survey tool, determined reliability of 
the survey.   
Cronbach Alpha requires only one test administration (Creswell, 1994) and can be 
used for both binary-type and large-scale data (Creswell, 1994; Nunnally, 1978).  It 
measures the squared correlation between observed scores and true scores or, in other 
words, it measures reliability in terms of the ratio of true score variance to observed score 
variance.  “A reliable test should minimize the measurement error so the error is not 
highly correlated with the true score.  On the other hand, the relationship between the true 
score and the observed score should be strong.  Cronbach Alpha examines this 
relationship” (Using SAS for Item Analysis and Test Construction, 2004).   
The Cronbach Alpha procedure returns two coefficients, raw and standardized.   
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The raw Cronbach Alpha is based on item correlation.  The stronger the items are inter-
related, the more likely the test is consistent.  Standardization is based on item 
covariance.  Variance is a measure of how a distribution of a single item or variable  
spreads out.  Covariance is a measure of the distribution of the two variables.  The higher 
the correlation coefficient, the higher the covariance.  Standardization is a linear 
transformation.   The higher the Alpha score, the more reliable the test.   Although there 
is no universally agreed upon “correct” Alpha, a score of 0.70 and above is generally 
deemed an acceptable score for reliability (Nunnally, 1978).  Additionally, a low Alpha 
score may not indicate a “poor” test.  Survey items must be grouped in order to assess 
their reliability.   Inappropriate grouping of items may result in poor Alpha results.  
Conversely, the test may measure several attributes or dimensions, rather than just one, 
which may also result in a lower Alpha score.  Remedies to these issues include a factor 
analysis, which may allow combination of several factors into fewer factors, and 
dropping test items that affect overall consistency which, may also increase the Alpha 
and produce better internal consistency (Using SAS for Item Analysis and Test 
Construction, 2004). 
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Analysis of Results 
 The pilot survey consisted of 43 items, which were assigned to one of five 
groupings (table 1). 
 
 
Table 1 - Pilot Survey Groups 
 
 
 
Group Number Survey Grouping Survey Items 
1  Beliefs about the 
appropriateness of 
pharmaceutical influence 
5a, 5b, 5c, 5d, 5e, 5f, 5g, 5h, 
5i, 5j, 5k 
2 Beliefs about pharmaceutical 
influence on personal practice 
and 
Beliefs about the reliability 
and accuracy of 
pharmaceutical company 
product information 
1, 2, 24, 25, 27, 28, 29, 30, 
31, 32 
 
3 Personal practices related to 
pharmaceutical interactions 
3,4,7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 18, 20, 21, 22, 
23, 26 
4 Beliefs about pharmaceutical 
company influence on other 
nurse practitioners 
17 
5 Demographics 6, 19, 33, 34, 35, 36, 37, 38, 
39, 40, 41, 42, 43 
 
 
Group 1 
 Group 1, beliefs about the appropriateness of pharmaceutical influence, showed 
an Alpha of .7674 demonstrating internal consistency (table 2).   Individual subscale 
reliabilities ranged from .7131 to .8107.  No changes were made to this grouping. 
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Table 2 - Group 1: Beliefs About Appropriateness of Pharmaceutical Influence 
 
 
____________________________________________________________________ 
 
Item                Scale          Scale              Corrected 
                Mean         Variance         item-              Squared            Alpha 
               if Item       if Item            Total              Multiple           if Item 
               Deleted      Deleted          Correlation     Correlation       Deleted 
 
5a                 19.6923      23.8974             .3043                .3918              .7665 
5b                  20.0000      24.3333             .4862                .8464              .7457 
5c                 20.0000      21.5000             .6967                .9455              .7131 
5d            19.3846     20.4231             .5686                 .7298              .7267  
5e            19.9231     27.5769            -.0568                .8966               .8107 
5f            20.0000     22.3333             .5831                .9315               .7285 
5g            18.3846     20.7564             .6454                .8024               .7150 
5h            19.6923     21.5641             .6405                .8424               .7190 
5i            18.0000     23.0000             .4953                .9722               .7400 
5j            18.0769     26.7436             .0759                .9603               .7863     
 
Alpha =   .7674             
______________________________________________________________________ 
                
 
                      
Group 2 
Group 2, beliefs about pharmaceutical influence on personal practice, showed an 
Alpha of  -.4140 and a standard deviation of  -.2525 indicating problems in the item 
grouping.   These findings indicate measurement of unrelated attributes or dimensions 
within the group.  This group needed to be reorganized to increase the internal reliability.    
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The survey items were placed into two new groups, Run 1 and Run 2, to improve 
correlation of attributes.  
Run 1 
Run 1 (items 1 and 2) beliefs about pharmaceutical influence on personal 
practice, yielded an improved Alpha of  .1111 (table 3).  However, this is still an 
unacceptable Alpha level.    To further improve Alpha, the items were regrouped again 
by separating  items 1 and 2   placing them into two different groups.   These final groups 
can be found in table 10.   
 
Table 3 - Run 1: Beliefs About Pharmaceutical Influence on Personal Practice 
 
________________________________________________________________________ 
 
Item              Scale           Scale       Corrected 
                Mean         Variance        Item-              Squared          Alpha 
               if Item         if Item        Total              Multiple          if Item 
               Deleted         Deleted     Correlation    Correlation      Delete 
 
1              3.0714            .3791                 .0629              .0040                . 
2               .7857               .1813                 .0629              .0040                . 
Alpha =   .1111 
______________________________________________________________________      
 
 
 
 
Run 2 
 
Run 2a (items 24, 25, 27, 28, 29, 30, 31, 32) beliefs about the reliability and 
accuracy of pharmaceutical company product information, yielded an Alpha of  .5397 
(table 4).    
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Table 4 - Run 2a: Beliefs about Pharmaceutical Influence   
 
______________________________________________________________________ 
 
Item        Scale             Scale          Corrected 
               Mean            Variance         Item-              Squared          Alpha 
              if Item            if Item           Total               Multiple         if Item 
              Deleted          Deleted      Correlation        Correlation     Deleted 
_____________________________________________________________________ 
24           17.1429         3.8242        .1356          .6852          -.3654 
25           16.7857         2.3352        .4592          .4227         -1.0816 
27           16.7143         3.7582        .0155          .4303          -.3036 
28           16.5000         3.6538        .1317          .2317          -.3965 
29           17.0714         4.2253       -.1399          .5342          -.1426 
30           15.5714         3.3407        .0123          .5025          -.3416 
31           16.2143         5.4121       -.4484          .7020           .2203 
32           15.5000         4.7308       -.3201          .3962           .1111 
 
Alpha =  -.2462            
______________________________________________________________________  
 
 
Reconfiguration of the items in this group had no impact on increasing Alpha to 
an acceptable level.   Removing items 29, 30, 31, and 32 resulted in an improved Alpha 
fro the remaining items.  However, the Alpha of .5397 remains too low for internal 
consistency  (table 5).   
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Table 5 - Run 2b: Beliefs about the Reliability and Accuracy of Pharmaceutical Company  
         Product Information 
 
 
_______________________________________________________________________ 
Item              Scale          Scale         Corrected 
                Mean         Variance    Item-            Squared         Alpha 
              if Item        if Item       Total            Multiple        if Item 
               Deleted      Deleted    Correlation    Correlation     Deleted 
______________________________________________________________________ 
 
24             6.3571         2.2473        .4939         .2558           .3814 
25             6.0000         1.6923        .3371         .1457           .4773 
27             5.9286         2.0714        .2981         .1050           .4934 
28             5.7143         2.3736        .2567         .1313           .5208 
 
Alpha =   .5397            
______________________________________________________________________ 
 
 
 
Expert review thought the items to be too similar for respondents to be able to 
differentiate between the individual items.   However, the focus of these items was 
thought to be integral to the study.   Based on analysis, it was decided to collapse items 
24, 25, 27, and 28 into two items related to NPs beliefs about the usefulness of the 
pharmaceutical representatives’ information.   Items 29 – 32 were reassigned to new 
groups.                             
Group 3 
 Prior to running statistical analysis on Group 3, personal practices related to 
pharmaceutical interactions (items 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21, 22, 
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23, 26), the grouping was reviewed.  Based on this review and the advice of content 
experts, it was decided to subdivide Group 3 into several smaller groups to better isolate 
the issues related to prescribing.   The original Group 3 was broken down and the items 
assigned to four new groups designated as Run1, Run 2, Run 3 and Run 4. 
Run 1 
Question 18, receipt of promotional products and gifts (items 18a, 18b, 18c, 18d, 
18e, 18f, 18g, 18h, 18i, 18j, 18k), was a multi-factorial question with 11 possible answer 
groupings.  Analysis of this group alone resulted in an Alpha of .7300  (table 6).     
 
Table 6 - Run 1a:  Receipt of Promotional Products and Gifts 
 
______________________________________________________________________ 
Item             Scale             Scale       Corrected 
               Mean            Variance        Item-             Squared          Alpha 
               if Item           if Item        Total              Multiple          if Item 
               Deleted           Deleted     Correlation    Correlation      Deleted 
 
18c            2.5000            2.2692         .4219            .                    .7031 
18d           3.1429            2.2857         .3073            .                .7327 
18e            2.5000            2.2692         .4219            .                .7031 
18f           2.5000            2.2692        .4219            .                .7031 
18g            3.1429            1.9780         .5872            .                .6600 
18h            3.1429            1.9780         .5872            .                .6600 
18i            3.2143            2.3352         .3565            .                .7172 
 
***  18A has zero variance  ***  18B has zero variance    ***  18J has zero variance 
 
Alpha =   .7300            
 ______________________________________________________________________ 
 Note: Statistics based on inverse matrix for scale ALPHA are meaningless  
and printed as   . 
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Based on item analysis, items 18d, conference registration fees,  and 18i sample 
drugs for your personal use, were deleted from the question to further improve the Alpha 
as they did not appear to be integral to the run.  This resulted in an improved Alpha of 
.7366 for the group (table 7). 
 
Table 7 - Run 1b:   Receipt of Promotional Products and Gifts 
 
______________________________________________________________________ 
Item             Scale             Scale       Corrected 
               Mean            Variance        Item-             Squared          Alpha 
               if Item           if Item        Total              Multiple          if Item 
               Deleted         Deleted     Correlation    Correlation      Deleted 
 
18c            2.1429            1.3626   .4148            .                    .7204 
18e            2.1429            1.3626   ..4148                 .              .7204 
18f           2.1429            1.3626   .4148            .                .7204 
18g            2.7857            1.1044         .6262            .                .6368 
18h            2.7857            1.1044         .6262            .                .6368 
 
***  18A has zero variance 
***  18B has zero variance 
***  18J has zero variance 
 
Alpha =   .7366            
 ______________________________________________________________________ 
 Note: Statistics based on inverse matrix for scale ALPHA are meaningless  
and printed as   . 
 
 
 
Run 2 
Next, items 3 and 4 were removed and placed in a group titled factors affecting 
prescription choices by NPs.  This run yielded an Alpha of  .0731 (table 8).  A low Alpha 
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was anticipated for this grouping as it represents two specific issues, the importance of 
patients request for a specific drug and the availability of samples in the office, both of 
which may affect NPs prescribing decisions..   At this time, it is not known how 
important these two factors are to the NPs prescriptive decisions and what other factors, 
such as geographic location, population type, and NP experience may also influence this 
issue.  Content experts felt these two issues were an important part of the study and 
should remain as stated. 
 
Table 8  - Run 2 : Factors Affecting Prescription Choices by NPs 
 
_________________________________________________________________ 
Item-total Statistics 
______________________________________________________________ 
               
   Scale          Scale       Corrected 
               Mean         Variance             Item-          Squared            Alpha 
              if Item         if Item                Total               Multiple           if Item 
              Deleted       Deleted              Correlation      Correlation       Deleted 
 
3          2.4167         1.1742         .0429          .0018          . 
        
4           2.3333          .4242         .0429          .0018                    . 
 
 
Alpha =   .0731             
_____________________________________________________________________ 
 
 
 
Run 3 
 Item 7, I have changed or modified my prescribing practice after attending a 
pharmaceutical company sponsored educational program or presentation or after 
receiving promotional items, is a single item with a dichotomous response and could not 
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be tested for internal consistency using Cronbach Alpha.  However, 55% of respondents 
indicated they have changed their prescribing practice after attending a pharmaceutical 
company sponsored event while 45% indicated they had not changed their prescribing 
practice after such an event.  This item was retained.  
Run 4 
 A final group was formed with the remaining items from the original Group 3 
(items  8, 9, 10, 11, 12, 13, 14, 15, 16) and titled personal practices related to accepting 
pharmaceutical company gifts.  This grouping yielded an Alpha of  .5906  (table 9).   
Item 11, as effective and had more convenient dosing, yielded zero variance  and was 
removed from the survey.    Reconfiguration of the items in this group had no impact on 
increasing Alpha to an acceptable level.  Again, a low Alpha was anticipated for this 
grouping as it represents reasons NPs change their practice after interaction during a 
pharmaceutical company sponsored event.  As all NPs do not attend the same programs 
or events, nor do they receive the same pharmaceutical company information from the 
same representative, there may be a wide range of reasons NPs change their practice in 
relation to pharmaceutical company sponsored events.   These items were felt by the 
experts to be an integral part of NPs prescriptive choice and may be the reason NPs 
choose to change medications for their patients, although it is not known at this time if 
this is related to pharmaceutical company influence.    
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Table 9 - Run 4:  Personal Practices Related to Accepting Pharmaceutical Company               
               Gifts 
 
______________________________________________________________________ 
               Scale          Scale       Corrected 
               Mean         Variance     Item-          Squared        Alpha 
   if Item        if Item      Total          Multiple       if Item 
   Deleted      Deleted      Correlation    Correlation   Deleted 
______________________________________________________________________ 
 
8             4.8333         3.2424          -.3789               .             .6869 
 
9             4.8333         2.8788          -.0309               .            .6263 
 
10            4.8333         2.6970          .1598               .             .5899 
 
12            5.2500         1.6591           .7433               .            .3623 
 
13            4.9167         2.4470           .2737               .             .5635 
    
14            5.3333         1.5152                .9084               .            .2800 
 
15            5.0000         2.9091              -.1179               .            .6806 
 
16            5.2500         1.6591              .7433              .            .3623 
 
Alpha =   .5906           Standardized item alpha =   .4310 *** Q11 has zero variance 
 
______________________________________________________________________ 
 
 
 
Group 4 
Item 17, NPs  beliefs about pharmaceutical company influence on other nurse 
practitioners was felt to be unrelated to any other question in the survey as it addresses  
NPs beliefs about other NPs practice.  The remainder of the survey items address 
the NPs personal interactions, experiences and demographics.   For this reason, this item 
stands alone in the group.   This is a single item with a dichotomous response and could 
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not be tested for internal consistency using Cronbach Alpha.   Seventy eight percent of 
respondents believe that other NPs are influenced by their pharmaceutical company 
interactions while 12% did not believe their peers were influenced.  This item was 
retained. 
Group 5 
          Group 5, demographics, did not require a test of internal consistency. 
 
Summary 
 Based on the Cronbach Alpha findings and the opinions of expert NPs, changes 
were made to some of the item groupings, as discussed above.  Items 11, 21, 22, 23, and 
32 were deleted.   Items 24, 25, 27, and 28 were collapsed into a new, combined question.  
Based on these changes, the survey tool was renumbered appropriately.  The final 
groupings for the revised survey tool can be found in table 10.   The pilot survey and the 
final revised survey used for the study can be found in appendix D. 
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Table 10 - Survey Groupings after Cronbach Alpha Analysis 
 
 
 
Survey Grouping Survey Items 
Beliefs about pharmaceutical influence on 
personal practice 
1, 10e  
Beliefs about the appropriateness of 
accepting pharmaceutical company gifts 
2, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k 
 
Personal practices related to accepting 
pharmaceutical company gifts 
8a, 8b, 8c, 8d, 8e, 8f, 8g, 8h, 8i, 8j, 9, 10b 
Beliefs about the reliability and accuracy of 
pharmaceutical company product 
information 
10a, 10c, 10d 
Beliefs about pharmaceutical company 
influence on other nurse practitioners 
7 
Reasons NPs changed prescribing practices 
after pharmaceutical company interaction 
5, 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6h 
Beliefs about adequacy of NP program 
information about NP / pharmaceutical 
company interaction 
13 
Factors affecting prescription choices by 
NPs 
3a, 3b 
Demographics 11, 12, 14, 15, 16, 17, 18, 19, 20 
 
 
Site and Sample Selection 
The sample for this study was obtained from the ANCC and NCC Nurse 
Practitioner certification lists.  An alternate method of obtaining names for the survey 
would be to request the NP licensure mailing lists from each state.   This method was 
deemed less appropriate than the certification mailing lists as NP licenses can be renewed 
in some states without a continuing education requirement therefore there is no guarantee 
that the NPs included in the State Board of Nursing sample would be practicing in their 
field.    
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 Both ANCC and NCC are able to randomly select, by computer, the requested 
sample from the total population of NPs in their certification database.    This allowed for 
simple random sampling of subjects.  Random selection occurred across gender lines, NP 
specialty, and geography.    Additionally, the ANCC and NCC lists generally utilize NPs 
home mailing addresses rather than employment addresses.  The researcher felt this 
would increase the accuracy of the mailing lists, as it avoided sending surveys to NPs 
who may have changed employment since their last certification. 
Utilization of the ANCC and NCC certification databases ensured the NPs 
included in the survey were practicing, had practiced within the last five years, or had 
graduated from an NP program within the last five years.  These NPs would have been 
required to attend a specified number of hours of continuing education programming 
within the last five years making it likely that they had been exposed to current clinical 
practice issues and recent pharmaceutical and practice changes.    
The study was conducted in three states: Pennsylvania, New York and Florida.  
These states where chosen in order to access NPs in a wide range of practice settings, 
serving a variety of patient populations, with multiple specialty practices, and with a 
diversity of educational backgrounds and years of NP experience, across a wide 
geographic area.  Although Pennsylvania and Florida do not require national certification 
to practice at this time (2004), the three states selected all have a diverse geography with 
urban centers, and suburban and rural communities plus very large NP populations; New 
York 9,789, Pennsylvania 5,230, Florida 6,114 (Pearson, 2002).   These numbers are only  
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exceeded by California , which has 11,028 NPs in the state (Pearson, 2002).   An NP is 
conducting this study and it is expected that other NPs, in the interest of the profession, 
will respond to the survey. 
Data Collection Plan 
This study utilized a questionnaire mailed to a total of 1,000 NPs in Florida, 
Pennsylvania and New York states.  A sample population of 1000 NPs was selected 
based on the Creative Research Systems sample size calculator (Creative Research 
Systems, 2002).  The sample size calculator demonstrates that a total of 377 completed, 
returned, surveys would provide a 95% confidence level with a confidence interval of P < 
.05 while 645 returned, completed, surveys would provide a confidence level of 99% 
with a confidence interval of P < .05.   The survey was a pen and paper design with an 
enclosed, postage paid, self-addressed reply envelope included in order to facilitate 
return.  The surveys were coded for tracking purposes utilizing a numeric coding system.  
The researcher rejected using electronic surveys because an online survey tool would 
require the respondent to enter an identification code at the time of online survey 
completion.  This presents an obstacle to completion of the survey, as it requires the NP 
to have the survey in-hand at the same time they are logged onto a computer.  Some NPs 
may not have computers at home and may only have access to them at their work site.  
Those NPs having computers at home would need to go to the computer with the survey 
in-hand in order to complete the survey.  Allowing the respondent to complete the survey, 
put it into the response envelope and be finished with it at the first encounter was thought 
to increase response rates and diminish the possibility of surveys being misplaced or lost 
before the NP logs onto a computer.   Surveys were mailed with a cover letter explaining 
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the purpose of the study, identifying that IRB approval had been obtained, and requesting 
that participants complete the survey and return it within three weeks, with a specific 
deadline date indicated.  The direct mailing containing the survey, a cover letter 
describing the study and assurance of anonymity, a self addressed, stamped envelope and 
two 3” x 5” cards were mailed to the sample population in early 2003.  Surveys were sent 
by U.S. postal service and were coded for tracking purposes.      
  A second mailing was sent to non-respondents four weeks after the initial 
mailing.  As completed surveys were received, data entry commenced.  A completed, 
returned survey was deemed agreement to participate in the study, as identified in the 
cover letter.   Survey analysis commenced ten weeks after the initial mailing was sent 
out. 
The literature shows that an incentive such as a small amount of cash ($1.00), 
opportunity to win a gift, or even a tea bag or bookmark enclosed with surveys, can 
increase the survey response rate by 20% to 60% (Berry & Kanouse, 1987; Church, 1993; 
Wiersma, 2000; Willimack, Schuman, Pennel, & Lepkowski, 1995).   This is believed to 
occur because the respondent perceives the establishment of a relationship between 
themselves and the researcher when they accept the incentive offered by the researcher.  
Despite the success of this approach, there has been criticism of incentive use, primarily 
because of concerns that providing incentives to participates in research activities sets a 
problematic precedent requiring future researchers to provide incentives in order to 
obtain participant participation (National Center for Health Services Research, 1997; 
Sheatsley & Loft, 1981).  Aday (1996, pg. 287) notes that a non-monetary incentive for 
professionals to complete a survey may be their interest in the survey.  Offering survey 
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participants the opportunity to obtain the completed survey results may simply be 
incentive enough for them to take the time to complete the survey.  Therefore, as an 
additional incentive, the subjects were offered the opportunity to obtain the final data 
from the study.  The survey cover letter also offered participants the opportunity to 
request the completed survey results.  Participants who desired a copy of the survey 
results were instructed to return the enclosed postage paid 3”x 5” card with, their name 
and mailing address, to the investigator indicating their desire to receive the survey 
results.  Written copies of the survey results were sent to these participants by U.S. mail. 
The survey respondents had the opportunity to win one of four $50.00 gift 
certificates to Amazon Books, if the survey is completed and returned.   Information 
about this incentive was included in the cover letter.   Survey respondents who wished to 
be considered for the gift certificate completed a separate check box on the request-for-
survey-results 3” x 5” postage paid index card.   These 3” x 5” cards were returned under 
separate cover and compiled.  One month after the initial surveys had been mailed, a 
follow up letter with a second copy of the survey will be mailed to non-respondents in an 
attempt to increase the response rate.  Approximately eight weeks after the initial surveys 
were mailed to the sample population, gift certificate winners were selected by a random 
drawing.   A chance of winning one of the four gift certificates was approximately 1-in-
113 based on 451 returned surveys. 
Although some may view the use of incentives in this study as an example of an 
attempt to affect NPs behaviors through influence, almost a mirror to the survey itself, the 
researcher believes that the importance of the data to be collected requires incentives be 
used in order to garner a significant response to the survey. 
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Delimitations 
 The results of this study, although generalizable to NP populations in 
Pennsylvania, Florida and New York, are not generalizable to a national population of 
certified NPs as regional variation may influence NPs interactions with pharmaceutical 
company representatives.  Sample bias may occur as the AANP and NAPNAP 
certification databases will not be used and only nationally certified NPs will be 
surveyed.   There is no information in the literature about why NPs may choose to 
become credentialed by ANCC rather than AANP.  Both the AACN and NCC 
certification examinations in Adult NP and Family NP cover the same content areas and 
are honored nationwide.   The lack of understanding about this decision, choosing AANP 
or NCBPNP/N rather than ANCC for certification, may exclude a portion of the 
practicing NP population from the sample.  Additionally, the NCBPNP/N database will 
not be used, as a practice requirement is not mandatory for re-certification.  Although 41 
states required national certification in 2004, the states of Florida and Pennsylvania did 
not require national certification to practice at that time.  However, due to the number of 
nationally certified NPs in these states, and the geographic make-up of the states, it was 
deemed necessary to use Florida and Pennsylvania in this survey.  This choice may result 
in some sample bias as NPs who work in these states who have chosen to become 
nationally certified may demonstrate characteristics different from non-certified NPs in 
those states. 
Limitations 
Certain NPs may choose not to complete and return the survey as some may view 
questions related to accepting gifts from pharmaceutical companies as personal 
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information.  Others may be concerned about the ethical or moral implications of 
receiving such gifts and not want the researcher to have this information about their 
personal practice.  
There may be sampling bias as there may not be equal population distribution by 
state, practice type, specialty and geographic location.  However, the efficacy of random 
computer sampling from the ANCC and NCC databases make this the most effective 
method of sample identification.  Some NPs may have moved since their last certification 
update in which case addresses may be invalid.  These surveys may be forwarded by the 
postal service, or if the NP moved some time ago, returned to the researcher.  Utilizing 
U.S. mail will allow equal access to all potential participants.   
Finally, as this survey is self-report, there may be some under estimation or over 
estimation of the extent of exposure to pharmaceutical company education, promotions 
and gifts either because of distance from the event encounter or because the NP does not 
wish to accurately identify his or her behaviors.  Some NPs may also overestimate or 
underestimate their encounters with pharmaceutical representatives, and or number of 
promotional products or gifts received. 
Data Analysis Plan 
 This study answered the following questions: a) Does the receipt of 
pharmaceutical company sponsored educational programs, promotional products, and  
gifts influence NP prescribing beliefs and practices?  b) Does the frequency of  
NP/pharmaceutical interaction influence the NP’s prescribing beliefs or prescribing  
practices? c) Does the age, race, sex, demographic region in which the NP practices,  
years of NP of practice, educational preparation or specialty practice type of the NP  
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affect their pharmaceutical company interaction?  d) What are the NP’s beliefs about  
the accuracy and usefulness of information obtained from pharmaceutical company  
educational programs, sales representatives, promotional products and gifts?  e) do NPs  
change or modify their prescribing after pharmaceutical company interaction?, f) do  
NPs recognize the influence pharmaceutical company interactions have on their  
prescribing practice and how does that relate to their perception of the influence?,  g)  
what is the importance of sample availability to the NPs practice?, h) Do NPs believe it  
is appropriate to accept sample drugs for their patients?, i) how useful do NPs believe  
pharmaceutical company information is to their practice? j) Do NPs believe  
pharmaceutical companies play an important role in patient and NP education?, k)  
Would NPs continue to see pharmaceutical company representatives if they provided 
items or information the NP viewed as useful to their practice?, and l) are NPs  
behaviors congruent with their beliefs about accepting pharmaceutical company  
promotions, products and gifts?, and finally, m) what, if any, influence does direct-to- 
consumer marketing have on NPs prescribing practice?   
 The dependent variables were defined as (a) self-reported prescribing beliefs and 
practices of NPs, and (b) NPs self-reported belief in the accuracy and usefulness of 
product information received through educational programs, promotions and gifts.   
Independent variables were defined as (a) number of encounters with pharmaceutical 
company representatives,  (b) receipt of pharmaceutical samples for professional or 
personal use, (c) receipt of other gifts including textbooks, medical products and supplies 
such as stethoscopes, penlights, patient teaching materials and food.   
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Data from this correlational study were analyzed using the Statistical Package for 
the Social Sciences (SPSS) version 10.    The following hypotheses were tested: (a) More 
frequent interactions with pharmaceutical company representatives will result in greater 
perceived influence on the prescribing practices of the nurse practitioner and  (b) The 
geographic location of the NPs practice (urban, suburban or rural) will influence the 
number of self-reported interactions with pharmaceutical company programs, promotions 
and gifts.  
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CHAPTER 4: ANALYSIS OF THE DATA 
Introduction 
 The purpose of this study was to assess the correlation between Nurse Practitioner 
(NP) self-reported prescribing behaviors and practices and self-reported pharmaceutical 
company interactions.     
Data for this study were obtained using an original survey derived from review of 
the literature and expert review.  The statistical analysis presented in this research study 
uses the data obtained from the sample population (certified nurse practitioners) to infer 
whether or not the hypotheses should be accepted or rejected (Bluman, 1992).  Data 
analysis is descriptive in order to organize, summarize, and understand the self-reported 
influences on  NPs prescribing practices as they relate to pharmaceutical company 
interaction.  Findings are reported in the following order: Survey demographics, 
demographics of NP sample population, survey analyses, hypotheses, and questions. 
Survey Demographics 
A total of 1,000 surveys were sent by U.S. mail to certified NPs in the states of 
Pennsylvania, New York and Florida.  The first mailing was sent on February 15, 2004 
with a follow-up mailing to the same 1,000 NPs on March 15, 2004.  A deadline of April 
30, 2004 was established for receiving survey returns. Participants were offered two 
incentives to complete the survey.  1) A copy of the survey results could be requested 
(372 respondents requested survey results) and 2) the opportunity to be entered into a 
drawing for one of four Amazon.com gift certificates for $50.00.   The drawing for the 
gift certificates occurred on May 15, 2004 and winners received their certificates by June 
1, 2004.    A total of 473 certified nurse practitioners from three states returned their 
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surveys; 393 completed the survey and 58 indicated that had not prescribed medications 
for patients or had not practiced during the last five years.  A gross response rate of 56% 
was achieved for the mailed sample.  Of the 1,000 surveys sent, 149 were returned as 
undeliverable due to change of address or unknown at that address.  Four hundred fifty 
one surveys were returned by the closing date for data collection, with 393 surveys 
complete and used in data analysis.  An additional 58 surveys were returned but not used 
for data analysis as the NP indicated that he or she had not prescribed medication for 
patients or practiced as an NP within the five years preceding the survey, a survey 
response option.  Twenty-two surveys were returned after the closing date for data 
collection.  These 22 surveys were not used for the study.  Table 11 illustrates survey 
responses. 
 
Table 11 - Survey Responses 
 
Total Surveys 
Mailed 
Undeliverable Returned after 
Closing Date 
Not practiced 
within 5 years 
Used in Data 
Analysis 
1,000 149 22 58 393 
 
 
There are a variety of opinions in the literature about acceptable levels of mailed 
survey response rates ranging from 20% to 90% (Aday, 1996; Benke & Hermanson, 
1987; Creative Research Systems, 2002; Schloss & Smith, 1999; Statistical confidence in 
a survey, 2003; Smith, 2002; Wiersma, 2000).   This study utilized the Creative Research  
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Systems sample size calculator (Creative Research Systems, 2002).  The sample size 
calculator demonstrates that a total of 377 completed, returned, surveys would provide a 
95% confidence level with a confidence interval of P < .05 for this survey.  A completed 
survey response rate of 393 surveys was obtained.  However, with a response rate of 
56%, data analysis must take into account the potential for non-respondent bias, the 
potential that some percentage of the non-respondent population may not have responded 
to the survey questions in the same way as the 56% of respondent surveys. 
Sample Population Demographics 
An almost equal geographic distribution of respondents occurred among the 393 
surveys used with 34% (n=134) respondents from New York State, 32% (n=124) 
respondents from Florida and 31% (n=122) respondents from Pennsylvania.  Thirteen 
respondents (3.3%) did not have their primary practice site in Pennsylvania, New York or 
Florida, however, they do live in those states.  These 13 surveys were used in data 
analysis.    
The majority of respondents (n=202) practice in urban settings while 139 practice 
in suburban settings and 52 practice in rural settings, as defined by the NP.  Table 12 
displays the respondents’ state and location of primary practice. 
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Table 12 - State and Location of primary practice 
 
p
73 40 84 5 202
36.1 19.8 41.6 2.5 100.0
39 52 41 7 139
28.1 37.4 29.5 5.0 100.0
12 30 9 1 52
23.1 57.7 17.3 1.9 100.0
124 122 134 13 393
31.6 31.0 34.1 3.3 100.0
Count 
 
Percent   
Count 
 
Percent 
Count 
 
PPercent 
Count 
 Percent 
Urban 
Suburban 
Rural 
Clinical 
practice 
site 
Total 
FL PA NY Othe
State
Total
 
 
 
The majority of the survey respondents were female (94%).  This is reflective of 
the nursing profession as a whole, which is predominately female.   Table 13 displays the 
age and gender of the respondents.  The mode was 31 to 40 years of age with no 
respondents over the age of 60 years. 
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Table 13 - Demographics – Gender and Age  
 
Gender * Age Crosstabulation
84 195 87 4 370
21.4% 49.6% 22.1% 1.0% 94.1%
5 13 5 23
1.3% 3.3% 1.3% 5.9%
89 208 92 4 393
22.6% 52.9% 23.4% 1.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Female
Male
Gender
Total
20-30 31-40 41-50 51-60
Age
Total
 
 
 
 
Survey participants were asked to indicate their highest level of education and 
years of both nursing and NP experience.  The majority of survey respondents (85%,  
n= 336) were MSN prepared.   Table 14 displays the educational preparation of the 
survey respondents. 
 
 
Table 14 - Educational Preparation of Survey Respondents. 
 Degree
17 4.3 4.3 4.3
11 2.8 2.8 7.1
24 6.1 6.1 13.2
336 85.5 85.5 98.7
3 .8 .8 99.5
2 .5 .5 100.0
393 100.0 100.0 
Diplom
Associate 
DBachelors 
DMaster 
DDoctorat
Post-Master's 
C ifi dTotal
Valid 
Frequency Percent Valid 
P
Cumulative
Percent
 
    
Over one third of survey respondents (35.6%, n-140) had 11 to 15 years of 
nursing experience, and 77.1% had five or less years of NP experience (n-303).  Table 15 
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shows the total years of nursing experience, cross-referenced with the number of years of 
NP experience, for the sample population.   
 
Table 15 – Demographics: Total Years of Nursing and NP experience 
  
Years of NP experience * Total years of nursing experience Crosstabulation
88 98 93 24 303
22.4% 24.9% 23.7% 6.1% 77.1%
13 38 15 66
3.3% 9.7% 3.8% 16.8%
9 13 22
2.3% 3.3% 5.6%
2 2
.5% .5%
88 111 140 54 393
22.4% 28.2% 35.6% 13.7% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
Count
% of Total
1-5
6-10
11-15
16-20
Years of NP
experience
Total
1-5 6-10 11-15 16-20
Total years of nursing experience
Total
 
 
 
 
Respondents were also asked to identify the patient population with whom they 
most frequently practice.  If the NP practiced with more than one population type they 
were asked to identify the type of practice in which they spent most of their clinical time 
(what was their major patient population).  Each respondent selected only one patient 
practice population.   The largest group of respondents (n=105, 26.7%) was NPs working 
in adult specialty practices such as cardiology, orthopedics, dermatology, surgery and 
others.  NPs working in women’s health care were the second largest response group at 
20.6% (n=81) while NPs working in family practices and pediatric specialty practices 
made up the third largest group with 45 respondents (11.5%) each.  These four practice 
populations account for 70.3% of the total responses.  Figure 3 displays primary practice 
populations of the NPs who responded to the survey. 
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Figure 3 - Primary Patient Practice Populations 
 
 
 
 
The survey sample population was obtained from the mailing lists of two national 
NP certifying bodies, ANCC and NCC.  All survey respondents were certified in at least 
one specialty area and 7% of respondents (n=29) held more than one national 
certification.    There was a preponderance of Family Nurse Practitioners (FNPs) 
responding to the survey (36.1%) with 142 respondents.   Women’s Health Care NPs 
(WHCNPs) were the second largest group represented with 87 returned surveys (22.1%) 
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and Adult Primary Care NPs (APCNPs) with 80 respondents (20.4%) rounded out the top 
three represented groups.  Table 16 displays the specialty practice certification type of the 
respondents. 
 
Table 16 - Specialty Practice Certification Type of the Respondents 
 
National Certification Respondents Percent of 
Respondents 
Family NP 142 36.1% 
Women’s Health Care 87 22.1% 
Adult Primary Care 80 20.4% 
Neonatal 53 13.5% 
Adult Psychiatric 16 4.1% 
Geriatric 16 4.1% 
Acute Care 15 3.8% 
Family Psychiatric 2 0.5% 
Other 14 3.6% 
 
 
Survey Analyses 
Hypotheses 
 
HO 1  
 More frequent interactions with pharmaceutical company  
representatives will result in greater perceived influence on the prescribing practices of  
the nurse practitioner. 
To address this hypothesis, it was necessary to determine the correlation between the 
self-reported frequency of interaction between NPs and pharmaceutical company 
representatives (survey question 11) and the NPs self-reported 
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belief about pharmaceutical company influence on prescribing behavior and 
practice (survey question 1).       
Responses to survey question 11 indicated the monthly frequency with which NPs 
interact with pharmaceutical company representatives at: clinical practice, at education 
meetings, continuing education conferences, grand rounds or other events.  Sixty-eight 
percent of respondents (n=267) reported that they interacted with pharmaceutical 
representatives one to four times monthly, 16%  five to nine times monthly, 5%  ten to  
fourteen times monthly and 5% interact with pharmaceutical representatives more than 
fourteen times monthly.  Twenty-four NPs (6%) reported no monthly interactions.   
Figure 4 displays the frequency of reported NP-Pharmaceutical company interactions 
monthly. 
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Figure 4  - NP-Pharmaceutical Company Monthly Interactions 
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Responses to survey question 1 indicate the degree to which respondents believe 
that their prescribing practices are influenced by pharmaceutical company sponsored gifts 
such as pens, note pads, textbooks; promotions such as drug samples for patients;  
educational programs at conferences, dinners or practice sites?.   Fifty one percent of 
respondents (n=201) indicated that their prescribing practices and behaviors are 
influenced by pharmaceutical company interactions while 48.3%  (n=190) indicated they 
were not influenced.  Two respondents (0.6%) wrote in that they are sometimes 
influenced and but did not circle a response number.  These data can be seen in table 17. 
 
 
Table 17 - Frequency of Interaction and Belief of Company Influence 
 
 
 Belief of company influence (q1) * Frequency of interaction with representatives  (q11) 
17 137 21 8 7 190
4.3% 34.9% 5.3% 2.0% 1.8% 48.3%
7 129 40 13 12 201
1.8% 32.8% 10.2% 3.3% 3.1% 51.1%
1 1 1
.3% .3% .3%
1 1
.3% .3%
24 267 62 21 19 393
6.1% 67.9% 15.8% 5.3% 4.8% 100.0%
Count 
% of Total
Count 
% of Total
Count 
% of Total
Count 
% of Total
Count 
% of Total
no 
yes 
sometimes 
both 
Belief of 
company 
influence 
(q1) 
Total 
0 1-4 5-9 10-14 >14 
Frequency of interation with representatives (q11) 
Total
 
 
 
Spearman Correlation was significant for this question (p= <0.001) indicating a 
strong correlation between interaction with pharmaceutical companies and the NPs 
beliefs about being influenced by those interactions.  Chi Square was also significant for 
this question  X2(4, N = 393) p = <0.001.  
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Among NPs reporting no monthly interactions with pharmaceutical company 
representatives, some may have annual encounters, up to 11 a year, at professional 
education programs, dinners or other sponsored events.  Therefore, some of these NPs 
may actually interact with pharmaceutical company representatives less than monthly, 
but still encounter and interact with them several times a year.    
Sixteen of the 24 NPs who indicated they do not interact with representatives 
monthly stated they work in neonatal intensive care units and have minimal or no access 
to pharmaceutical representatives.  One neonatal NP wrote that instead of seeing 
pharmaceutical company representatives she saw baby formula representatives, which 
she considered very similar.   
Further analysis was undertaken to determine if there were differences between  
those who interact with pharmaceutical representatives and those who reported no 
interaction.   The data set was collapsed from four groups to two groups, representing 
those NPs who stated they never interacted with pharmaceutical companies (n=24, 6.1%)  
and those who do interact with pharmaceutical companies (n=369, 94%).  This data is 
displayed in table 18. 
 
Table 18 – NP Interaction with Representatives   
 
 
24 6.1 6.1 6.1 
369 93.9 93.9 100.0 
393 100.0 100.0
No interaction 
Have interaction 
Total 
 
Frequency Percent Valid Percent
Cumulative 
Percent 
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The respondents self-reported beliefs about pharmaceutical company influence on 
their prescribing behavior, survey question 1, was correlated to survey question 11, the 
average number of reported interactions.  Statistical analysis was performed using Chi 
Square.  For those NPs who stated they have pharmaceutical company interaction 
(interaction > 1 per month), there is no statistically significant difference in whether or 
not they believed they are influenced by the encounters X2(3, N = 393), p= 0.231.  
Therefore, the hypothesis, more frequent interactions with pharmaceutical company 
representatives will result in greater perceived influence on the prescribing practices of 
the nurse practitioner is rejected. 
HO 2 
The geographic location of the NPs practice (urban, suburban or rural) will 
influence the number of self-reported interactions with pharmaceutical company 
programs, promotions and gifts. 
        Survey question 18 asked the NPs where is your primary clinical practice 
site located?  (If more than one site, please select the site in which you see the 
most patients.   Correlation of the number of pharmaceutical company interactions 
and the NPs clinical practice site (urban, suburban, rural) was then run.  Spearman Rho 
found a statistically high level of significance (p= 0.008) between the location 
of the clinical practice site and number of pharmaceutical company interactions.  For  
respondents who have one or more pharmaceutical company interactions monthly, the 
number of urban NPs who have pharmaceutical company interaction is statistically 
significant (urban > rural  p= <0.001; urban  >suburban  p= 0.004).  Thus, urban NPs  
have more pharmaceutical company interactions monthly than suburban NPs and both  
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urban and suburban NPs have more monthly pharmaceutical company interactions than  
rural NPs.  Therefore, the hypothesis, the geographic location of the NPs practice (urban, 
suburban or rural) will influence the number of self-reported interactions with 
pharmaceutical company programs, promotions and gifts, is accepted. 
Interestingly, for NPs who reported no pharmaceutical company interaction, a statistically 
significant number of urban NPs had no interaction than either suburban or rural NPs  
(urban > suburban p= 0.022; urban > rural   P=  <0.001).  This may be due in part to 
populations of NPs who work in isolated urban settings such as intensive care units,  
operating suites and, neonatal ICUs, where pharmaceutical company interaction is 
restricted by the patient care environment.   
Questions 
 The following is analysis of the data tool grouped according to topic. 
  
A. Questions 5 and 11- Change or modification in prescribing after pharmaceutical 
company interaction 
In order to identify whether the number of NP-pharmaceutical company 
interactions has any relationship to the NPs prescriptive changes, survey question 5,  have 
you ever modified or changed your prescribing after a pharmaceutical company 
interaction and survey question 11, average number of monthly pharmaceutical company  
interactions were correlated.  Eighty percent of respondents (n=313) said they had 
changed or modified their prescribing practice after a pharmaceutical company encounter 
while 20% of respondents (n=80) said they had never changed or modified their 
prescribing practice after such encounters.  Spearman correlation shows statistical 
significance (p=< 0.001) indicating a strong relationship between the number of 
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pharmaceutical company encounters and the NPs self-reported change or modification in 
their prescribing behavior.  
The data set was collapsed from four groups to two groups, to determine if there 
were differences between NPs who stated they never interacted with pharmaceutical 
companies (n=24, 6.1%)  and those who do interact with pharmaceutical companies 
(n=369, 94%).   
Correlation between the 94% of respondent NPs who have pharmaceutical 
company interaction and their self-reported change or modification in prescribing after an 
interaction shows that 77.6% (n= 305) of the respondent NPs sometimes change their 
prescribing after pharmaceutical encounters while 20.4% (n = 80) never change their 
prescribing practice after an encounter and 2% (n = 8) report always changing their 
prescribing practice after a pharmaceutical company sponsored interaction (more NPs 
change sometimes than never or always).  More NPs never change their prescribing 
practice after an encounter than always change (p= < 0.001) and there is no statistically 
significant difference in the other groups, category 2 & 3 (p = 0.070). 
B. Questions 5 and 1 - Change in prescribing versus perceived influence    
Data were analyzed identity if any correlation exists between the NPs self-
reported change or modification of prescribing practice (survey question 5,)  and the  NPs 
belief about pharmaceutical company influence on their prescribing practice (survey 
question 1).   
Eighty percent of respondents (n=313) said they had changed or modified their 
prescribing practice after a pharmaceutical company interaction while 20% of 
respondents (n=80) said they had never changed or modified their prescribing practice 
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after encounters.  However, only 48% of respondent NPs stated they did not feel they 
were influenced by pharmaceutical encounters while 51% felt they were influenced 
(Table 19). 
 
Table 19 – Belief about Influence and Prescribing Change after Encounters 
 
 Believing of Company Influence * Prescribing changes After 
C t b l ti
61 82 45 2 190
15.5% 20.9% 11.5% .5% 48.3%
19 90 88 6 203
4.8% 22.9% 22.4% 1.5% 51.7%
80 172 133 8 393
20.4% 43.8% 33.8% 2.0% 100.0
%
Coun
t% of 
T lCoun
% of 
T lCoun
t% of 
T l
no
yes
Believing of 
influenc
Total
Never 2 3 Always
Prescribing changes 
Total
 
 
Chi-square analysis demonstrates this significance (p= <0.001).  Further 
examination with Wilcoxon Signed Ranks Test validates this significance (p= <0.001)  
indicating that the number of NPs who actually change or modify their prescribing 
behavior after one or more pharmaceutical company encounters is significantly greater 
than the number of NPs who believe they are not influenced by those encounters.  
 When asked about perceptions of influence by pharmaceutical companies on 
other NPs prescribing behaviors, 274 NPs (69.7%) reported believing other NPs are 
influenced by their pharmaceutical company interactions.  This is in contrast to the 203 
NPs (51.7%) who believe they are influenced by these same encounters.  Chi Square 
shows this 18% discrepancy in NP beliefs to be statistically significant (p= < 0.001).    
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The comparatively small number of NPs in this study who stated they had never 
changed their prescribing practice after pharmaceutical company encounters (6.1%, 
n=24) may be different in other geographic regions of the country. 
C. Question 6 - Reasons for prescribing change after pharmaceutical company 
interaction 
Respondents were asked to specify why they had changed or modified their 
prescribing practice after attending a pharmaceutical company sponsored event from a 
list of eight possible reasons.  Most NPs selected more than one reason for changing or 
modifying their prescribing with a mean of 4.478 reasons.  The most frequently cited 
reason was more ‘effective for the problem’ (74.6%, n= 293), followed by ‘as effective 
with less side effects’ (71.2%, n=280), and ‘as effective and less costly’ (68.4%, n=269) 
(figure 5). 
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Figure 5 – NPs reasons for prescriptive change after pharmaceutical company 
interaction                                                                                                                   
 
Many NPs wrote comments, as invited, at the end of the survey and some of these 
pertained to changes or modifications in practice after interactions.  Six write-in 
comments addressed the fact that samples are not allowed in their practice site.  Twenty-
nine of the 36 write-in comments mention how important it is to have samples available 
in the office.    The complete list of write-in comments can be found in Appendix F.   A 
few of the write-in comments addressing the importance of sample availability follow in 
table 20:   
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Table 20 – Sample Survey Comments  
 
Survey 
Number 
Comment Practice Type 
29 I also volunteer at a clinic that relies heavily on 
samples with limited resources available.  Sample 
availability strongly affects what the patent is 
given (as does cost). 
Occupational 
Health 
70 Samples are sometimes the only way my patients 
have of receiving needed meds.  I feel fortunate 
that we can provide meds when our patients can’t 
afford them 
Adult Primary Care
186 I run a free family practice clinic 1 day a week 
and depend on drug reps samples to give away 
Geriatric Long 
Term Care 
143 Cost effective medication selection is important 
in the population of clients I see.   
Adult Primary Care
190 I use samples as a trial for side effects before pt’s 
purchase the full script 
Family Practice 
39 Practices influenced because I am more aware of 
their products 
Cardiology 
263 My patients however must have free samples 
until we wake up and provide universal health 
insurance. Samples are great for the uninsured 
Geriatric primary 
care 
376 Samples are great for the uninsured Geriatrics 
307 Drug reps do not visit NICUs [neonatal intensive 
care units] very frequently.  We do tend to see 
formula reps more often (I consider these 
extremely similar) 
Neonatal ICU 
 
 
  Other issues cited as influencing prescribing practice after pharmaceutical 
company interaction included:  1) third party payers (insurance carriers) who only 
allow certain medications to be prescribed under their coverage plans, 2) hospital 
or institutional formularies, which identify which drugs, are able to be prescribed in 
the facility and are carried by the institutions’ pharmacy 3) influence such as when  
the NP is more aware of the pharmaceutical products because of an 
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interaction, 4) cost to the patient, and 5) lack of patient health insurance to pay for 
medications.   
D. Question 3b and 6 - Importance of Sample Availability 
    
NPs were asked in survey question 3b, when selecting a prescription drug for 
your patients, how important is having samples available in the office when choosing 
which drug to prescribe?    Sixty percent of the respondents stated that having samples 
available in the office was very important or somewhat important in choosing which 
prescription drug to select for their patients (figure 6).  This is reflective of the number of 
write-in comments on the survey, addressing the importance of samples. 
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Figure 6 – Importance of Sample Availability 
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Survey question 6 asked, if you have ever changed or modified your prescribing 
practice after a pharmaceutical company sponsored event, which of the following factors 
affected your decision?  Having samples available in the office was choice 6f.   Fifty five 
percent of the respondents (n=217) stated that they had modified or changed their 
prescribing practice after a pharmaceutical company sponsored event because sample 
medications were available in the office for their patients. 
E.  Question 4 - Appropriateness of accepting sample drugs for patient use 
Survey question 4 asked the NP to rate the appropriateness of accepting sample 
drugs for your patients.   Only 17% (n=67) of NPs felt it inappropriate or very 
inappropriate to accept prescription medication samples for their patients while 82% of 
the respondents felt it appropriate or very appropriate to accept samples for patient use.   
 The number of write-in comments that address the issue highlights the importance 
of free sample medications in the practice site.  Comments such as “sample availability 
strongly affects what the patient is given “,  “free samples for geriatric patients have been 
helpful in compliance with medications for those who are unable to afford the 
medications”, “samples are great for the uninsured”, “I prefer to try a patient on samples 
before they spend their own money on a medication that they may not be able tolerate”, 
“I think the positive aspect of the drug companies is the free sample for patients without 
prescription coverage.  I find this to be very helpful”, “samples are important to our 
practice as many of out patients can’t afford the needed meds without the samples”,  “I 
would say I am not influenced by pens, notepads, dinners in the office, but I am 
influenced by what samples are available in the office”, “Most of patients I see have no 
insurance. I rely on samples” and simply, “samples have been very beneficial”.  
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  F.  Question 10a - Usefulness of pharmaceutical company information  
 
 Survey question 10a asked the NP to indicate strength of agreement or 
disagreement with the statement pharmaceutical representatives provide useful 
information about pharmaceutical products.  Eighty eight percent (n=348) of respondents 
agreed or strongly agree that pharmaceutical companies provide useful information about 
pharmaceutical products.   
G.  Question 10d - NPs perception of bias in pharmaceutical company information 
Survey question 10d asked the NP to indicate strength of agreement or 
disagreement with the statement pharmaceutical representatives provide unbiased 
information about pharmaceutical products.  Only 15% of respondents agreed or strongly 
agreed that the information provided by pharmaceutical company representatives is 
unbiased.  Eighty five percent of respondents felt the pharmaceutical company 
information   was biased to some degree.  This finding is further illustrated by survey 
comments such as:  “I do feel this information is biased (naturally) and this is why I do 
not let it influence my prescribing”, “I am cautious about info given by sales 
representatives.  Most do not have medical or clinical background and parrot information 
they have been fed by marketing divisions”, “Reps are biased”, “Sometimes reps present 
a biased viewpoint pointing only to the positive studies/aspects of their drug”,   “The drug 
reps often flash research studies that may or may not be valid as a way to persuade me to 
prescribe”, and “I think NPs  are smart enough to use reps stuff to better serve patient 
populations, staff, etc,  and not be influenced by their used car salesman tactics”.  With 
the above comments in mind, the question arose, who are the 15% of NPs who believe 
pharmaceutical company information is unbiased?  Correlation of those NPs who agreed 
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or strongly agreed that pharmaceutical company information is unbiased with practice 
site, gender and specialty practice produced the following results.   
A statistically significant number of females believed the information to be 
unbiased (p= <0.001) when compared with their male counterparts. More urban and 
suburban NPs believed the information to be unbiased than rural NPs (urban and rural p= 
<0.001, suburban and rural p= <0.002).  There was no significant difference between 
urban and suburban NP populations (p=0.555).   Looking at practice populations,  the 
Spearman analysis for this correlation was not significant due to low numbers in some of 
the cells.     
H. Question 10c - Pharmaceutical company role in education 
Survey question 10c then asked the NPs to indicate strength of agreement or 
disagreement with the statement pharmaceutical representatives provide an important 
education function.  Eighty two percent of the respondents agreed or strongly agreed that 
pharmaceutical companies provide an important education function.  This data is 
corroborated by the NPs comments on the survey, some of which were very specific.  “I 
believe samples and educational materials are extremely useful”,  “I like the dosing charts 
for antibiotics”,  “I find pharmaceutical reps very helpful and informative”,  “I enjoy 
interacting with most reps because they have the ability to answer specific questions or 
get the answer in an efficient manner”,  “I enjoy the updates and articles the reps bring”,  
“I have to admit a free lunch brought to me on a busy day is nice sometimes”, “I also get 
patients signed up for pharm company free medication programs”, “Drug reps sponsored 
activities often provide venue for learning, CEU (continuing education units) and 
networking”,  I believe that pharmaceutical reps are helpful in providing information and 
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samples to my patients”, “We do see reps occasionally for education/lectures…”, and 
finally, “Since starting to practice I have learned a great deal by attending drug company 
sponsored educational activity.  I have found this educational help invaluable…”.   
However, 18% of the respondents felt pharmaceutical companies did not provide an 
important education function.  Who are the NPs who believe this?  Correlation of the 
three factors gender, practice site and specialty practice type revealed the following 
significant finding.   More rural NPs believe pharmaceutical companies provide an 
important education function than either urban or suburban NPs (urban > rural  p= 
<0.001, suburban > rural p=0.001).   There was no statistically significant difference 
between urban and suburban (p= 0.051) NP populations, gender or practice populations.  
 I.  Question 13 - Preparation in NP Education Program 
 NPs were asked if they felt they were adequately prepared during their initial NP 
program to interact with pharmaceutical company representatives.  Survey question 13 
asked the NP to indicate their level of agreement or disagreement with the statement 
during my nurse practitioner education program I was given adequate information  
concerning how a nurse practitioner should interact with pharmaceutical representatives 
so that I could make informed prescribing decisions.  Sixty two percent of the 
respondents strongly disagreed with the statement and a total of 87% of the NPs 
disagreed or strongly disagreed that they were given adequate information in their NP 
education program (figure 7). 
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Figure 7 – NP program provided adequate information about NP-pharmaceutical 
company interaction 
 
 
 
J.  Question 9 - Repeat Encounters 
Question 9 asked, if you received an item useful to you in your practice such as 
an educational monograph, product information, patient samples, note pads or pens, 
from a pharmaceutical representative, how likely would you be to see that 
pharmaceutical representative again?   Eighty nine percent (n=350) of the respondents 
stated they would be likely or very likely to see a pharmaceutical representative again if 
they had provided an item useful to them in their practice.  Less than 9% stated it was 
somewhat unlikely they would see the representative again and only 2% stated it was not 
very likely they would see the representative again in their practice.   
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K. Question 8 – Gifts accepted by NP respondents 
Question 8 asked the respondents; have you ever received any of the following 
promotional gifts or products from pharmaceutical representatives in you clinical 
practice site, at an educational dinner or luncheon, grand rounds, local or national 
conferences or by mail?   Office supplies was the most frequently accepted gift with 99% 
(n = 389) of NPs acknowledging they accepted small office supplies such as pens, coffee 
mugs, paper clips or notepads.  Educational materials for patients was second with 95% 
(n = 374), food brought to the clinical practice site by pharmaceutical representatives was 
third with 94% (n = 371)  and food at educational meetings rounded out the top four gift 
with 78% (n = 341).  Figure 8 illustrates the remaining responses. 
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Figure 8 -  Gifts and Promotions Received by NP Respondents 
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L. Questions 4 and 8 - Beliefs about appropriateness of accepting promotions, 
products, and gifts versus behaviors related to accepting gifts                  
 
 
 NPs were asked in survey question 4 to rate their opinion of the appropriateness 
of accepting specific promotional products, gifts and events related to their practice.  
Survey question 8 asked the NPs to identify which, if any, of the same list of promotional 
products, gifts or events they had actually accepted.  A correlation was performed for the  
two questions.   A two-tiered Spearman’s rho found the correlation to be statistically 
significant for all items identified (Table 21).    
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Table 21 – Beliefs versus behavior regarding accepting pharmaceutical company  
       promotions, products and gifts 
 
 
 
 
Item 
 Office 
Suppy 
Food in 
office 
Antibiotic 
guides, etc. 
Food at 
meeting 
Sample drugs 
patients 
Trips & 
events 
Honoraria Sample 
drugs 
Personal 
Patient educations 
materials 
Sample 
drugs 
Family 
Office 
Supplies 
Correlation 
Coefficient 
Sig (2-tailed) 
-0.14 
 
0.004 
         
Food in office Correlation 
Coefficient 
Sig (2-tailed 
 -0.23 
 
0.000 
        
Antibiotic guides, 
etc 
Correlation 
Coefficient 
Sig (2-tailed 
  -0.14 
 
0.007 
       
Food at meetings Correlation 
Coefficient 
Sig (2-tailed 
   -0.22 
 
0.000 
      
Sample drugs 
patients 
Correlation 
Coefficient 
Sig (2-tailed 
    -0.29 
 
0.000 
     
Trips & events Correlation 
Coefficient 
Sig (2-tailed 
     -0.17 
 
0.000 
    
Honorarium Correlation 
Coefficient 
Sig (2-tailed 
      -0/18 
 
0.000 
   
Sample drugs 
Personal 
Correlation 
Coefficient 
Sig (2-tailed 
       -0.33 
 
0.000 
  
Patient 
educations 
materials 
Correlation 
Coefficient 
Sig (2-tailed 
        -0.20 
 
0.000 
 
Sample drugs 
Family 
Correlation 
Coefficient 
Sig (2-tailed 
         -0.29 
 
0.000 
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These findings demonstrate that NPs’ beliefs about accepting pharmaceutical 
company promotions and gifts are not congruent with their actions in accepting these 
items.   Although the correlations are small, the results are strongly significant. 
M.  Question 3b and 6e  - Direct –to-Consumer Marketing 
 Finally, the issue of the potential influence of direct-to-consumer marketing on 
the NPs practice was addressed.  Survey question  3b asked the NP to indicate how 
important a patient’s request for a specific drug is when choosing which drug to 
prescribe.  Sixty two percent of the respondents stated that a patient’s request for a 
specific drug was very important or somewhat important in their prescriptive decision-
making while 37% of respondents felt it was not important to their prescriptive 
decisions.  Survey question 12 asked during the last year, how many times a month 
have you had a patient request a specific drug because they have seen it advertised on 
television, billboards, magazines or other media sources or because a friend or 
relative suggested it?  Eighty nine percent of respondents stated they had had at least 
one patient request a month for a specific drug, and frequently many more, as a result 
of direct to consumer marketing (figure 9). 
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Figure 9 – Number of Patient Requests Monthly for Specific Drugs 
 
 
 
Survey question 6 then asked the NP if you have ever changed or modified 
your prescribing practices after attending a pharmaceutical company sponsored 
event, which of the following factors affected your decision?  Thirty seven percent 
(n=146) of the NPs stated they had changed or modified their prescribing practice 
because the patient requested the drug. 
  Further analysis examined the correlation between the importance of patient 
request for a specific drug and the NPs change or modification in practice due to a 
patient request and after a pharmaceutical company interaction.  Spearman analysis for 
this correlation was not significant due to low numbers in some of the cells.    
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Chapter Summary 
HO 1 
Results of data analysis reject hypothesis 1, more frequent interactions with 
pharmaceutical company representatives will result in greater perceived influence on 
the prescribing practices of the nurse practitioner.   NPs who have some 
pharmaceutical company interaction (interaction > 1 per month), show no statistically 
significant difference in whether or not they believe they are influenced by 
pharmaceutical company interactions.  An unexpected finding is that the number of 
NPs who actually change their prescribing practice after a pharmaceutical company 
interaction is significantly greater than the number of NPs who believe they are 
influenced by the encounter.   
HO 2 
  Hypotheses two, the geographic location of the NPs practice (urban, suburban 
or rural) will influence the number of self-reported interactions with pharmaceutical  
company programs, promotions and gifts, is accepted. Urban NPs have more 
interactions with pharmaceutical representatives than suburban or rural NPs. However, 
more urban NPs also report no pharmaceutical company interaction than either  
suburban or rural NPs.  This may be due in part to NPs who work in isolated urban 
settings such as intensive car units,operating suites and neonatal ICUs, where  
pharmaceutical company interaction is restricted by the patient care environment. 
Change or Modification in Prescribing after Pharmaceutical Company Interaction. 
Correlation between the 94% of respondent NPs who do have 
pharmaceutical company interaction and their self-reported change or 
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modification in prescribing shows that more NPs sometimes change their 
prescribing after pharmaceutical encounters than never change their practice or   
always change their practice . 
Change in Prescribing Practices versus perceived Influence. 
Although only 20% of the respondents stated they had never changed or 
modified their prescribing practices after a pharmaceutical company interaction, 48% 
of the NPs felt they were not influenced by those interactions.   The number of NPs 
who actually change or modify their prescribing behavior after one or more 
pharmaceutical company encounters is significantly greater than the number of NPs 
who believe they are not influenced  by those encounters. 
Reasons for Prescribing Change after Pharmaceutical Company Interaction. 
Most NPs reported more than one reason for changing or modifying their 
prescribing with a mean of 4.478 reasons.  The most frequently cited reason was 
‘more effective for the problem’ (74.6%, n= 293), followed by ‘as effective with 
less side effects’ (71.2%, n=280), and ‘as effective and less costly’ (68.4%, 
n=269). 
Importance of Sample Availability. 
Sixty percent of the respondents stated that having samples available in the 
office was very important or somewhat important in choosing which prescription drug 
to select for their patients.  Fifty five percent of respondents stated that they had 
modified or changed their prescribing practice after a pharmaceutical company 
sponsored event because samples medications were available in the office for their 
patients.  
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Appropriateness of Accepting Sample Drugs for Patient Use. 
Eighty two percent of respondents felt it appropriate or very appropriate to 
accept samples for patient use.   
Usefulness of Pharmaceutical Company Information. 
Eighty eight percent of respondents agreed or strongly agreed that 
pharmaceutical companies provide useful information about pharmaceutical products.   
NPs Perception of Bias in Pharmaceutical Company Information. 
Eighty five percent of respondents felt pharmaceutical company information 
provided to them was biased to some degree.  More females believed the information 
to be unbiased than their male counterparts. More urban and suburban NPs believed 
the information to be unbiased than rural NPs .  
Pharmaceutical Company Role in Education. 
  Eighty two percent of respondents agreed or strongly agreed that 
pharmaceutical companies provide an important education function.  Eighteen percent 
of  respondents felt pharmaceutical companies did not provide an important education 
function.    More urban and suburban NPs believe pharmaceutical companies do not 
provide an important education function than rural NPs.  
Preparation in NP Education Program. 
Eighty seven percent of NPs felt they were not given adequate information in 
their NP education program concerning how a nurse practitioner should interact with 
pharmaceutical representatives in order to make informed prescribing decisions. 
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Repeat Encounters. 
Eighty nine percent of respondents stated they would be likely or very likely to 
see a pharmaceutical representative again if they had provided an item useful to them 
in their practice.   
Beliefs about Appropriateness of Accepting Promotions, Products, and Gifts versus 
Behaviors Related to Accepting Gifts 
 
 The findings demonstrate that NPs’ beliefs about accepting pharmaceutical 
company promotions and gifts are not congruent with their actions in accepting these 
items.    
Direct –to-Consumer Marketing. 
Sixty two percent of respondents stated that patient request for a specific drug 
was very important or somewhat important in their prescriptive decision-making.  
Eighty nine percent of NPs reported at least one patient request monthly for a specific 
drug as a result of direct to consumer advertising.  Thirty seven percent of the NPs 
stated they had changed or modified their prescribing practice because of a patient 
request for a specific drug. 
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Table 22 - Summary of Hypotheses and Survey Findings   
 
 
Hypothesis Results 
HO1.  More frequent interactions with pharmaceutical 
company representatives will result in greater perceived 
influence on the prescribing practices of the nurse 
practitioner.   
Rejected.  There is no statistically significant difference between 
NPs who have one pharmaceutical interaction and NPs who have 
multiple interactions monthly. 
HO2.  The geographic location of the NPs practice 
(urban, suburban or rural) will influence the number of 
self-reported interactions with pharmaceutical company 
programs, promotions and gifts. 
Accepted.  More urban NPs interact with pharmaceutical 
companies than  suburban or rural NPs.  However, more urban 
NPs also report no pharmaceutical company interaction when 
compared with either suburban or rural NPs (sub population of 
NPs in ICU’s, OR’s, neonatal units?) 
Questions Results 
A.  Change or modification in prescribing after 
pharmaceutical company interaction 
More NPs sometimes change their prescribing after pharmaceutical 
encounters (78%) than never change their prescribing (20%) or 
always change their prescribing (2%) after encounters 
B.  Change in prescribing practices versus perceived 
influence.   
The number of NPs who actually change or modify their prescribing 
behavior after one or more pharmaceutical company encounters is 
significantly greater than the number of NPs who believe they are not 
influenced  by those encounters 
C.  Beliefs about appropriateness of accepting 
promotions, products, and gifts versus behaviors related 
to accepting gifts 
Findings demonstrate that NPs’ stated beliefs about accepting 
pharmaceutical company products, promotions, and gifts are not 
congruent with their actions in accepting these items.    
D.  NPs reasons for prescribing change after 
pharmaceutical company interaction 
Most NPs reported more than one reason for changing or modifying 
their prescribing after pharmaceutical company interaction.  The most 
frequently cited reasons were; more effective for the problem, as 
effective with less side effects, as effective for the problem and less 
costly 
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E.  Importance of Sample Availability.   60% of the respondents stated that having samples available in the 
office was important in choosing which prescription drug to select for 
their patients.  55% percent of respondents stated that they had 
modified or changed their prescribing practice after a pharmaceutical 
company sponsored event because samples medications were 
available in the office for their patients 
F.  Appropriateness of accepting sample drugs for patient 
use 
82% of respondents felt it appropriate to accept samples for patient 
use.   
G.  Usefulness of pharmaceutical company information.   88% percent of respondents agreed that pharmaceutical companies 
provide useful information about pharmaceutical products.   
H.  NPs perception of bias in pharmaceutical company 
information.   
 
85% of respondents felt pharmaceutical company information 
provided to them was biased to some degree.  More females believed 
the information to be unbiased than males.   More urban and suburban 
NPs believed the information to be unbiased than rural NPs.  
I.  Pharmaceutical company role in education 82% of respondents agreed that pharmaceutical companies provide an 
important education function.    More rural NPs believe 
pharmaceutical companies provide an important education function 
than urban or suburban NPs 
J. Preparation in NP Education Program.   87% of  NPs felt they did not receive adequate information in their 
NP education program about NP-pharmaceutical company interaction 
K.  Gifts accepted by NP respondents 99% of NPs have accepted small office supplies such as pens, 
coffee mugs, paper clips or notepads.  95% accepted patient 
education materials, 94% accepted food brought to the clinical 
practice site by pharmaceutical representatives and 78% 
accepted food at educational meetings 
L.  Repeat Encounters.   89% of respondents stated they would be likely to see a 
pharmaceutical representative again if they had provided an item 
useful to them in their practice.   
M.  Direct –to-Consumer Marketing.   62% of respondents stated patient request for a specific drug was 
important in their prescriptive decision-making.   
89% of NPs reported at least one patient request monthly for a 
specific drug as a result of direct to consumer advertising.   
37% stated they had changed or modified their prescribing practice 
because of a patient request for a specific drug.   
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CHAPTER 5: SUMMARY AND IMPLICATIONS FOR FURTHER RESEARCH 
 
Introduction 
This study explored the influence of pharmaceutical company promotions, 
products and gifts on the self-reported prescribing beliefs and practices of certified nurse 
practitioners in three states.  The purpose of this study was to assess the correlation 
between Nurse Practitioner’s (NP) self-reported pharmaceutical company interactions 
and their self-reported prescribing behaviors and practices.  During the course of the 
study, several additional questions related to the NPs beliefs and practices were 
identified.   
At the beginning of this study, three stakeholder groups were identified: 
practicing NPs, NP faculty, and professional NP organizations including state boards of 
nursing.  Two additional stakeholder groups emerged during data analysis.  It was felt 
that the results of this study would 1) assist NPs in identifying influences that affect their 
personal prescribing practices, allowing them to modify their behaviors if warranted, 2) 
assist faculty in NP programs to identify influences on NPs prescribing practices and 
incorporate information about those issues when developing or revising curricula, and 3) 
begin to build a base of information about NPs prescribing practices that may be used by 
NP professional organizations in establishing guidelines for NP-pharmaceutical company 
interactions such as those developed by many physician organizations.  The two 
additional stakeholder groups identified are pharmaceutical companies and patients.   
Pharmaceutical companies spend millions of dollars annually on marketing their 
products.  Knowing how their marketing influences the NP population is important 
information.  Some patients, who are already beginning to notice pharmaceutical 
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company marketing through direct-to-consumer advertising and news media reports, will 
want to know how this marketing may affect their health care providers’ prescriptive 
choices and whether these promotions and gifts adversely, or positively, affect prescribed 
medications.  The conclusions and implications of this study will be addressed in relation 
to these five stakeholder groups. 
Practicing Nurse Practitioners 
 The first hypothesis asserted that the number of NP-pharmaceutical company 
interactions would affect the NPs beliefs about being influenced.  That is, the more NP-
pharmaceutical company interactions, the more likely the NP would be to believe that he 
or she was influenced by the interactions.  As would be expected, NPs who stated they 
had no pharmaceutical company interaction did not feel they were influenced at all.  
However, for the group that cited pharmaceutical company interaction (one or more 
encounters monthly) there was no significant relationship between the numbers of NP 
pharmaceutical interactions and the NPs beliefs about whether or not they were 
influenced.  It appears that an NP who has only one pharmaceutical company encounter 
is just as likely to recognize the potential influence of that encounter as an NP who has 14 
or more encounters monthly.  Conversely, the NP with multiple pharmaceutical company 
interactions is just as likely to be influenced, and not recognize that influence, as an NP 
who has only one encounter.   The quality of the encounter, perhaps the benefit the NP 
perceives from the encounter, may be more significant than the actual number of 
interactions between the NP and the pharmaceutical representative.  The perceived 
benefit may be a benefit to the practicing NP herself, or a perceived benefit to his or her 
patients.  Therefore, the more beneficial the NPs view the encounter, the more likely they 
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would be to interact with pharmaceutical representatives again.  This conclusion is 
corroborated by the 89% of respondents who stated they would be likely to see a 
pharmaceutical representative again if the representative had provided an item useful   in 
their practice.   
This study did not specifically ask the NP respondents to identify what 
pharmaceutical company products, promotions and gifts they found useful to their 
practice.   However, we may assume that the items NP respondents selected on the 
products, promotions and gifts list on the survey, and addressed by the write-in 
comments, could be considered useful to them.   These items range from office supplies 
such as pens and coffee cups to small, inexpensive, antibiotic guides, to patient education 
materials, educational dinners and lunches, granting of continuing education credits and 
sample medications for the office practice. Two items were identified as being highly 
valued by the NPs: sample medications for patients and pharmaceutical company 
education programs.  These two items, and other key findings, are discussed below. 
Sample Medications 
 The first item NPs identified as important to their practice was pharmaceutical 
samples for patients.  This finding was expected based on the review of the literature and 
are reflected in the NP respondents’ comments.  Reasons for sample use include:     
• NPs work with a high percentage of indigent and underserved populations, 
resulting in a high percentage of patients in the practice without prescription 
coverage 
• Samples are used as a method of trialing a specific drug, especially expensive 
drugs before writing a prescription for the patient to fill 
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• Sample medications are used as a means to start a patient on a drug immediately, 
perhaps antibiotics or pain medication, prior to the patient filling the written 
prescription, or for patients seen in an off-hours practice such as an emergency 
department or urgent care center 
• Samples are used as a source of short term medication dispensing for patients 
without health insurance who can not afford medications and who may be eligible 
for pharmaceutical company free medication programs for ongoing medication 
maintenance.   
 The comments from this survey are reflective of information in the literature.  
However, one implication that can be drawn from this data is that there are patient 
populations that NPs manage entirely on free sample medications.  The researcher 
expected that NPS working with indigent or under-insured populations would write 
prescriptions for low-cost generic drugs, rather than start patients on expensive, newer, 
sample drugs.  Indigent patients are those patients who fall through the cracks of the 
health insurance and coverage system and may not qualify for Medicaid, employer health 
benefits or pharmaceutical company free medication programs.    However, contrary to 
the researchers expectation, the data infer that a significant number of NPs manage 
patients on samples alone, rather than starting with low-cost generic drug choices.  The 
following are a few of the write-in comments about sample use and importance.  They 
come from NPs with a variety of practice populations in varying geographic locations. 
• Samples are sometimes the only way my patients have of receiving needed meds.  
I feel fortunate that we can provide meds when our patients can’t afford them 
• As a rural practice, many of my patients fall into the “working poor”, uninsured 
group.  I use free samples to treat those who cannot afford or at least to reduce 
their financial burden 
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• Believe me, I work in an underprivileged area and look to use samples for my 
patients who can’t afford meds 
• I give samples to patients who don’t even have medical assistance 
• Most of patients I see have no insurance. I rely on samples 
• Most NPs see large percentage of their practice with indigent or "working poor” 
populations.  If not for samples, many of these patients would not be able to start 
treatment due to expense 
• I run a free family practice clinic 1 day a week and depend on drug reps samples 
to give away 
• I like to have birth control pill samples for instructions and demonstration to the 
patient, as many insurance policies do not cover contraception for patients.  I like 
having samples for them.   
• Samples are important to our practice as many of our patients can’t afford the 
needed meds without the samples. 
• Samples are great for the uninsured 
• Samples provided for our clinic have truly been “life savers” for those oncology 
patients with chronic pain (Vioxx samples) and nausea (Zofram) and no insurance 
coverage 
• Samples are great for the uninsured 
• Free samples for geriatric patients have been helpful in compliance with meds for 
those who are unable to afford the medications 
 
The researcher’s assumption was that NPs would report dispensing a large number of 
sample medications to patients who are indigent or underserved.  Therefore, they would 
use more drug samples because of lack of insurance.  These assumptions were upheld by 
the comments of the respondents.   However, the inference from these comments is 
slightly different from anticipated in that NPs are dispensing free sample medications 
rather than prescribe less expensive alternatives for their patients.   
The importance of sample medications for dispensing is not an issue that appears in 
the physician literature addressing pharmaceutical company influence. This feedback 
from NPs appears to be unique to the NP population.  However, PAs and MDs may see 
similar patient populations and may well have the same opinions and beliefs about the 
importance of sample availability.  In-depth investigation into how NPs utilize sample 
medications should be the focus of further research.  Additionally, a study of NP sample 
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medication dispensing should be undertaken, to include income and health insurance 
coverage of the NPs’ patient population and the percentage of NP patients who are 
managed entirely on sample medications. 
 Pharmaceutical Company Education Programs 
The second item repeatedly mentioned as useful to the NPs practice was 
pharmaceutical company sponsored education programs, both for health care providers 
and pharmaceutical company sponsored patient education literature.  In fact, 34% (n= 
133) of the respondent NPs stated they had changed a patient’s medication after a 
pharmaceutical company encounter due, at least in part, to education materials being 
available from the pharmaceutical company.   
Another aspect of the pharmaceutical company education programs, and perhaps 
the one most important to practicing NPs, is the pharmaceutical company sponsored 
education program.  Since the early 2000’s, pharmaceutical companies have begun to 
recognize the importance of non-physician health care providers in both marketing and 
promoting pharmaceutical products.  Both NPs and PAs have been increasingly targeted 
for educational dinners, office visits and online, audio and interactive education programs 
aimed at promoting the company’s products.  Most NPs in the survey group found these 
education programs to be very useful.  Issues cited included new research and data 
monographs, resource text such as antibiotic prescribing guides, access to experts in 
specialty practice fields through education symposia, and obtaining free continuing 
education units (CEU’s).  All NPs need some number of CEU’s in order to re-certify in 
their specialty area and/or for state licensure or certification as an NP.  Many of these 
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pharmaceutical sponsored CEU events are convenient for the NP as they are offered in a 
variety of formats from interactive online, to audiotapes, from self-study modules to 
office lunches and dinner at three and four star restaurants.   Selected NPs comments 
concerning these activities are below: 
• Since starting to practice I have learned a great deal by attending drug company 
sponsored educational activity.  I have found this educational help invaluable  
• I do feel the information that they provide very helpful.  Especially recent studies 
and data essential to my prescribing practice.   
• Drug reps sponsored activities often provide venue for learning, CEU and 
networking 
• They [pharmaceutical companies] are the only ones who provide free, accessible 
contact with experienced practitioners  
• I enjoy interacting with most reps because they have the ability to answer specific 
questions or get the answer in an efficient manner.   
• I find pharmaceutical reps very helpful and informative.  It helps keep me up my 
knowledge of new medications and changes to treatment guidelines. 
• I like the dosing charts for antibiotics.  
• I find it very helpful to talk to reps. They summarize information in the 
prescribing guide which I don’t always have time to read and inform me of new 
indications and new research for a drug.   
• They should give away less junk and provide more educational seminars (I like 
nice dinners but that is not why I go) 
• Educational programs at conferences and dinners 
• Even if the reps did not supply lunch, I would still take the time to briefly talk 
with them re: new indications, warning, etc.  regarding their drugs. 
• I believe samples and educational materials are extremely useful. 
• The educational material and studies they provide with re: to efficacy, etc…are 
important. 
 
 Buyer Behavior - Stimulus-Response Model 
 
The Buyer Behavior - Stimulus-Response Model (S-R)  is one of many used by 
marketing professionals to promote products. It illustrates the many factors that go into 
marking choices and decisions by pharmaceutical companies and others wishing to sell a 
product or service.  One can assume the purpose of most pharmaceutical company 
incentives such as samples and education programs is to influence or persuade NPs to 
change their prescribing behavior and prescribe a drug from the sponsor company’s’ 
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array of products.    Generally, S-R models assume that an incentive of some type, with 
appropriate modification for specific groups and populations, will result in a response 
that can be predicted by the marketer; that is, the marketer’s offer to take a health care 
provider to a high priced restaurant for dinner and an educational program about a new 
drug, or a new use for an existing drug, will result in the healthcare provider prescribing 
more of the pharmaceutical company’s product presented at the dinner.   
In the S-R model, marketing questions and other factors enter the “black box” 
known as the customer (in this case, the NP) and produce certain responses.   
Pharmaceutical company marketing personnel must try to decide how the NP thinks and 
emotionally responds to the stimulus offered (dinner, continuing education credits, gifts, 
sample medications).  The NP buyer characteristics will influence how they understand, 
interpret and perceive the stimuli.  This is both a cognitive and an emotional response to 
the stimulus.    Then, a decision-making process occurs which ultimately determines 
what, if any, buying (or prescribing) behavior the NP exhibits. 
The literature assumes the stimulus for the NP in this scenario is the free dinner, 
the response is going to the restaurant, and the reward is continuing education credits.  
Pharmaceutical company motivation for providing the dinner event is obviously a 
potential change in the NPs prescribing behavior, resulting in the NP writing more 
prescriptions for product X.  Therefore, in this stimulus-response-reward model, the 
reward of increased pharmaceutical sales goes to the pharmaceutical company and the NP 
gets dinner at a nice restaurant and CEU’s. 
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NP Stimulus = offer of a free dinner and continuing education credits 
NP Response = NP goes to dinner event 
NP Reward =  free dinner and continuing education credits 
The buyer stimulus-response model is similar to the Elaboration Likelihood 
Model (ELM) of persuasion theory.  Both theories require both emotion and cognition in 
order for the individual to be persuaded.    ELM cites motivation to change as 1) the 
individuals’ personal involvement or interest in the issue, 2) their ability to process 
persuasive arguments and attention factors, and 3) whether they have the time or 
inclination to focus on the issue.  Petty and Cacioppo (1985) found that the less the 
individuals interest in the issue, the less attention they paid to the information presented 
and the less motivated they were to cognitively process the argument.  When motivation 
for the issue was low, peripheral cues became more important (Jowett & O’Donnell, 
1999).  
A New Model 
The model suggested by this study makes a different assumption; i.e. that the real 
reward in this scenario goes not to the pharmaceutical company in the form of increased 
sales, but instead, to the NP. This new model combines the premise of the ELM and the 
buyer stimulus response models but views the pharmaceutical company-NP interaction in 
a different way.   When an NP, PA or MD is invited to dinner at a highly priced 
restaurant, the assumption in the literature is that the dinner (or free gift, money or other 
incentive product) is, in itself, the reward for the health care provider.  This new 
combination model makes the assumption that the reward is not the dinner or CEU’s, but 
rather the information received as a result of accepting the incentive.  This is a clear 
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departure from the concept that NP’s or MD’s change their prescribing practice because 
they receive a gift, in this case a nice dinner.  The decision to attend a pharmaceutical 
company sponsored event, involves several elements including; 1) interest level in the 
topic  2) investment of time to attend, and  3) the worth of this event compared to other 
like events    This is the  “black box” area of the stimulus-response-reward model where 
the invitee makes a series of decisions that result in a determination to attend or not 
attend the function.   The data suggests attending a pharmaceutical company sponsored 
event provides the NP the opportunity to carve out a protected period of time from their 
busy schedule in which they have the time to actually listen to a presentation.  I refer to 
this period of time as protected-reflective time.  This is a block of time which, without an 
incentive to “make the time”; the health care provider would never have carved out of 
their schedule.  This period of protected-reflective time allows the health care provider 
the time to listen to an educational presentation, discuss and debate the issues with the 
presenter and other health care providers in a learning environment.  This opportunity 
permits the health care provider to then reflect on the information received, weigh the 
choices and make a critical decision about whether or not this new drug or therapy might 
be appropriate for their patient population.  The attendee also has the opportunity to 
discuss the information with his or her peers and integrate their opinions into his or her  
decision-making.   Often, without the protected-reflective time offered by these 
educational programs at dinner meetings, professional educational programs or other 
sponsored events, the health care provider may not take the time to hear the information 
presented at the program and therefore not be able to make a critical, informed decision 
about a new product.   
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This new theory of protected-reflective time is echoed by comments on the 
returned surveys. 
• I agree that money used for dinner programs/seminars can be high, however, this 
is the time slot where I am not seeing patients and am able to digest the 
information.  
• They [pharmaceutical companies] are the only ones who provide free, accessible 
contact with experienced practitioners (who are almost always) very informed 
about their general topics and usually happy to be a source of information.    
• Drug reps sponsored activities often provide venue for learning, CEU and 
networking 
• I attend dinners for education and to hear cases of use, problems, success by other 
health care providers.  I like to think I have a “thoughtful practice”.  The 
information can only be helpful  -  how I use it is my choice.   
 Many NPs also wrote in comments about the need for sample medications for their 
patients and their beliefs about their ability to “cut through the hype” and make informed 
clinical decisions based on the data rather than the “trinkets”.   
• I am cautious about info given by sales representatives.  Most do not have 
medical or clinical background and parrot information they have been fed by 
marketing divisions. 
• Yes, I take their samples and goods, but I still prescribe according to supportive 
research studies of the products  
• I enjoy the updates and articles the reps bring but I try to keep a level head and 
evaluate for myself.   
• If a company can convince me with the research that their drug is better or 
cheaper, I will use it.  The junk never influences my decision 
• So although drug reps may “push their product” we feel the samples for our 
children are worth a few minutes of hype! 
• I think NPs are smart enough to use reps stuff to better serve patient populations, 
staff, etc, etc. and not be influenced by their used car salesman tactics 
• The information can only be helpful  - how I use it is my choice. 
• Changed prescribing after educational program – sometimes, after receiving a gift 
– never 
• I find it somewhat unethical however I have been guilty on occasion attending 
dinners that were given to our entire practice. 
These comments are also reflective of a model that requires both emotion and 
cognition in order decide whether to be persuaded or not.   The NPs comments reflect 
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both emotional aspects of the process (caution, enjoyment, feelings, and guilt) as well as 
aspects of their cognitive process (“prescribe according to supportive research”, “keep a 
level head and evaluate for myself”, “thoughtful practice…how I use it is my choice”. 
Perceived Pharmaceutical Company Influence and Prescribing Behavior 
 Studies have shown that physicians are influenced by pharmaceutical company 
interactions and, in fact, are not aware of the extent of that influence on their prescribing 
behaviors and practices (Steinman, Shlipak & McPhee, 2001; Wazana, 2000).  Likewise, 
this study demonstrates that NPs are also influenced by pharmaceutical company 
interaction and often do not recognize this influence.  That is, 51% of the NP respondents 
believed they were influenced by pharmaceutical encounters and 80% report they 
changed their prescribing practices after such an encounter.  
 There remains the discrepancy between the 48% of NPs who do not believed they are 
influenced by pharmaceutical encounters and the 80% of NPs who report having changed 
their prescribing practices after such an event.  The data indicates that 32% of the NPs 
surveyed did not recognize any relationship between exposure to product information 
through education programs, office visits, or other methods, and changes in their own 
prescribing behavior.  Survey results indicate that the number of NPs who actually 
change or modify their prescribing behavior after one or more pharmaceutical company 
encounters is significantly greater than the number of NPs who believe they are not 
influenced by those encounters.  This finding indicates a lack of understanding by NPs 
about the nature of influence.  
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Survey results also revealed a statistically significant difference in NPs perception of 
whether or not pharmaceutical company products, promotions, and gifts influence their 
own prescribing practices, and whether or not these influence their NP colleagues same 
encounters.   While 69.7% of the NP respondents felt their fellow NPs were influenced 
by pharmaceutical company interactions, only 51.7% of the same NP respondents felt 
their own prescribing behaviors were influenced by pharmaceutical company 
interactions.  This 18% discrepancy between NPs beliefs about influence on their 
personal prescribing practices and their perceptions about other NPs level of influence, 
although statically significant, is actually lower than results in the  MD literature.   
Steinman’s (2000) study asked medical residents about the appropriateness of accepting 
promotions and gifts from pharmaceutical companies and the influence of these items on 
their prescribing behavior.   His study found that 84% of medical residents believed their 
fellow medical residents were influenced by pharmaceutical company promotions and 
gifts while only 39% of the same medical residents felt their own prescribing behavior 
was influenced by the pharmaceutical company promotions and gifts.  The data in this 
study show that NPs are not realistic about the effect of pharmaceutical company 
influence on their own practice.  It appears that they may be able to identify and assess 
the effect of pharmaceutical company’s influence on their peers, yet fail to recognize it in 
their own practice.   
NP Reasons for Prescriptive Changes after Pharmaceutical Company Interaction 
NP responses to the survey identified an average of 4.478 reasons for changing 
prescribing behavior after a pharmaceutical company encounter.  The top four choices in 
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rank order are ; 1) were more effective for the problem,  2)  as effective with less side 
effects,  3) as effective and less costly, and  4) a new alternative for my patient.  These 
reasons are reflected in the NPs comments on the survey and are congruent with the 
literature addressing what NPs believe to be important to their practice.  The fact that NPs 
are influenced to change their prescribing after a pharmaceutical company interaction, in 
and of itself, is  less of an issue than why the NP chooses to change his or her prescribing 
after the encounter.  If the change occurs because of a period of protected reflective time 
at a dinner meeting or because of a critical review of the literature revealing a more 
effective drug alternative for the for the patient because of cost, taste, route, or number of 
medications a day taken by the patient,  the influence would be deemed positive.  That is, 
the encounter provided the NP with the necessary information to provide better care for 
his or her patients.  If, however, a gift or promotional product is the reason for the 
prescriptive change, the patient could potentially suffer the consequences of a less 
effective drug, a more costly drug or frequent medication schedules which may be 
disruptive to the patients’ daily life.  None of the NPs surveyed identified a free gift or 
dinner as the reason for changing their prescribing practices.  However, the potential of 
either the influence of the free gift (dinner, coffee mug, CEU’s, etc.) or a sense of 
obligation the pharmaceutical company representative, much like the sense of obligation 
evoked when receiving an unsolicited gift in the mail to encourage completion of a 
survey, cannot be eliminated based on this study.    One NP  commented “I have found 
this [pharmaceutical company] educational help invaluable, but often feel expected to 
prescribe their drug”, and another stated “I find it somewhat unethical, however I have 
been guilty on occasion attending dinners that were given to our entire practice”.  
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Another respondent noted,  “Maybe you should ask, would I go to a presentation that did 
not include dinner.  Answer-maybe”.   For these respondents, the influence of the gift 
alone (dinner, trinkets, pens, etc.)  could be the motivating factor in their prescriptive 
change. 
 Further, data from this survey shows that more NPs change their prescribing 
practices after a pharmaceutical company encounter (78%) than never change their 
prescribing after such an encounter (20%).  The results indicate that the pharmaceutical 
company stands a good to excellent chance of the NP changing his or her prescribing 
once an encounter has occurred.  From a pharmaceutical company standpoint, the effort 
is probably worth the return.  The issue for NPs becomes, is the time and energy involved 
in engaging pharmaceutical companies worth it?  Results raise the question, to what 
degree do prescribing changes occur after a pharmaceutical company interaction due to 
the NPs sense of obligation to respond in kind to “freebies”?  Or is the decision a 
calculated move on the NPs part to obtain what they need to improve practice?     
The survey comments appear to support the NPs recognition of the marketing 
game and their willingness to endure the hype in order to obtain what their patients need.   
Eighty-nine percent of the survey respondents said they would be likely or very likely to 
see a pharmaceutical company representative again if they had provided an item useful to 
them in their practice.    If NPs recognize the “game” and can and do manipulate the 
marketers to obtain what they need for themselves and for their patients in order to 
provide better care, how much more could NPs accomplish in an organized approach to 
pharmaceutical companies with respect to improving care for patients instead of the 
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individual hit and miss approach currently employed.   Melanie Balestra, President of the 
American College of Nurse Practitioners   affirmed that NPs prescribe more than 350 
million drugs for patients each year.  She noted the need for NPs and pharmaceutical 
companies to work together to improve patient care and outcomes and to continue to 
learn.   She encouraged NPs to attend professional conferences and interact with 
pharmaceutical companies for mutual benefit (Balestra, 2004).  
Small Gifts 
The majority of NP respondents to this survey reported no interest in office 
supplies such as pens, pencils, clocks and coffee mugs although 99% of the NPs had 
accepted these items and 72% felt it appropriate or very appropriate to accept them.  
Fifteen NP respondents stated they thought the money spent of these items should be 
channeled into more valuable uses such as lowering the cost of medications or increasing 
education programs.  Some of these comments are: 
• The trinkets (coffee mugs) could be forgotten in my opinion 
• I do feel the pharmaceutical companies spend too much time on superficial 
giveaways 
• I am not influenced by trinkets 
• I would say I am not influenced by pens, notepads 
• If pharmaceutical companies spent less on marketing (pens, clocks, note pads, 
etc.) and lowered the cost of the drugs, samples wouldn’t be as great a need.  
Non-medical items are left in the office but are not an influence on my prescribing 
practice 
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• I could really care less about the JUNK that they (the pharmaceutical companies) 
give us.  Rarely do I find something useful 
• They should give away less junk and provide more educational seminars (I like 
nice dinners but that is not why I go), decrease advertising so they can offer a 
drug at a lower cost and have more patient assistance programs.   
• The gifts such as pens, notepads, etc. is not an influence.   
Survey results indicate that pharmaceutical companies could save money by 
discarding promotional “trinkets”   and invest their money more effectively in 
educational programs for NPs.  It should be noted however, that 99% of the NPs in this 
study have accepted at least some of these items and 72% thought it appropriate or very 
appropriate to accept them.  As a marketing tool, it is unclear how influential having a 
product name in constant view might be to the pharmaceutical company’s goal of 
promoting their product.  Clearly, many offices, clinics and practices use pens, coffee 
mugs and candy bowls, filled daily with a pharmaceutical product name or logo items in 
clear sight.  Further, the survey did not consider the “dribble down” or “pass-on” effect of 
these inexpensive promotional products.  This study has no estimate of the number of 
pens, coffee mugs or note pads with names and logos that go home with NPs, office staff 
and patients.  These more subtle influences may be known and anticipated by the 
pharmaceutical companies and justify the cost.   A study looking at name recognition for 
specific drug products associated with promotional items in practice would be warranted. 
  Patient request for specific medication 
 Sixty-two percent of the NP respondents revealed that patient requests for a 
specific drug was important in their prescriptive decision-making while 89% of NPs 
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reported at least one patient request monthly for a specific drug as a result of direct to 
consumer advertising.  However, only 37% reported changing or modifying their 
prescribing practice because of a patient request for a specific drug.  This may reflect the 
NPs’ commitment to patient education while caring for their health and wellness. Direct-
to-consumer advertising is often misunderstood or incomplete from the patients’ 
perspective.  This has been attributed to a lack of balance in the advertising, change in 
tempo and presentation style during the listing of adverse effects, the use of medical 
terminology during the advertisement and other marketing techniques that result in only 
34% of consumers being able to identify that the drug may not work for everyone 
(Kaphingst & DeJong, 2004).    
It is often the path of least resistance for health care providers to write out a 
prescription or give out the sample that the patient asks for, whether it is indicated or 
appropriate for the presenting complaint.  Writing a prescription and instructing the 
patient with directions on how to appropriately use the drug takes several minutes.  
Taking the time to explain to the patient why the requested drug is not appropriate for the 
presenting complaint takes significantly more time.  A perfect case in point is the patient 
who arrives in the office with a request for “an antibiotic for my cold”.  After the history 
and examination, the NP diagnosis the patient with a viral illness, a condition for which 
an antibiotic is neither required, nor appropriate.  The NP must then   take the time to 
explain the difference between a bacterial and a viral illness, the history and physical 
exam findings that support his or her diagnosis, and the rationale for the medication (if 
any) that is prescribed or ordered in lieu of the requested antibiotic, all in language 
understandable by the patient.  Occasionally, an argument ensues and the patient will 
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demands the requested antibiotic.  The NP then needs to restate the case and attempt to 
help the patient understand the clinical situation.  This process requires significantly more 
time than simply writing out a prescription.  Eighty-nine percent of respondents reported 
at least one request by a patient for a specific drug monthly, yet only 37% had actually 
changed or modified their prescribing because of the patient request.  This is indicative of 
the NPs ability to withstand the direct-to-consumer marketing onslaught and continue to 
evaluate each patient and their requests on an individual basis.   
The fact that only 62% percent of the respondents stated that patient request for a 
specific drug was very important or somewhat important in their prescriptive decision-
making was surprising.  The researcher would assume that all NPs would consider a 
patient request very important or at least somewhat important when making prescriptive 
decisions.  This less than 100% response may be reaction to the availability of sample 
medications in the practice.  That is, if the NP knows that there is no sample of the 
requested medication available, and the patient does not have prescription insurance and 
would be unable to afford the prescription for the requested drug, perhaps the NP lowers 
the importance of the patients’ request, knowing that what the patient wants is simply not 
available to them.   
The physician literature reveals concern about MDs responses to patients’ 
requests for specific drugs, especially due to DTC marketing.  Wolfe noted,  “There is 
evidence that many drug advertisements are not balanced or accurate and duped 
gatekeepers may not adequately resist patients’ exhortations to write a prescription” 
(2002, p.525).   These concerns were mirrored by a British Journal of Medicine (2002) 
study    that examined U.S. and a Canadian primary care practice sites to determine 
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whether or not MDs were influenced by their patients’ requests for prescription drugs.   
After controlling for many of the variables, the authors concluded that the patient’s 
request for a prescription medication significantly influenced the choice of drugs that 
physicians prescribed.  “In most cases physicians prescribed requested medications but 
were often ambivalent about the choice of treatment” (Mantes, et al., 2002, pg. 279).   
Similar issues should be further investigated in the NP population, looking for variations 
in responses to patient’s requests for specific drugs and  NPs rationale for denying or 
honoring such requests.   
Nursing Faculty 
Nursing faculty are the second stakeholder group identified in this study.  Results 
revealed that 87% of NP respondents felt their NP program did not provide them with 
adequate information about NP-pharmaceutical company interaction.  This perception 
appears to indicate a gap in content material in NP education programs.  Although the 
question did not ask NPs what was lacking in their education or how it should be 
addressed, responses such as “I have found this educational help invaluable, but often 
feel expected to prescribe their drug” and “I have been guilty on occasion attending 
dinners that were given to our entire practice” indicate that some NPs are not comfortable 
in these pharmaceutical company interactions.  The ethical issues imbedded in NP-
pharmaceutical company interaction should be threaded throughout NP curricula.     
Curriculum content for NPs needs to include influence theory and marketing 
tactics.  Health policy or health promotion courses could include assignments that 
examine the influence of pharmaceutical company programs such as sample medications 
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and free prescription programs on prescribing practice.  Students could identify areas in 
which they feel pharmaceutical companies might have an impact or improve care for 
patient populations or groups.  Content might also include critique of pharmaceutical 
company educational materials for reading level and messages.  Students could then 
suggest improvements or revisions.  Research courses need to not only address critical 
reading of research data from studies and monographs, but also need to directly tie this 
content into how the pharmaceutical company presents clinical data supporting their 
findings.  Pharmaceutical company monographs and literature generally indicate that 
their drug product is the best.   A valuable exercise would be to have NP students critique 
2 pharmaceutical company presentations or monographs about why similar drugs are the 
best for a specific health care problem such as diabetes, hypertension or 
hypercholesteremia.  The student would then identify the missing pieces, data 
inconsistencies, or research methodology inadequacies in the material presented on the 
health care problem. This assignment would give the NP student an opportunity to 
critically analyze research data and identify the potential spin placed on the drug for 
marketing purposes.  In a clinical course, NP students could be assigned to investigate the 
marketing materials for a specific drug, present those findings to the class, and well 
armed with information, approach the pharmaceutical representative to ask questions 
related to the research findings.  The results of such exercises would be a heightened 
level of confidence for the student NP in reading pharmaceutical company research 
reports, addressing questions with representatives and receiving feedback, and ultimately, 
becoming more informed prescribers and consumers of pharmaceutical products.  
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Professional Nursing Organizations 
The third stakeholder identified in this study is professional nursing organizations and 
State Boards of Nursing. These organizations develop standards of care, professional 
guidelines and scope of practice statements.   Results of this study demonstrate that NPs 
are influenced by pharmaceutical company interaction, promotions and gifts.  Further, the 
data has shown that at least some NPs are not aware of the influence exerted by the 
pharmaceutical companies and that 87% of NPs do not feel they were given adequate 
information in their initial NP program concerning how a nurse practitioner should 
interact with pharmaceutical representatives in order to make informed prescribing 
decisions.  These findings have implications for professional nursing organizations. 
NP Professional Organizations 
 NP professional groups are the organizations that practicing NPs, other 
professionals and the legal system recognize to delineate roles, propose education 
program guidelines and standards of care for the profession.  Nurse Practitioner 
professional organizations such as the American Academy of Nurse Practitioners and the 
American College of Nurse Practitioners, and specialty NP groups such as the 
Association of Women's Health, Obstetric and Neonatal Nurses are comprised of 
individuals with clinical, educational and political expertise in NP practice.   Professional 
Standards of Care and Position Statements are developed in response to pressing social, 
economic and educational imperatives within the profession or healthcare delivery 
system.  Existing Position Statements include topics such as prescriptive privileges, role, 
nurse practitioner curriculum, end-of-life care, and nurse practitioners and direct-to-
consumer advertising. 
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As early as 1990 the American College of Physicians stated its concern about the 
influence of pharmaceutical company sponsored educational programs and gifts on 
physicians’ and medical students’ prescribing practices.  Even with such guidelines in 
place, many physicians were still unaware of the problem.  In 2002, the American 
College of Physicians issued a second position statement on physician-pharmaceutical 
company interaction.    This new statement reiterated the need for awareness of the 
implications of pharmaceutical company sponsored education and its influence on 
prescribing practices and recommended that all medical students, residents and 
physicians receive training on this issue (Coyle, 2002b).   
Results of this study indicate that professional NP organizations need to develop a 
Position Statement on NP-Pharmaceutical Company interaction.  Further, adding NP-
pharmaceutical interaction, as a topic in the Position Statement on Nurse Practitioner 
Education should be considered.  This recognition of the interaction between the 
pharmaceutical industry and the practicing NP would be an important step in the 
acknowledging that pharmaceutical influence extends well beyond the physician 
population. 
Several NP professional organizations such as the American Academy of Nurse 
Practitioners (AANP), American College of Nurse Practitioners (ACNP) and the National 
Organization of Nurse Practitioner Faculties (NONPF) sponsor continuing education 
programs, conferences, CE events and professional publications. Results from this study 
demonstrate that NPs do not feel comfortable with influence theory and marketing 
content.  This content should to be addressed through these professional venues.  
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In a workshop format, NPs could investigate the marketing materials for a 
specific drug through a group presentation format.  A short presentation on influence and 
marketing could precede the participants breaking into small work groups.  With the 
assistance of the workshop facilitator, NPs could examine the literature, discuss the 
findings, and present those findings to the workshop group.   The results of such a 
workshop group would be a heightened level of confidence for the NP in reading   
pharmaceutical company research reports, addressing questions with representatives and 
receiving feedback.   Similar information could be published in NP professional journals.   
Ultimately, this would help the practicing NP become a more informed prescriber and 
consumer of pharmaceutical products and services 
National Organization of Nurse Practitioner Faculties 
The National Organization of Nurse Practitioner Faculties (NONPF) develops 
curricular guidelines for NP education. NONPF’s document The Criteria for Evaluation 
of Nurse Practitioner Programs (NONPF, 1997) and the Curriculum Guidelines and 
Program Standards for Nurse Practitioner Education (NONPF, 1995) are acknowledged 
by nursing program accrediting bodies, the National League for Nursing Accrediting 
Commission and the American Association of Colleges of Nursing, as the framework for 
NP curriculum.  The results of this study point to the need for the integration of issues 
related to NP-pharmaceutical company interaction into every NP curriculum.   
 State Boards of Nursing 
State Boards of Nursing (SBN) are responsible for the Scope of Practice for nurses 
and nurse practitioners, although in some cases SBNs share that responsibility with a 
physician board.  SBN are ultimately responsible for nursing licensure and certification 
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including development of the nurses Scope of Practice and any continuing education 
requirements imposed on nurse and nurse practitioner re-licensure.  Most SBN’s require 
some continuing education credits for re-licensure and also some pharmacology 
continuing education credits for NPs.   
The results of this study indicate that State Boards of Nursing should ensure that not 
all NP pharmacology continuing education credits are obtained through pharmaceutical 
company sponsored education programs.  Having NPs obtain some   of their required 
pharmacology continuing credits through professional nursing journal self-learning 
modules, nursing continuing education programs, or collegiate pharmacology courses and 
updates, would ensure that not all the pharmacology credits obtained by the NP originate 
with pharmaceutical company marketing sources. 
Pharmaceutical Companies 
The results of this study may influence pharmaceutical companies to work with NPs 
collaboratively for the benefit of both and for the patient.  Pharmaceutical companies 
need to reach out to NPs through educational programs about new drug products and new 
indications for older drugs.  This will result in increased patient management information 
available to the NP.   Further, this collaboration opens lines of communication between 
the two groups and allows both pharmaceutical companies and NPs to better understand 
the knowledge base and resources available within the two groups.  Ultimately, it allows 
the NP and the pharmaceutical company to interact at levels such as those identified 
below.  
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1.  NPs should be recruited for patient guideline panels and steering groups and be 
involved in the development of patient education materials.  NP insights into patients, 
families and communities can be an invaluable asset to pharmaceutical company 
education committees and programs, not only in program development but also in 
preparation of education materials to accompany new and older pharmaceutical products.  
NPs can also be valuable assets to pharmaceutical companies as presenters at seminars, 
conferences and programs for both patients and healthcare professionals.    
2.  Program planning is an area in which in which pharmaceutical companies 
significantly under use NPs as a resources.   Pharmaceutical companies need to approach 
NPs to serve on patient education panels, “think tanks” and information gathering 
sessions.  As nurses are repeatedly identified as the most trusted profession in public 
opinion surveys, NPs working closely with patients, families and community resources 
can provide a perspective different from physicians and Pas.    An example might be the 
emphasis NPs in this study placed on the availability of sample medications for patients 
in their practices.  As patient advocates, NPs could brainstorm with pharmaceutical 
companies to identify target populations and communities for pharmaceutical company 
support, identify criteria for free sample medication distribution based on the needs of 
patient populations and communities rather than the more prevalent system of 
indiscriminate distribution.  Pharmaceutical companies distribute sample medications in 
an effort to increase sales of their profit-producing product lines.  However, perhaps there 
are additional, as yet unidentified, ways to support underserved populations for which 
NPs have the key.   
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3.  NPs and pharmaceutical companies could also increase their interaction is in 
the area of clinical trials research.  NPs work with a variety of populations across all ages, 
ethnic, social and illness continuums.  These clinical practices could well support clinical 
trials research while providing a service to patients in the practice.       
4.  NPs need to highlight their special expertise and offer to work with the 
pharmaceutical companies for the mutual benefit of patients.  Pharmaceutical companies 
need to provide NPs with their articles and monographs highlighting the company’s 
products, to provide educational materials and resources for patients and to continue to 
work with NPs to provide pharmaceutical coverage for indigent and underserved patients 
through sample medications and access to pharmaceutical programs.  Pharmaceutical 
companies need to know exactly what NPs “find useful to their practice”.   
5.  Finally, NPs should approach pharmaceutical companies to fund NP research 
on patient populations, NP outcomes, and community based needs.   Further, additional, 
research on NPs utilization of pharmaceutical company services and samples is 
necessary, and should be developed through partnerships linking practicing NPs and 
pharmaceutical companies.  NPs need to collaborate with the pharmaceutical companies 
in supporting NP education as they become more informed consumers of pharmaceutical 
company services. 
Patients 
The fifth stakeholder group identified in this research is patients.  Pharmaceutical 
companies target patients through direct-to-consumer marketing (DTC) using the media 
including television, newspapers and magazines.  Pharmaceutical company information is 
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also available through brochures and pamphlets, in health care providers’ offices, and 
online through pharmaceutical company websites. 
 This study has demonstrated that DTC marketing has an impact on NP-patient 
interaction.  Eighty-nine percent of the respondent NPs reported at least one patient 
request monthly for a specific drug and 62% of respondent NPs reported that patient 
request for a specific drug was important or very important to their prescribing choices.  
As pharmaceutical research become more accessible to the general public through news 
reports, advertising and website access, patients who already notice pharmaceutical 
company marketing through DTC advertising, will want to know how their requests for 
specific drugs affects their health care providers’ prescriptive choices.  Further, advocacy 
organizations such as the American Association of Retired Persons (AARP) who are 
involved in healthcare spending analyses and lobbying will want to know the impact 
pharmaceutical spending on DTC advertising has on prescription medication costs.  
Additionally, these organizations need to know how DTC marketing affects the 
prescriber, ultimately influencing the patients’ prescribed medications. 
 Patients are the end users of prescription medications.   The availability of sample 
medications at a practice site should be assumed to be an important issue for patients.  
Patients need to ask their healthcare provider about prescription drugs that may be helpful 
to their medical condition when they see them advertised.  However, there needs to be 
balance in the advertising permitted in DTC marketing.  Patients and advocacy 
organizations need to critically assess the prescription drug information provided through 
DTC marketing.  Informational brochures, articles, and television programming 
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explaining influence and pharmaceutical company marketing of prescription drugs should 
be developed and disseminated. 
Conclusions 
NPs are influenced by their interactions with pharmaceutical companies.  This 
does not mean that pharmaceutical company-NP interactions are negative.  There are 
many benefits to NP-pharmaceutical company affiliation that result in increased access to 
medications for patients, education opportunities for NPs, educational resources for 
patients and potentially, increasing opportunities for NP-pharmaceutical company 
cooperation in education and research.   However, the practicing NP needs to be able to 
recognize and acknowledge the influence of pharmaceutical company promotions in 
order to utilize the information appropriately in the service of the patient.  
NPs value pharmaceutical interactions and recognize the benefits accrued.  Like 
their physician counterparts, some NPs do not recognize the influence pharmaceutical 
companies have on their prescribing practice.  Professional nursing organizations need to 
develop position statements on NP-pharmaceutical company interaction, educators need 
to integrate pharmaceutical marketing and influence issues into their curricula and 
practicing NPs need to become critical users of pharmaceutical company services. 
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Physician–Industry Relations. Part 1: Individual Physicians  
Susan L. Coyle, PhD, for the Ethics and Human Rights Committee, American College of 
Physicians–American Society of Internal Medicine*  
 
5 March 2002 | Volume 136 Issue 5 | Pages 396-402  
This is part 1 of a 2-part paper on ethics and physician-industry relationships. Part 1 offers advice 
to individual physicians; gives recommendations to medical education providers and medical 
professional societies. 
Physicians and industry have a shared interest in advancing medical knowledge. Nonetheless, 
the primary ethic of the physician is to promote the patient’s best interests, while the primary ethic 
of industry is to promote profitability. Although partnerships between physicians and industry can 
result in impressive medical advances, they also create opportunities for bias and can result in 
unfavorable public perceptions. 
Many physicians and physicians-in-training think they are impervious to commercial influence. 
However, recent studies show that accepting industry hospitality and gifts, even drug samples, 
can compromise judgment about medical information and subsequent decisions about patient 
care. It is up to the physician to judge whether a gift is acceptable. A very general guideline is that 
it is ethical to accept modest gifts that advance medical practice. It is clearly unethical to accept 
gifts or services that obligate the physician to reciprocate. 
Conflicts of interest can arise from other financial ties between physicians and industry, whether 
to outside companies or self-owned businesses. Such ties include honorariums for speaking or 
writing about a company’s product, payment for participating in clinic-based research, and 
referrals to medical resources. All of these relationships have the potential to influence a 
physician’s attitudes and practices. This paper explores the ethical quandaries involved and offers 
guidelines for ethical business relationships. 
 
In 1990, the American College of Physicians published a position statement titled "Physicians and 
the Pharmaceutical Industry" to address ethical issues in relationships between industry and the 
medical profession (1). The statement, which was prompted in large part by evidence of the drug 
industry’s influence on physician behavior and concern for professional integrity and patient care, 
examined potential conflicts of interest in relationships with industry and provided ethical advice in 
certain areas. Since the statement was originally released, evidence of industry’s influence on 
medical practice, research, and education has continued to emerge, and physician-industry 
relationships have multiplied. Once again, the American College of Physicians–American Society 
of Internal Medicine reminds physicians and industry to be vigilant about potential conflicts and 
ethical problems. The College recognizes that while there are no easy answers to many ethical 
questions, guidance in certain areas can be useful. 
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This is part 1 of a 2-part paper on ethics and physician-industry relationships. In part 1, the 
College offers recommendations to individual physicians, mainly clinicians and clinician-
researchers, regarding acceptance of gifts and other financial relationships with industry. 
addresses medical education providers and medical professional societies that accept corporate 
funding for organizational projects or membership events, such as meetings and symposiums. 
Despite the introduction in the early 1990s of ethical standards for physicians regarding 
physician-industry relationships, concerns persist and evidence accumulates that commercial 
rewards can unduly affect clinical judgment (2-9). Industry allocates substantial resources to 
promote its products to physicians. In 1999, the pharmaceutical industry spent nearly $8.0 billion 
(U.S.) to send sales representatives to physician offices and to exhibit products at medical 
conferences and events (10). Such costly corporate overtures raise questions about undue 
influence and could undermine genuine educational efforts. 
In addition to the pharmaceutical industry, physicians are increasingly courted by newly emerging 
industries (biotechnology, pharmacogenetics, e-commerce), and potential conflicts of interest, 
whether real or perceived, are pervasive. Physicians meet industry representatives at the office 
and at professional meetings, collaborate in community-based research, and develop or invest in 
health-related industries. In all of these spheres, partnered activities often offer important 
opportunities to advance medical knowledge and patient care, but they also create an opportunity 
for the introduction of bias. 
This paper offers two positions to help guide individual physicians in making ethical decisions 
about interacting with industry. The positions are based on the profession’s fundamental 
principles of responsibility, that is, acting in a patient’s best interests (beneficence), protecting the 
patient from harm (nonmaleficence), having respect for the patient and fostering informed choice 
(autonomy), and promoting equity in health care (justice). To uphold these principles, the primary 
purpose of entering relationships with industry should be the enhancement of patient care and 
medical knowledge. While the ethics of medicine and the ethics of business sometimes diverge, 
both are legitimate, and a thoughtful collaboration of physicians and industry can result in the best 
of patient care. 
 
 
Position 1. Industry Gifts, Hospitality, Services, 
nd Subsidies  a 
 
The acceptance of individual gifts, hospitality, trips, and subsidies of all types from industry by an 
individual physician is strongly discouraged. Physicians should not accept gifts, hospitality, 
services, and subsidies from industry if acceptance might diminish, or appear to others to 
diminish, the objectivity of professional judgment. Helpful questions for gauging whether a gift 
relationship is ethically appropriate include 1) What would my patients think about this 
arrangement? What would the public think? How would I feel if the relationship was disclosed 
through the media? 2) What is the purpose of the industry offer? 3) What would my colleagues 
think about this arrangement? What would I think if my own physician accepted this offer? 
Rationale  
Physicians understand that to maintain their professional objectivity they must be mindful of 
potential biases in medical information (7, 11). In fact, the entire infrastructure of science and 
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much of physician education is built on the fundamental notion of eliminating, or at least 
controlling for, the many and powerful biases inherent in generating and interpreting scientific 
data. Ethically and professionally, the objective evaluation of medical information is critical for 
deciding on best clinical practices (beneficence) and avoiding risks to patient safety 
(nonmaleficence) (12-14). Thus, physicians have an obligation to themselves, their profession, 
and society to evaluate, correct for, and eliminate potential bias in medical information from all 
sources. 
Recent studies and reports have examined industry influence on physician objectivity and 
behavior (15, 16), particularly prescribing practices, formulary choices, and assessment of 
medical information (3, 7, 17-25). Physicians frequently do not recognize that their decisions have 
been affected by commercial gifts and services (26) and in fact deny industry’s influence (3, 15, 
17-22), even when such enticements as all-expenses-paid trips to luxury resorts are provided 
(23). Research, however, shows a strong correlation between receiving industry benefits and 
favoring their products (23, 25, 27). 
What Would My Patients Think about This Arrangement?  
The dictates of professionalism require the physician to decline any industry gift or service that 
might be perceived  to bias their judgment, regardless of whether a bias actually materializes. A 
perception that a physician is dispensing medical advice on the basis of commercial influence is 
likely to undermine a patient’s trust not only in the physician’s competence but also in the 
physician’s pledge to put patients’ welfare ahead of self-interest. Recent research on patient 
attitudes shows that patients are more likely than physicians to perceive industry gifts as 
inappropriate or influential on medical practice (19, 28, 29). More particularly, a significant number 
of patients believe that industry gifts bias their physicians’ prescription practices and ultimately 
drive up medical costs. Patients make a distinction, however, between acceptable and 
unacceptable gifts. Most think that inexpensive incentives designed for office use (pens, 
notepads) and patient care (drug samples, medical texts) do not have a negative effect on health 
care. They are much more likely, however, to disapprove of items for personal use (radios, 
coffeemakers), especially as the gifts become more costly (dinners, trips) (28, 29). 
What Is the Purpose of the Industry Offer?  
The potential for bias in industry-prepared information becomes especially precarious when such 
information is accompanied by a gift or free service. Even when the amenity is medically related, 
a major aspect of the offer involves the establishment of a gift relationship, a phenomenon much 
studied in social science research. In culture after culture, there has emerged "a vivid sense of the 
immense pervasiveness of the social obligation" that a gift elicits (30). Social scientists agree that 
the prevailing purpose of the gift is to establish the identity of the donor in the mind of the recipient 
and to oblige the recipient to reciprocate (30-32). It is not just lavish amenities that are in question. 
The acceptance of even small gifts can affect clinical judgment and heighten the perception (as 
well as the reality) of a conflict of interest (12). 
From a certain perspective, drug samples can be characterized as "gifts." Because physicians 
can distribute such medications to patients at no apparent cost (33), the practice may seem to 
promote the profession’s core principle of equitable access and justice in health care. The 
practice does allow the patient to try out a new medication before being committed to an expense. 
However, the sample mainly serves to encourage physicians to prescribe the new product. 
Research shows that once a patient exhausts a free supply of medication, the physician typically 
writes a prescription for the same brand (33, 34). Because few samples are for older or less 
expensive products (35), higher patient costs generally result. Moreover, physicians and their 
families and staff use approximately one third of the samples (33, 34, 36, 37), which illustrates 
how the practice fosters access to physicians’ offices and encourages a gift relationship. 
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In addition to drug samples, industry may distribute product literature or "patient care services," 
such as education aids or disease management software. It is understandable that, in a busy 
practice, physicians would welcome industry’s materials and technologies to keep themselves 
and their patients current with the latest developments in the medical field. Physicians must keep 
in mind, however, that industry-supplied medical information, although neutrally packaged, is in 
fact promotional (4). Physicians should never rely solely on industry-provided information or 
services as a substitute for an objective review of the literature and understanding of patients’ 
conditions. 
What Would My Colleagues Think about This Arrangement?  
The issue of industry gifts, hospitality, and subsidies arises as early as medical school and 
residency programs (18, 20-22, 27, 38-42). Medical students and physicians-in-training often have 
opportunities to receive instructional materials, medical equipment, or even educational dinner 
programs. While it is recognized that such arrangements can benefit the medical education 
experience and that medical students and residents have unique financial and work 
circumstances, it is also necessary to note that medical training includes instruction on 
professional ethics, including appropriate relationships with industry. Medical students, 
physicians-in-training, and practicing physicians should apply the same ethical standards to their 
interactions with industry (43). 
Physicians do not always agree about the appropriateness of gifts. Ideally, physicians should not 
accept any promotional gifts or amenities, whatever their value or utility, if they have the potential 
to cloud professional judgment and compromise patient care. As a practical matter, many 
physicians are comfortable with limiting their acceptance of gifts to items that enhance medical 
practice or knowledge and that are of modest value. Differences of opinion will undoubtedly arise 
because of the ways in which an item or service is valued in different practice environments and 
communities. Nonetheless, such debates are important because they remind physicians of the 
need to gauge regularly whether a gift relationship is ethically appropriate. 
Recommendations  
The inherent difficulty in defining what makes a gift appropriate has, to an extent, contributed to 
lapses in judgment by otherwise ethical persons. It is difficult to set with any precision a monetary 
value that would render a gift unacceptable. There is no consensus model for determining relative 
value, and one will not be recommended here. Instead, some specific guidance is offered in the 
following examples of generally acceptable industry gifts: inexpensive gifts for office use (such as 
pens and calendars), low-cost gifts of an educational or patient-care nature (such as medical 
books), and modest hospitality (such as a reception or other food and drink) that is connected 
with a legitimate educational program. 
Understandably, even these "generally acceptable" examples are subject to interpretation and will 
frustrate some readers. Together with the fundamental questions listed in Position 1, physicians 
should use these recommendations as guides in making a good-faith effort to evaluate the 
potential for influence and to determine what kinds of amenities are ethically appropriate to 
accept. It is unethical for physicians to accept any industry gift or subsidy that is predicated on 
recommending a particular product or taking a particular clinical action. The preceding examples 
cannot and should not be used as a perfunctory substitute for self-appraisal. 
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Position 2. Financial Relationships between 
hysicians and Industry  P 
 
Physicians who have financial relationships with industry, whether as researchers, speakers, 
consultants, investors, owners, partners, employees, or otherwise, must not in any way 
compromise their objective clinical judgment or the best interests of patients or research subjects. 
Physicians must disclose their financial interest in any medical facilities or office-based research 
to which they refer or recruit patients. 
Rationale  
Like gifts, financial relationships between physicians and industry can jeopardize professional 
objectivity. While collaborations in pharmaceutical development and biotechnology are often 
effective spearheads for advancing therapies and patient care, research and investment ties can 
create dual commitments or conflicts of interest (12) and risk the confidentiality of patient 
information. Some physicians own, hold stock in, or have other financial stakes in the medical 
industry and biotechnology; others work for industry as researchers or are university-based 
researchers who receive industry grants. Increasingly, clinicians are invited to act as industry 
consultants or to participate in clinical trials of newly developed drugs or devices, often by 
enrolling their own patients as subjects (12, 44). 
Ownership or Other Financial Interest in Medical Resources  
Physician ownership or other financial interest in medical equipment, health care facilities, 
laboratories, and other medically related resources raises ethical and legal concerns that 
physician self-interest may lead to inappropriate self-referrals or overuse of resources. For 
example, one study found that physician-owned clinics generated 50% more patient visits than 
independent clinics, suggesting that self-referral had induced unnecessary demand (45). Because 
a physician’s primary duty is to act in the best interests of patients, physicians cannot allow 
financial arrangements to influence their judgment about what constitutes an appropriate level of 
care. It is unethical for physicians to overutilize resources or make unnecessary referrals to goods 
and services for their own financial benefit. It is also unethical to participate in any arrangement 
that links income generation explicitly or implicitly to equipment or facility usage or revenues 
generated by investor-physicians. There are instances, of course, in which self-referrals are 
acceptable, such as in remote or isolated settings where there is a dearth of alternative medical 
resources. In any event, if physicians refer patients to resources in which they have a material 
interest, they need to disclose their financial investments and, to the extent practicable, specify 
alternative sources of goods and services (12). 
Consulting, Speaking, or Writing on Behalf of Industry  
Industry may pay clinicians well to act as consultants, speak on behalf of a company, or 
participate in community-based industry trials. As a rule of thumb, related payments from industry 
are acceptable for teaching and for research that advances medical and professional knowledge 
(for example, honorariums for presentations at symposiums), commensurate with the extent of 
the physician’s services and reasonable travel expenses. 
Physicians should guard against conflicts of interest when invited to consult or speak for pay on 
behalf of a company. It is likely that a company will retain only individuals who make statements 
or recommendations that are favorable to its products, thus compromising the physician’s 
scientific objectivity. Physicians should accept honorariums only for services provided and must 
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disclose any industry sponsorship or affiliation and other potential conflicts of interest to formal 
lecture audiences and publication editors (31, 46). 
Physicians should also be circumspect if asked to deliver educational programming developed by 
a medical education and communication company. Such companies, which are largely financed 
through the pharmaceutical industry, are for-profit developers and vendors of continuing medical 
education (47). It is important that physicians retained as lecturers in such settings control the 
content of the educational modules they deliver rather than allow their presentations to be scripted 
by the company. Lecturers should screen industry-prepared presentation aids (such as slides and 
reference materials) to ensure their objectivity and should accept, modify, or refuse them on that 
basis. Presenters using such materials should disclose their source to audience members. 
Paid efforts to influence the profession or public opinion about specific medical products are 
particularly suspect. It is unethical, for example, for physicians to accept commissions for articles, 
editorials, or medical journal reviews that are actually ghostwritten by industry or public relations 
firms in an attempt to "manage the press" about certain products or services (48). 
Participation in Industry-Sponsored Research  
Participation in practice-based research can contribute to our understanding of the benefits and 
risks of a new product, thereby promoting medicine’s underlying principles of beneficence and 
nonmaleficence. Still, physicians are responsible for ensuring that any clinical research in which 
they participate is potentially of significant value and is ethically conducted (12, 49). In particular, 
physicians invited to join "postmarketing studies" that require the prescribing of a company’s 
product need to consider the scientific validity of the research and its potential to enhance medical 
progress (44, 50, 51). Physicians should not participate in studies that are, in effect, thinly 
disguised promotional schemes to entice physicians to use new products. 
Physicians also have an ethical obligation, based on the principle of patient autonomy and 
informed choice, to disclose their commercial ties to patients who are prospective study 
participants (12). Physicians who involve their own patients in office-based trials must also be 
aware of potential conflicts between what is best for the patient-subject and what is optimal for the 
conduct of the research. In weighing the two interests, clinicians must consider their role as 
physician first and as investigator second (12, 52). It is reasonable for the clinician to receive 
compensation commensurate with time and expenses incurred in study recruitment. However, 
physicians may not accept compensation simply for referring their patients to an industry study, 
regardless of whether the physician directly participates in the trial. Known as "finder’s fees," such 
arrangements represent pure profit and create an inherent conflict with the best interests of the 
patient (12, 49, 53). 
Finally, physicians involved in commercial trials must guard against bias in publishing research 
outcomes. Several studies show that physicians with financial ties to pharmaceutical 
manufacturers are significantly more likely than independent reviewers to report findings that 
support the sponsor’s drugs; likewise, they are less likely to report unfavorable findings (48, 54-
57). To maintain objectivity, it is recommended that physicians secure pre-performance 
agreements with sponsors ensuring that negative results will not be quashed and that findings will 
be made publicly accessible. Physicians should also be aware that the International Committee of 
Medical Journal Editors recently agreed not to publish any studies conducted under conditions in 
which the sponsor can control the data or prevent publication (58). If a company explicitly or 
implicitly encourages a physician to suppress particular outcomes, the physician must not 
participate in the research and should report the incident to the institutional review board 
overseeing the research, and to the U.S. Food and Drug Administration if the research is a drug 
trial. 
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Dealing with Institutional Product Bias  
Physicians employed by managed care organizations are obligated to abide by drug formularies 
and practices of pharmacy benefit management. Formularies specify a list of drugs that are 
considered most useful and cost-effective, and managed care organizations often limit 
reimbursement to these drugs. Pharmacy benefit management companies, which increasingly are 
owned by pharmaceutical manufacturers, act as intermediaries among pharmacies, 
pharmaceutical companies, physicians, and third-party payers to review prescribing practices and 
negotiate prescription prices. Pharmacy benefit management companies have access to 
confidential patient records and may try to influence changes in patients’ drug regimens, 
sometimes to reduce costs and sometimes to favor a manufacturer (59, 60). Current state and 
federal policies regarding third-party access are not consistent and can, at times, jeopardize the 
confidentiality of patient information. Cost savings are certainly encouraged, especially as a 
matter of justice and equity in health care. However, any agreement to change drugs should be 
evidence-based, not company-biased. If faced with institutional bias in drug formularies, individual 
physicians should be prepared to insist on waivers for unlisted drugs when it is in the best 
interests of their patients. 
Electronic Technology  
Finally, the development of "e-commerce" has led to ethical issues not envisioned in the 1990 
position paper. Since that time, the importance of electronic commerce and Internet technology to 
the practice of medicine has increased dramatically. Health care systems in the 21st century will 
undoubtedly take advantage of electronic technology to collect and analyze clinical data, support 
consumer access to health information, and complement the physician’s management of patient 
care (13). 
As valuable as consumer access is, information provided electronically can be biased by its 
sponsor. To mitigate this potential conflict, physicians who have a material interest in "e-health" 
businesses or who interact with Internet hosts to publish their own Web sites have an obligation to 
control the site’s medical content and regularly maintain it. Such sites should disclose all sources 
of industry support and clearly distinguish any commercial advertisements or sponsored content 
from substantive content, both in form and in placement. Physicians with commercially sponsored 
Web sites also need to alert users if a sponsor plans to conduct any online tracking. 
 
 
Conclusion   
 
The guidelines offered here identify several examples of financial and other material relationships 
between physicians and industry, but the list is not exhaustive. As opportunities for commercial 
ties continue to grow, physicians should be increasingly wary of threats to their professionalism 
and independent judgment about patient care. Providers of medical education and professional 
medical societies face similar problems of potential influence. Part 2 of this statement on industry 
relations will address the ethical risks and responsibilities of professional medical associations 
and educators. 
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This is part 2 of a 2-part paper on ethics and physician-industry relationsips. offers advice to 
individual physicians; part 2 gives recommendations to medical education providers and medical 
professional societies. 
Industry often sponsors programs for graduate and continuing medical education, as well as 
major events of medical professional societies. Industry is an abundant source of advances in 
medicine and technology and plays a crucial role in disseminating up-to-date medical information. 
Although industry information fills an important need, studies suggest that it is often biased. 
Providers of graduate and continuing medical education have a duty to present objective and 
balanced information to their participants; thus, they should not accept any funds that are 
contingent on a sponsor’s ability to shape programming. Medical educators need to evaluate and 
control the planning, content, and delivery of education provided under their auspices. They 
should disclose industry sponsorship to students, faculty, and continuing medical education 
participants and should adopt explicit organizational policies about acceptable and unacceptable 
interactions with industry. 
Medical professional societies have a duty to promote the independent judgment and 
professionalism of their members. Organizers of industry-sponsored meetings should clearly 
separate product promotion from impartial medical education. Adopting specific policies for 
dealing with industry sponsorship can also help professional societies guard against outside 
influence. The American College of Physicians–American Society of Internal Medicine’s core 
ethical principles for external funding and relationships serve as an example. 
 
In 1990, the American College of Physicians published a position statement titled "Physicians and 
the Pharmaceutical Industry," which addressed industry relations with individual physicians and 
medical professional groups (1). The statement was prompted in large part by evidence of the 
drug industry’s influence on medicine and the ensuing concern for professional integrity and 
patient care. Since that time, the influence of industry on medical practice, research, and 
education has continued to increase, as have physician-industry relationships. In response, the 
American College of Physicians–American Society of Internal Medicine (ACP-ASIM) has 
prepared an updated, 2-part set of ethical positions. addresses individual physicians and their 
relationships with industry through gifts and collaborative activities. The current paper, which is 
part 2, addresses ethical concerns relevant to medical education providers, academic units that 
accept industry support, and medical professional societies. 
A responsible and productive alliance between medical organizations and industry is crucial for 
medical progress. At the same time, providers of graduate medical education (GME) and 
continuing medical education (CME) and medical professional societies are also responsible for 
regulating their dealings with industry. These groups should evaluate their external funding 
relationships not only for prospective benefits but also for potential conflicts of interest and other 
ethical problems, such as real or perceived improprieties and bias in the materials they offer, their 
policies, and projects they undertake. 
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Given the rapid pace of technological developments and therapeutic advancements in medicine 
and biotechnology, both students and practicing physicians rely on education providers and 
professional societies for objective, up-to-date health care information. Commercially sponsored 
information offered in such settings can be biased in favor of manufacturers and has the potential 
to unduly affect the independent judgment of medical professionals (2-5). To help overcome this 
conflict, this paper offers two positions on the external funding of educational programming and 
activities of medical professional societies. The College’s positions described in part 1 are 
numbered 1 and 2; the positions appearing here are numbered 3 and 4. 
 
 
Position 3. Industry-Supported Graduate and 
ontinuing Medical Education  C 
 
Public and private GME and CME providers that accept industry support for educational programs 
should be aware of potential conflicts of interest and should develop and enforce explicit policies 
that maintain complete control of program planning, content, and delivery. (This position 
addresses education providers that accept industry support, not industry-held educational 
programs.) 
Rationale  
Continuing medical education is a multibillion-dollar business (6), and the role of the health care 
industry is considerable (7). The commercial role is expected only to grow as new, for-profit 
medical education and communication companies begin providing CME (8). Industry support of 
GME is difficult to quantify but is potentially of great importance. A 1990 survey of internal 
medicine residency programs revealed that 90% of program directors allowed industry to sponsor 
educational conferences for their students; of these, 30% reported not having alternative funds for 
such events (9). 
Continuing medical education is critically important for physicians to keep abreast of the latest 
developments in patient care. Indeed, physicians have sometimes been slow to adopt efficacious 
new therapies into routine clinical practice and therefore to improve patient care (10). Because 
industry is an abundant source of advances in medicine and technology, its desire to quickly 
disperse information about its products helps to fill an important need (11). The presentation of 
medical information, however, must be objective, and this becomes the responsibility of medical 
education providers and medical professional societies. 
Commercial funding for CME usually takes the form of general course grants or speaker funds, 
although it is sometimes provided for hospitality and travel expenses related to educational 
symposiums. Many medical schools also accept commercial sponsorship of educational 
conferences, as well as funds for student organizations, publications, and awards (2). While 
support for GME and CME is often welcomed, commercial support can create an opportunity for 
the subtle or not so subtle introduction of bias through industry-oriented programming. For 
example, a study of CME courses funded by rival manufacturers showed that course contents 
were biased in favor of each funder’s product (12). Further study showed that physicians who 
attended industry-supported CMEs subsequently altered their prescription practices in favor of the 
funder’s products (13). 
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Education provided through a reputable academic institution or medical professional society is 
expected to offer expert teaching and "best evidence" information (14). However, professional 
impartiality about what constitutes best evidence can be tested if industry selects the teacher or 
underwrites the program. To enhance the impartiality of CME, groups such as the Accreditation 
Council for Continuing Medical Education (ACCME) have recommended guidelines for 
relationships between educators and industry (15). The guidelines advise CME providers to plan 
for balanced program content and ensure that their programs are free of commercial bias for or 
against any product or service. While the ACCME guidelines are a step in the right direction, 
commentators have noted that they are not difficult to skirt (3, 8). 
Medical education organizations have an obligation to the profession and society to evaluate and 
correct for potential bias. When faculty or speakers must use trade names in a GME or CME 
presentation, they should cite similar products or services of several companies rather than 
focusing on a single supporting company. Faculty, deans, and program directors should also 
promote sensitivity to potential biases by providing specific education to help their students, 
physician trainees, and medical fellows evaluate industry-provided information. For education and 
sensitivity training to be successful, however, faculty must act as positive role models. Chief 
residents and medical school faculty members should set ethical examples to students by 
conducting their relationships with industry in a highly principled manner and disclosing their own 
commercial ties. 
Medical education providers must also administer the budgets of any programming provided 
under their auspices. If an organization allows industry-sponsored hospitality, the hospitality 
should be modest and arranged so that social activities do not compete with educational events 
(15). Providers of CME must also control access to registrants’ mailing addresses and should 
disclose any commercial support to registrants through general program materials. Providers 
should ban the distribution of promotional materials in educational sessions unless the materials 
are clearly related to instruction. 
Medical education programs are also responsible for discussing industry sponsorship with invited 
speakers, including support for such presentation aids as slides or literature reviews. This 
disclosure will give speakers the opportunity to screen the aids and accept or refuse them (16), or 
make modifications to ensure objectivity. (Speakers who use industry-developed aids should 
disclose that information to the audience.) In addition, faculty and program directors should 
disclose any support they receive individually as consultants, investigators, or shareholders, and 
they should be sure that their relationships are explicitly listed in the CME program (16, 17). 
Finally, faculty and program directors may accept industry honorariums or subsidies only for 
services rendered and, if applicable, reasonable travel expenses. 
In sum, it is unethical for academic institutions and educational organizations to accept any 
support that is explicitly or implicitly conditioned on industry’s opportunity to influence the selection 
of instructors, speakers, invitees, topics, or content and materials of educational sessions. To 
reflect this position, medical education providers should adopt and enforce specific organizational 
policies about acceptable and unacceptable interactions with industry (9). 
 
 
Position 4. Support for Medical Society Activities   
 
Medical professional societies that accept industry support or other external funding should be 
aware of potential bias and conflicts of interest and should develop and enforce explicit policies 
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that preserve the independent judgment and professionalism of their members and maintain the 
ethical standards and credibility of the society. 
Rationale  
Medical professional societies share the physician’s duty to advocate and act in the best interest 
of the patient and society, and they are expected to serve as independent and trustworthy 
sources of health care information and education for members and the public. In developing 
specific projects or meetings to achieve these goals, many professional associations seek 
external funding to defray costs. While such arrangements are legitimate, they can result in dual 
commitments or conflicts of interest. External funding has the potential to alter an organization’s 
agenda, influence its policy positions, or weaken its credibility (18). To avert potential conflict or 
bias, which in turn may affect members, professional societies need to adopt specific institutional 
policies governing their relationships with industry. 
One of the premiere events of the medical professional society is its annual or semiannual 
membership meeting, at which scientific sessions, symposiums, workshops, and exhibitions are 
offered to disseminate medical knowledge and enhance clinical skills. Such meetings offer 
excellent opportunities to educate members about issues of bias in medical information and to 
present ethical positions on physician-industry relationships. These meetings usually also offer 
the opportunity for commercially sponsored exhibits and events. 
Physician organizations and professional societies need to conduct professional meetings in a 
highly principled manner. To be sure, industry’s presence can have positive effects. Industry is a 
significant source of innovative development in medicine and is responsible for informing 
physicians about the benefits (and risks) of promising diagnostic and therapeutic discoveries. 
However, industry presence at medical society events may divert interest from the scientific 
agenda and detract from the meeting’s focus on professionalism and other organizational goals. 
In addition, industry attractions create potentially fertile ground for providing biased medical 
information. To lessen this possibility, meeting organizers should ensure that product promotion 
activities are separated from impartial medical information. Presentation of industry findings and 
product developments, whether through displays or teaching exercises, should take place only in 
designated exhibition space or in funded lectures that the program clearly identifies as being 
independently organized and separate from official scientific sessions. 
To help preserve members’ independence of views, medical societies also need to ensure that 
meeting programs are balanced and reflect the needs and interests of members and patients, not 
sponsors. To prevent any real or apparent corporate favoritism, and to stay true to the 
organization’s core missions, medical professional societies should avoid endorsing specific 
products and services. ACP-ASIM policy, for example, sets out specific criteria for vetting 
requests for corporate endorsements to avoid influencing internal policy or promoting an agenda 
to serve external interests. Other medical professional societies are encouraged to adopt such 
internal policies. 
Professional groups should also develop policies to guide the acceptance and disclosure of 
industry and other external funding and to avoid reliance on outside sources of support. The 
College recently adopted a set of core ethical principles to guide its dealings with external funding 
sources and to serve as an example for other professional societies as they develop their own 
policies. These principles can be found in the Appendix. 
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Conclusion   
 
The positions discussed here and in part 1 are derived from medicine’s basic responsibilities to 
advocate for and protect a patient’s best interests and pave the way for informed choice. To these 
ends, medical education providers and medical professional societies should avoid all industry 
interactions that might diminish, or appear to others to diminish, their objectivity or concern for 
patients’ best interests. To do otherwise is to endanger the integrity of the profession and the 
public confidence it enjoys. 
Appendix: ACP-ASIM Core Principles for External Funding and 
Relationships, as Approved by the Board of Regents on 15 July 
2001  
Commercial, government, foundation, and other funding and relationships can help the College 
promote its goals and its mission of enhancing the quality and effectiveness of health care. 
However, some financial arrangements might bias, or be seen to bias, the College as an 
independent, trustworthy, and credible source of health care information, policy, and education. 
The following principles should guide financial and other relationships with outside organizations. 
(See also the College’s corporate endorsement and conflict of interest policies. To obtain copies, 
contact Lois Snyder at 215-351-2835.) 
1. The College’s values, its mission, and its commitment to professionalism and excellence 
in medicine must drive all external relationships and externally funded activities.  
2. Relationships with external organizations and funders should promote the health and 
welfare of the public or patient care. Member benefits resulting from external 
arrangements should enhance professionalism and physician practice.  
3. In representing the College in external relationships, College leadership and staff must 
adhere to the values and ethical standards of the organization and should act to promote 
professionalism and trust in the organization and the medical profession.  
4. External funding arrangements and external relationships must be disclosed to relevant 
parties on a regular basis and with sufficient detail and visibility to allow concerned parties 
to reach independent conclusions about potential sources of influence and real or 
perceived conflicts of interest.  
5. Specific instances in which a financial arrangement or relationship might have the 
potential to influence the College’s actual or perceived independence, credibility, and 
trustworthiness should undergo College review to minimize or eliminate such influence.  
6. The College should monitor its overall reliance on commercial sources of funding and 
ensure that its core activities could continue if such support were diminished.  
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APPENDIX B: AMERICAN MEDICAL ASSOCIATION - GIFTS TO 
PHYSICIANS FROM THE INDUSTRY
 
 
AMERICAN MEDICAL ASSOCIATION 
Professional Resources 
 
Gifts to physicians from industry
The following opinion of the Council on Ethical and Judicial Affairs of the American Medical Association, 
issued December 1990, has been incorporated into the AMA's Code of Medical Ethics. 
Opinion 8.061
Many gifts given to physicians by companies in the pharmaceutical, device, and medical equipment 
industries serve an important and socially beneficial function. For example, companies have long provided 
funds for educational seminars and conferences. However, there has been growing concern about certain 
gifts from industry to physicians. Some gifts that reflect customary practices of industry may not be 
consistent with the Principles of Medical Ethics. To avoid the acceptance of inappropriate gifts, physicians 
should observe the following guidelines:  
Any gifts accepted by physicians individually should primarily entail a benefit to patients and should not be of 
substantial value. Accordingly, textbooks, modest meals, and other gifts are appropriate if they serve a 
genuine educational function. Cash payments should not be accepted. The use of drug samples for personal 
or family use is permissible as long as these practices do not interfere with patient access to drug samples. 
It would not be acceptable for non-retired physicians to request free pharmaceuticals for personal use or use 
by family members. (I)  
Individual gifts of minimal value are permissible as long as the gifts are related to the physician's work (e.g., 
pens and notepads).  
The Council on Ethical and Judicial Affairs defines a legitimate "conference" or "meeting" as any activity, 
held at an appropriate location where, (a) the gathering is primarily dedicated, in both time and effort, to 
promoting objective scientific and educational activities and discourse (one or more educational 
presentation(s) should be the highlight of the gathering, and (b) the main incentive for bringing attendees 
together is to further their knowledge on the topic(s) being presented. An appropriate disclosure of financial 
support or conflict of interest should be made.  
Subsidies to underwrite the costs of continuing medical education conferences or professional meetings can 
contribute to the improvement of patient care and therefore are permissible. Since the giving of a subsidy 
directly to a physician by a company's representative may create a relationship that could influence the use 
of the company's products, any subsidy should be accepted by the conference's sponsor who in turn can 
use the money to reduce the conference's registration fee. Payments to defray the costs of a conference 
should not be accepted directly from the company by the physicians attending the conference.  
Subsidies from industry should not be accepted directly or indirectly to pay for the costs of travel, lodging, or 
other personal expenses of physicians attending conferences or meetings, nor should subsidies be 
accepted to compensate for the physicians' time. Subsidies for hospitality should not be accepted outside of 
modest meals or social events held as a part of a conference or meeting. It is appropriate for faculty at 
conferences or meetings to accept reasonable honoraria and to accept reimbursement for reasonable travel, 
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lodging, and meal expenses. It is also appropriate for consultants who provide genuine services to receive 
reasonable compensation and to accept reimbursement for reasonable travel, lodging, and meal expenses. 
Token consulting or advisory arrangements cannot be used to justify the compensation of physicians for 
their time or their travel, lodging, and other out-of-pocket expenses.  
Scholarship or other special funds to permit medical students, residents, and fellows to attend carefully 
selected educational conferences may be permissible as long as the selection of students, residents, or 
fellows who will receive the funds is made by the academic or training institution. Carefully selected 
educational conferences are generally defined as the major educational, scientific or policymaking meetings 
of national, regional or specialty medical associations.  
No gifts should be accepted if there are strings attached. For example, physicians should not accept gifts if 
they are given in relation to the physician's prescribing practices. In addition, when companies underwrite 
medical conferences or lectures other than their own, responsibility for and control over the selection of 
content, faculty, educational methods, and materials should belong to the organizers of the conferences or 
lectures.  
(I) Issued June 1992 based on the report, "Gifts to Physicians from Industry," adopted December 1990; 
(JAMA. 1991; 265: 501 and Food and Drug Law Journal.1992; 47: 445-458); Updated June 1996 and June 
1998.  
Last updated: Dec 22, 2004 
Content provided by: Division of CPPD 
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E-Addendum II: Council on Ethical and Judicial Affairs Clarification of Gifts to 
Physicians from Industry (E-8.061) 
Opinion 8.061, "Gifts to Physicians from Industry" is intended to provide ethical guidance to physicians. 
Other parties involved in the health care sector, including the pharmaceutical, devices and medical 
equipment industries and related entities or business partners, should view the guidelines as indicative of 
standards of conduct for the medical profession. Ultimately, it is the responsibility of individual physicians to 
minimize conflicts of interest that may be at odds with the best interest of patients and to access the 
necessary information to inform medical recommendations. 
The guidelines apply to all forms of gifts, whether they are offered in person, through intermediaries, or 
through the Internet. Similarly, limitations on subsidies for educational activities should apply regardless of 
the setting in which, or the medium through which, the educational activity is offered. 
General Questions 
(a) Do the guidelines apply only to pharmaceutical, device, and equipment manufacturers? 
"Industry" includes all "proprietary health-related entities that might create a conflict of interest." 
Guideline 1 
Any gifts accepted by physicians individually should primarily entail a benefit to patients and should 
not be of substantial value. Accordingly, textbooks, modest meals and other gifts are appropriate if 
they serve a genuine educational function. Cash payments should not be accepted. The use of drug 
samples for personal or family use is permissible as long as these practices do not interfere with 
patient access to drug samples. It would not be acceptable for non-retired physicians to request free 
pharmaceuticals for personal use or for use by family members. 
(a) May physicians accept gram stain test kits, stethoscopes or other diagnostic equipment? 
Diagnostic equipment primarily benefits the patient. Hence, such gifts are permissible as long as they are 
not of substantial value. In considering the value of the gift, the relevant measure is not the cost to the 
company of providing the gift. Rather, the relevant measure is the cost to the physician if the physician 
purchased the gift on the open market. 
(b) May companies invite physicians to a dinner with a speaker and donate $100 to a charity or medical 
school on behalf of the physician? 
There are positive aspects to the proposal. The donations would be used for a worthy cause, and the 
physicians would receive important information about patient care. There is a direct personal benefit to the 
physician as well, however. An organization that is important to the physician - and one that the physician 
might have ordinarily felt obligated to make a contribution to - receives financial support as a result of the 
physician's decision to attend the meeting. On balance, physicians should make their own judgment about 
these inducements. If the charity is predetermined without the physician's input, there would seem to be little 
problem with the arrangement. 
(c) May contributions to a professional society's general fund be accepted from industry? 
The guidelines are designed to deal with gifts from industry which affect, or could appear to affect, the 
judgment of individual practicing physicians. In general, a professional society should make its own 
judgment about gifts from industry to the society itself. 
(d) When companies invite physicians to a dinner with a speaker, what are the relevant guidelines? 
        166                          
First, the dinner must be a modest meal. Second, the guideline does allow gifts that primarily benefit patients 
and that are not of substantial value. Accordingly, textbooks and other gifts that primarily benefit patient care 
and that have a value to the physician in the general range of $100 are permissible. When educational 
meetings occur in conjunction with a social event such as a meal, the educational component must have 
independent value, such as a presentation by an authoritative speaker other than a sales representative of 
the company. Also, the meal should be a modest one similar to what a physician routinely might have when 
dining at his or her own expense. In an office or hospital encounter with a company representative, it is 
permissible to accept a meal of nominal value, such as a sandwich or snack. 
(e) May physicians accept vouchers that reimburse them for uncompensated care they have provided? 
No. Such a voucher would result directly in increased income for the physician. 
(f) May physicians accumulate "points" by attending several educational or promotional meetings and then 
choose a gift from a catalogue of education options? 
This guideline permits gifts only if they are not of substantial value. If accumulation of points would result in 
physicians receiving a substantial gift by combining insubstantial gifts over a relatively short period of time, it 
would be inappropriate. 
(g) May physicians accept gift certificates for educational materials when attending promotional or 
educational events? 
The Council views gift certificates as a grey area which is not per se prohibited by the guidelines. Medical 
text books are explicitly approved as gifts under the guidelines. A gift certificate for educational materials, 
i.e., for the selection by the physician from an exclusively medical text book catalogue, would not seem to be 
materially different. The issue is whether the gift certificate gives the recipient such control as to make the 
certificate similar to cash. As with charitable donations, pre-selection by the sponsor removes any question. 
It is up to the individual physician to make the final judgment. 
(h) May physicians accept drug samples or other free pharmaceuticals for personal use or use by family 
members? 
The Council's guidelines permit personal or family use of free pharmaceuticals (i) in emergencies and other 
cases where the immediate use of a drug is indicated, (ii) on a trial basis to assess tolerance and (iii) for the 
treatment of acute conditions requiring short courses of inexpensive therapy, as permitted by Opinion E-
8.19: Self-Treatment or Treatment of Immediate Family Members. It would not be acceptable for physicians 
to accept free pharmaceuticals for the long-term treatment of chronic conditions. 
(i) May companies invite physicians to a dinner with a speaker and offer them a large number of gifts from 
which to choose one? 
In general, the greater the freedom of choice given to the physician, the more the offer seems like cash. A 
large number of gifts presented to physicians who attend a dinner would therefore be inappropriate. 
There is no precise way of deciding an appropriate upper limit on the amount of choice that is acceptable. 
However, it is important that a specific limit be chosen to ensure clarity in the guidelines. A limit of eight has 
been chosen because it permits flexibility but prevents undue freedom of choice. Each of the choices must 
have a value to the physicians of no more than $100. 
(j) May physicians charge for their time with industry representatives or otherwise receive material 
compensation for participation in a detail visit? 
Guideline 1 states that gifts in the form of cash payments should not be accepted. Also, Guideline 6 makes 
clear that, in the context of the industry-physician relationship, only physicians who provide genuine services 
may receive reasonable compensation. When considering the time a physician spends with an industry 
representative, it is the representative who offers a service, namely the presentation of information. The 
physician is a beneficiary of the service. Overall, these guidelines do not view that physicians should be 
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compensated for the time spent participating in educational activities, nor for time spent receiving detail 
information from an industry representative. 
Guideline 2 
Individual gifts of minimal value are permissible as long as the gifts are related to the physician's 
work (e.g., pens and notepads). 
(a) May physicians, individually or through their practice group, accept electronic equipment, such as hand 
held devices or computers, intended to facilitate their ability to receive detail information electronically? 
Although Guideline 2 recognizes that gifts related to a physician’ s practice may be appropriate, it also 
makes clear that these gifts must remain of minimal value. It is not appropriate for physicians to accept 
expensive hardware or software equipment even though one purpose only may pertain to industry-related 
activities of a modest value. 
Guideline 3 
The Council on Ethical and Judicial Affairs defines a legitimate "conference" or "meeting" as any 
activity, held at an appropriate location, where (a) the gathering is primarily dedicated, in both time 
and effort, to promoting objective scientific and educational activities and discourse (one or more 
educational presentation(s) should be the highlight of the gathering), and (b) the main incentive for 
bringing attendees together is to further their knowledge on the topic(s) being presented. An 
appropriate disclosure of financial support or conflict of interest should be made. 
Guideline 4 
Subsidies to underwrite the costs of continuing medical education conferences or professional 
meetings can contribute to the improvement of patient care and therefore are permissible. Since the 
giving of a subsidy directly to a physician by a company's sales representative may create a 
relationship which could influence the use of the company's products, any subsidy should be 
accepted by the conference's sponsor who in turn can use the money to reduce the conference's 
registration fee. Payments to defray the costs of a conference should not be accepted directly from 
the company by the physicians attending the conference. 
(a) Are conference subsidies from the educational division of a company covered by the guidelines? 
Yes. When the Council says "any subsidy," it would not matter whether the subsidy comes from the sales 
division, the educational division or some other section of the company. 
(b) May a company or its intermediary send physicians a check or voucher to offset the registration fee at a 
specific conference or a conference of the physician's choice? 
Physicians should not directly accept checks or certificates which would be used to offset registration fees. 
The gift of a reduced registration should be made across the board and through the accredited sponsor. 
Guideline 5 
Subsidies from industry should not be accepted directly or indirectly to pay for the costs of travel, 
lodging or other personal expenses of physicians attending conferences or meetings, nor should 
subsidies be accepted to compensate for the physicians' time. Subsidies for hospitality should not 
be accepted outside of modest meals or social events held as a part of a conference or meeting. It is 
appropriate for faculty at conferences or meetings to accept reasonable honoraria and to accept 
reimbursement for reasonable travel, lodging and meal expenses. It is also appropriate for 
consultants who provide genuine services to receive reasonable compensation and to accept 
reimbursement for reasonable travel, lodging and meal expenses. Token consulting or advisory 
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arrangements cannot be used to justify the compensation of physicians for their time or their travel, 
lodging, and other out-of-pocket expenses. 
(a) If a company invites physicians to visit its facilities for a tour or to become educated about one of its 
products, may the company pay travel expenses and honoraria? 
This question has come up in the context of a rehabilitation facility that wants physicians to know of its 
existence so that they may refer their patients to the facility. It has also come up in the context of surgical 
device or equipment manufacturers who want physicians to become familiar with their products. 
In general, travel expenses should not be reimbursed, nor should honoraria be paid for the visiting 
physician's time since the presentations are analogous to a pharmaceutical company's educational or 
promotional meetings. The Council recognizes that medical devices, equipment and other technologies may 
require, in some circumstances, special evaluation or training in proper usage which can not practicably be 
provided except on site. Medical specialties are in a better position to advise physicians regarding the 
appropriateness of reimbursement with regard to these trips. In cases where the company insists on such 
visits as a means of protection from liability for improper usage, physicians and their specialties should make 
the judgment. In no case would honoraria be appropriate and any travel expenses should be only those 
strictly necessary. 
(b) If the company invites physicians to visit its facilities for review and comment on a product, to discuss 
their independent research projects or to explore the potential for collaborative research, may the company 
pay travel expenses and an honorarium? 
If the physician is providing genuine services, reasonable compensation for time and travel expenses can be 
given. However, token advisory or consulting arrangements cannot be used to justify compensation. 
(c) May a company hold a sweepstakes for physicians in which five entrants receive a trip to the Virgin 
Islands or airfare to the medical meeting of their choice? 
No. The use of a sweepstakes or raffle to deliver a gift does not affect the permissibility of the gift. Since the 
sweepstakes is not open to the public, the guidelines apply in full force. 
(d) If a company convenes a group of physicians to recruit clinical investigators or convenes a group of 
clinical investigators for a meeting to discuss their results, may the company pay for their travel expenses? 
Expenses may be paid if the meetings serve a genuine research purpose. One guide to their propriety would 
be whether the NIH conducts similar meetings when it sponsors multi-center clinical trials. When travel 
subsidies are acceptable, the guidelines emphasize that they be used to pay only for "reasonable" 
expenses. The reasonableness of expenses would depend on a number of considerations. For example, 
meetings are likely to be problematic if overseas locations are used for exclusively domestic investigators. It 
would be inappropriate to pay for recreation or entertainment beyond the kind of modest hospitality 
described in this guideline. 
(e) How can a physician tell whether there is a "genuine research purpose?" 
A number of factors can be considered. Signs that a genuine research purpose exists include the facts that 
there are (1) a valid study protocol, (2) recruitment of physicians with appropriate qualifications or expertise, 
and (3) recruitment of an appropriate number of physicians in light of the number of study participants 
needed for statistical evaluation. 
(f) May a company compensate physicians for their time and travel expenses when they participate in focus 
groups? 
Yes. As long as the focus groups serve a genuine and exclusive research purpose and are not used for 
promotional purposes, physicians may be compensated for time and travel expenses. The number of 
physicians used in a particular focus group or in multiple focus groups should be an appropriate size to 
accomplish the research purpose, but no larger. 
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(g) Do the restrictions on travel, lodging and meals apply to educational programs run by medical schools, 
professional societies or other accredited organizations which are funded by industry, or do they apply only 
to programs developed and run by industry? 
The restrictions apply to all conferences or meetings which are funded by industry. The Council drew no 
distinction on the basis of the organizer of the conference or meeting. The Council felt that the gift of travel 
expenses is too substantial even when the conference is run by a non-industry sponsor. (Industry includes 
all "proprietary health-related entities that might create a conflict of interest.") 
(h) May company funds be used for travel expenses and honoraria for bona fide faculty at educational 
meetings? 
This guideline draws a distinction between attendees and faculty. As was stated, "[i]t is appropriate for 
faculty at conferences or meetings to accept reasonable honoraria and to accept reimbursement for 
reasonable travel, lodging, and meal expenses." 
Companies need to be mindful of the guidelines of the Accreditation Council on Continuing Medical 
Education. According to those guidelines, "[f]unds from a commercial source should be in the form of an 
educational grant made payable to the CME sponsor for the support of programming." 
(i) May travel expenses be reimbursed for physicians presenting a poster or a "free paper" at a scientific 
conference? 
Reimbursement may be accepted only by bona fide faculty. The presentation of a poster or a free paper 
does not by itself qualify a person as a member of the conference faculty for purposes of these guidelines. 
(j) When a professional association schedules a long-range planning meeting, is it appropriate for industry to 
subsidize the travel expenses of the meeting participants? 
The guidelines are designed to deal with gifts from industry which affect, or could appear to affect the 
judgment of individual practicing physicians. In general, a professional society should make its own 
judgment about gifts from industry to the society itself. 
(k) May continuing medical education conferences be held in the Bahamas, Europe or South America? 
There are no restrictions on the location of conferences as long as the attendees are paying their own travel 
expenses. 
(l) May travel expenses be accepted by physicians who are being trained as speakers or faculty for 
educational conferences and meetings? 
In general, no. If a physician is presenting as an independent expert at a CME event both the training and its 
reimbursement raise questions about independence. In addition, the training is a gift because the physician's 
role is generally more analogous to that of an attendee than a participant. Speaker training sessions can be 
distinguished from meetings (See 5d) with leading researchers, sponsored by a company, designed 
primarily for an exchange of information about important developments or treatments, including the 
sponsor's own research, for which reimbursement for travel may be appropriate. 
(m) What kinds of social events during conferences and meetings may be subsidized by industry? 
Social events should satisfy three criteria. First, the value of the event to the physician should be modest. 
Second, the event should facilitate discussion among attendees and/or discussion between attendees and 
faculty. Third, the educational part of the conference should account for a substantial majority of the total 
time accounted for by the educational activities and social events together. Events that would be viewed (as 
in the succeeding question) as lavish or expensive should be avoided. But modest social activities that are 
not elaborate or unusual are permissible, e.g., inexpensive boat rides, barbecues, entertainment that draws 
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on the local performers. In general, any such events which are a part of the conference program should be 
open to all registrants. 
(n) May a company rent an expensive entertainment complex for a evening during a medical conference and 
invite the physicians attending the conference? 
No. The guidelines permit only modest hospitality. 
(o) If physicians attending a conference engage in interactive exchange, may their travel expenses be paid 
by industry? 
No. Mere interactive exchange would not constitute genuine consulting services. 
(p) If a company schedules a conference and provides meals for the attendees that fall within the guidelines, 
may the company also pay for the costs of the meals for spouses? 
If a meal falls within the guidelines, then the physician's spouse may be included. 
(q) May companies donate funds to sponsor a professional society's charity golf tournament? 
Yes. But it is sensible if physicians who play in the tournament make some contribution themselves to the 
event. 
(r) If a company invites a group of consultants to a meeting and a consultant brings a spouse, may the 
company pay the costs of lodging or meals of the spouse? Does it matter if the meal is part of the program 
for the consultants? 
Since the costs of having a spouse share a hotel room or join a modest meal are nominal, it is permissible 
for the company to subsidize those costs. However, if the total subsidies become substantial, then they 
become unacceptable. 
Guideline 6 
Scholarship or other special funds to permit medical students, residents, and fellows to attend 
carefully selected educational conferences may be permissible as long as the selection of students, 
residents, or fellows who will receive the funds is made by the academic or training institution. 
Carefully selected educational conferences are generally defined as the major educational, scientific 
or policy-making meetings of national, regional or specialty medical associations. 
(a) When a company subsidizes the travel expenses of residents to an appropriately selected conference, 
may the residents receive the subsidy directly from the company? 
Funds for scholarships or other special funds should be given to the academic departments or the 
accredited sponsor of the conference. The disbursement of funds can then be made by the departments or 
the conference sponsor. 
(b) What is meant by "carefully selected educational conferences?" 
The intent of Guideline 6 is to ensure that financial hardship does not prevent students, residents and 
fellows from attending major educational conferences. For example, we did not want to deny cardiology 
fellows the opportunity to attend the annual scientific meeting of the American College of Cardiology or 
orthopedic surgery residents the opportunity to attend the annual scientific meeting of the American 
Academy of Orthopedic Surgeons. However, it was not the intent of the guideline to permit reimbursement of 
travel expenses in other circumstances, such as when conferences or symposia are designed specifically for 
students, residents or fellows. 
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Accordingly, "carefully selected educational conferences" should be interpreted as follows: funds may be 
used for the reasonable travel and lodging expenses of students, residents and fellows to attend the major 
educational, scientific or policymaking meetings of national, regional or specialty medical associations. 
The Council recognizes that there may be some exceptional conferences for all physicians or even for just 
students, residents, or fellows that do not fall within this definition of carefully selected educational 
conferences but that meet the spirit of Guideline 6. Accordingly, the Council will consider proposals for travel 
and lodging subsidies for such conferences on a case-by-case basis and grant approval to those that meet 
the spirit of the guidelines. 
Guideline 7 
No gifts should be accepted if there are strings attached. For example, physicians should not accept 
gifts if they are given in relation to the physician's prescribing practices. In addition, when 
companies underwrite medical conferences or lectures other than their own, responsibility for and 
control over the selection of content, faculty, educational methods, and materials should belong to 
the organizers of the conferences or lectures. 
(a) May companies send their top prescribers, purchasers, or referrers on cruises? 
No. There can be no link between prescribing or referring patterns and gifts. In addition, travel expenses, 
including cruises, are not permissible. 
(b) May the funding company itself develop the complete educational program that is sponsored by an 
accredited continuing medical education sponsor? 
No. The funding company may finance the development of the program through its grant to the sponsor, but 
the accredited sponsor must have responsibility and control over the content and faculty of conferences, 
meetings, or lectures. Neither the funding company nor an independent consulting firm should develop the 
complete educational program for approval by the accredited sponsor. 
(c) How much input may a funding company have in the development of a conference, meeting, or lectures? 
The guidelines of the Accreditation Council on Continuing Medical Education on commercial support of 
continuing medical education address this question. 
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CODE 
O N I N T E R A C T I O N S W I T H H E A L T H C A R E P R O F E S S I O N A L S 
 
CODE 
O N I N T E R A C T I O N S W I T H H E A L T H C A R E P R O F E S S I O N A L S 
2 
The Pharmaceutical Research and Manufacturers of America (PhRMA) repres 
e n ts re s e a rch-based pharma ce u tical and biote c h n ol ogy co m p a n i e s. Ou r 
members develop and market new medicines to enable patients to live longer 
and healthier lives. 
Ethical relationships with healthcare professionals are critical to our mission of 
helping patients by developing and marketing new medicines. An important 
part of achieving this mission is ensuring that healthcare professionals have the 
latest, most accurate information available regarding prescription medicines, 
which play an ever-increasing role in patient healthcare. This document focuses 
on our interactions with healthcare professionals that relate to the marketing of 
our products. 
Preamble 
3 
Effective marketing of medicines ensures that patients have access to the products 
they need and that the products are used correctly for maximum patient 
benefit. Our relationships with healthcare professionals are critical to achieving 
these goals because they enable us to – 
w inform healthcare professionals about the benefits and risks of our products, 
w provide scientific and educational information, 
w support medical research and education, and 
w obtain feedback and advice about our products through consultation with 
medical experts. 
In interacting with the medical community, we are committed to following the 
highest ethical standards as well as all legal requirements. We are also concerned 
that our interactions with healthcare professionals not be perceived as inappropriate 
by patients or the public at large. This Code is to reinforce our intention 
that our interactions with healthcare professionals are to benefit patients and to 
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enhance the practice of medicine. The Code is based on the principle that a 
h e a l t h c a re pro fe s s i o na l ’s care of pati e n ts should be based, and should be 
perceived as being based, solely on each patient’s medical needs and the healthcare 
professional’s medical knowledge and experience. 
Th e re fo re, PhRMA adopts, effe c ti ve July 1, 2002, the fol l owing vol u n t a ry Code on 
re lationships with healthcare pro fe s s i o na l s. This Code addresses inte ra c tions wit h 
respect to ma r k e ted pro d uc ts and re lated pre - launch acti viti e s. It does not addre s s 
re lationships with clinical inve s tigato rs re lating to pre - a p p roval stud i e s. 
Basis of Interactions 
4 
Our relationships with healthcare professionals are intended to benefit patients 
and to enhance the practice of medicine. Interactions should be focused on 
informing healthcare professionals about products, providing scientific and 
educational information, and supporting medical research and education. 
5 
Informational Presentations by or 
on Behalf of a Pharmaceutical Company 
6 
Informational presentations and discussions by industry representatives and 
others speaking on behalf of a company provide valuable scientific and educational 
benefits. In connection with such presentations or discussions, occasional 
meals (but no entertainment/recreational events) may be offered so long as 
they: (a) are modest as judged by local standards; and (b) occur in a venue and 
manner conducive to informational communication and provide scientific or 
educational value. Inclusion of a healthcare professional’s spouse or other guests 
is not appropriate. Offering “take-out” meals or meals to be eaten without a 
company representative being present (such as “dine & dash” programs) is not 
appropriate. 
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7 
T h i rd-Party Educational or Professional Meetings 
8 
w Continuing medical education (CME) or other third-party scientific and educational 
conferences or professional meetings can contribute to the improvement of patient 
care and therefore, financial support from companies is permissible. Since the giving 
of any subsidy directly to a healthcare professional by a company may be viewed as an 
inappropriate cash gift, any financial support should be given to the conference’s 
sponsor which, in turn, can use the money to reduce the overall conference registration 
fee for all at te n d e e s. In addition, when companies underwrite medical 
conferences or meetings other than their own, responsibility for and control over the 
selection of content, faculty, educational methods, materials, and venue belongs to the 
organizers of the conferences or meetings in accordance with their guidelines. 
w F i na n c ial support should not be offe red for the co s ts of travel, lodgi n g, or other pers o na l 
expenses of non-fa c u l ty healthcare pro fe s s i o nals at tending CME or other third - p a rty 
s c i e n ti fic or educ ati o nal co n fe re n ces or pro fe s s i o nal meeti n g s, either dire c tly to the indivi 
d uals at tending the co n fe re n ce or indire c tly to the co n fe re n ce’s sponsor (except as set 
out in section 6 below). Simila r l y, funding should not be offe red to co m p e n s ate for the 
time spent by healthcare pro fe s s i o nals at tending the co n fe re n ce or meeti n g. 
w F i na n c ial support for meals or re cep tions may be provided to the CME sponsors who in 
t u rn can provide meals or re cep tions for all at te n d e e s. A co m p a ny also may provi d e 
meals or re cep tions dire c tly at such eve n ts if it complies with the sponsoring orga n i z ati 
o n’s guidelines. In either of the ab ove sit uati o n s, the meals or re cep tions should be 
modest and be co n d uc i ve to discussion among fa c u l ty and at te n d e e s, and the amount of 
time at the meals or re cep tions should be clearly subord i nate to the amount of ti m e 
spent at the educ ati o nal acti vities of the meeti n g. 
w A conference or meeting shall mean any activity, held at an appropriate location, 
where (a) the gathering is primarily dedicated, in both time and effort, to promoting 
objective scientific and educa tional activities and discourse (one or more educational 
presentations(s) should be the highlight of the gathering), and (b) the main incentive 
for bringing attendees together is to further their knowledge on the topic(s) being 
presented. 
9 
        176                          
C o n s u l t a n t s 
10 
It is appropriate for consultants who provide services to be offered reasonable 
compensation for those services and to be offered reimbursement for reasonable 
travel, lodging, and meal expenses incurred as part of providing those 
services. Compensation and reimbursement that would be inappropriate in 
other contexts can be acceptable for bona fide consultants in connection with 
their consulting arrangements. Token consulting or advisory arrangements 
should not be used to justify compensating healthcare professionals for their 
time or their travel, lodging, and other out-of-pocket expenses. The following 
factors support the existence of a bona fide consulting arrangement (not all 
factors may be relevant to any particular arrangement): 
w a written contract specifies the nature of the services to be provided and the 
basis for payment of those services; 
w a legitimate need for the services has been clearly identified in advance of 
requesting the services and entering into arrangements with the prospective 
consultants; 
w the criteria for selecting consultants are directly related to the identified 
purpose and the persons responsible for selecting the consultants have the 
expertise necessary to evaluate whether the particular healthcare professionals 
meet those criteria; 
w the number of healthcare professionals retained is not greater than the 
number reasonably necessary to achieve the identified purpose; 
w the retaining company maintains records concerning and makes appropriate 
use of the services provided by consultants; 
w the venue and circumstances of any meeting with consultants are conducive 
to the consulting services and activities related to the services are the primary 
focus of the meeting, and any social or entertainment events are clearly 
subordinate in terms of time and emphasis. 
It is not appropriate to pay honoraria or travel or lodging expenses to nonfa 
c u l ty and non-consultant at tendees at co m p a ny- s p o n s o red meeti n g s 
including attendees who participate in interactive sessions. 
11 
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Speaker Training Meetings 
12 
It is appropriate for healthcare professionals who participate in programs 
intended to recruit and train speakers for company sponsored speaker bureaus 
to be offered reasonable compensation for their time, considering the value of 
the type of services provided, and to be offered reimbursement for reasonable 
travel, lodging, and meal expenses, when (1) the participants receive e xtensive 
t raining on the co m p a ny’s drug pro d uc ts and on co m p l ia n ce with FDA reg u lato ry 
re q u i re m e n ts for co m m u n i c ations about such pro d uc ts, (2) this training will re s u l t 
in the parti c i p a n ts providing a va l uable servi ce to the co m p a ny, and (3) the parti c ip 
a n ts meet the crite ria for co n s u l t a n ts (as discussed in part 4.a. ab ove ) . 
13 
Scholarships and Educational Funds 
14 
Financial assistance for scholarships or other educational funds to permit 
medical stud e n ts, re s i d e n ts, fe l l ow s, and other healthcare pro fe s s i o nals in 
training to attend carefully selected educational conferences may be offered so 
long as the selection of individuals who will receive the funds is made by the 
academic or training institution. “Carefully selected educational conferences” are 
generally defined as the major educational, scientific, or policy-making meetings 
of national, regional, or specialty medical associ ations. 
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15 ational and Practice-Related Items 
16 
w Items primarily for the benefit of patients may be offered to healthcare 
professionals if they are not of substantial value ($100 or less). For example, 
an anatomical model for use in an examination room primarily involves a 
patient benef it, whereas a VCR or CD player does not. Items should not be 
offered on more than an occasional basis, even if each individual item is 
appropriate. Providing product samples for patient use in accordance with 
the Prescription Drug Marketing Act is acceptable. 
w Items of minimal value may be offered if they are primarily associated with a 
h e a l t h c a re pro fe s s i o na l ’s pra c ti ce (such as pens, notep a ds, and simila r 
“reminder” items with company or product logos). 
w Items intended for the personal benefit of healthcare professionals (such as 
floral arrangements, artwork, music CDs or tickets to a sporting event) 
should not be offered. 
w Payments in cash or cash equivalents (such as gift certificates) should not be 
offered to healthcare professionals either directly or indirectly, except as 
compensation for bona fide services (as described in parts 4 and 5). Cash or 
equivalent payments of any kind create a potential appearance of impropriety 
or conflict of interest. 
17 
dependence and Decision Making
18 
No grants, scholarships, subsidies, support, consulting contracts, or educational 
or practice related items should be provided or offered to a healthcare professional 
in exchange for prescribing products or for a commitment to continue 
prescribing products. Nothing should be offered or provided in a manner or on 
conditions that would interfere with the independence of a healthcare professional’s 
prescribing practices. 
19 
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A d h Code 
20 
Each member company is strongly encouraged to adopt procedures to assure 
adherence to this Code. 
21 
Re 
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APPENDIX D: PILOT SURVEY TOOL 
 
 
 
 
The Influence of Pharmaceutical Company Sponsored Educational 
Programs, Promotions and Gifts on the Self-Reported Prescribing Beliefs 
and Practices of Certified Nurse Practitioners in Three States 
 
 
 
 
 
 
 
 
Please answer the following questions based on your experience as a 
Nurse Practitioner over the last five years, except where otherwise indicated.   If 
you have not practiced and/or have not prescribed medications for patients during 
the last five years, please indicate so below and return the survey, completing 
only questions 35 - 43.    
If you have any additional comments please feel free to make them on the 
reverse side of this, or any other page of the survey. 
 
Again, thank you for your time! 
 
 
 
 
 
_______ I have not practiced as a nurse practitioner and/or have not 
prescribed medications for patients during the last five years 
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Nurse Practitioner Prescribing Practices Survey 
 
1. Do you believe your prescribing practices are influenced by pharmaceutical 
company sponsored gifts such as pens, note pads, textbooks; promotions such as 
drug samples for patients; or educational programs at conferences, dinners or your 
office? 
 
A. Yes   B. No  
 
2. Do you believe it is appropriate to accept promotional products, drug 
samples,  educational information or programming, or gifts from 
pharmaceutical company  representatives? 
 
Never      Always 
 1  2          3       4  
 
When selecting a prescription drug for your patients, how important are each of 
the following factors when choosing which drug to prescribe?   
 
                     Very                                                                  Not 
                         Important                                                      Important 
        1   2         3              4           
 
 
3. Patient request for a specific drug     1  2  3  4   
 
4. Samples available in the office      1  2  3  4   
 
 
5. Please rate your opinion of the appropriateness of accepting each of the following 
pharmaceutical promotional products, gifts and events related to your practice 
 
                              Very                                     Very 
                               Appropriate                                                       Inappropriate 
            1   2   3             4      
 
 
A. pens, notepads, coffee mugs, paperclips, small desk clocks 1  2  3  4   
 
B. dinner, lunch, snacks or other foods in your clinical   1  2  3  4   
practice site while listening to a presentation about  
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pharmaceutical product information 
 
C. antibiotic and other pocket guides, textbooks, calculators 1  2  3  4   
 
D. conference registration fees     1  2  3  4   
 
E. breakfast lunch or dinner educational meeting  
at a restaurant or conference     1  2  3  4   
 
F. sample drugs for your patients     1  2  3  4   
 
G.        day trip or event such as theater, concert or sports event which  1  2  3  4   
includes an educational presentation which is paid for by a  
pharmaceutical company 
 
H. receipt of an honorarium for consultation or a speaking  1  2  3  4   
engagement supported by a pharmaceutical company (consultation or  
meeting presentation) 
 
I. sample drugs for your personal use     1  2  3  4   
 
J. patient education materials      1  2  3  4   
 
K. sample drugs for use by your family members   1  2  3  4   
 
 
6. On average, how many times a month do you interact with pharmaceutical company  
representatives while attending: your clinical practice, at educational meetings, 
continuing education conferences, grand rounds or other events? Please select only 
ONE. 
 
a. 0 
b. 1-4 
c. 5-9 
d. 10-14 
e. more than 14 times per month 
 
7. I have changed or modified my prescribing practice after                 
attending a pharmaceutical company sponsored educational  
program or presentation or after receiving  promotional items.  
(if disagree, please skip to question 17) 
 
Agree              Disagree 
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If you have ever changed or modified your prescribing practices after attending a  
pharmaceutical company sponsored event, which of the following factors affected 
your decision?    The drug was: 
   
 
8.     As effective and less costly       Yes No 
9.    More effective for the problem      Yes No 
10. As effective had less side effects      Yes No 
11. As effective and had more convenient dosing for the patient  Yes No 
12. Product had associated patient education materials    Yes No 
13. A new alternative for my patient (a combination drug, a new  Yes No 
class of drug, etc.)   
14. Requested by the patient       Yes No 
15. Samples available in the office      Yes No 
16. More palatable (taste) or a new route of administration available  Yes No 
 
 
17. Do you believe other Nurse Practitioners’ prescribing practices  are influenced by 
pharmaceutical company sponsored gifts such as pens, note pads, textbooks; 
promotions such as drug samples for patients; or educational programs at 
conferences, dinners or their offices? 
 
  A. Yes  B.  No 
 
 
18.      Have you ever received any of the following promotional gifts or products from   
pharmaceutical representatives in you clinical practice site, at an educational 
dinner or luncheon, grand rounds, local or national conferences or by mail?  
Please circle the corresponding response :                   
 
A. pens, notepads, coffee mugs, paperclips, small desk clocks  Yes No 
 
B. dinner, lunch, snacks or other foods in your clinical   Yes No 
practice site while listening to a presentation about  
pharmaceutical product information 
 
C. antibiotic and other pocket guides, textbooks, calculators  Yes No 
 
 D. conference registration fees      Yes No 
 
E. breakfast lunch or dinner educational meeting  
at a restaurant  or conference     Yes No 
 
 F. sample drugs for your patients     Yes No 
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F. day trip or event such as theater, concert or sports event  Yes No 
which includes an educational presentation which is paid  
for by a pharmaceutical company 
 
 
H. receipt of an honorarium for consultation or a speaking  Yes No 
engagement supported by a pharmaceutical company 
(consultation or meeting presentation) 
 
I. sample drugs for your personal use     Yes No 
 
J. patient education materials     Yes No 
 
K. sample drugs for use by your family members   Yes No 
 
 
19. During the last year, on average, how many times a month have you had a patient 
request a specific drug because they have seen it advertised on television, 
billboards, magazines or other media sources or because a friend or relative has 
suggested it? 
 
A. 0  B. 1-5  c. 6-10  D. 11-15  E. 16-20 F. >20 
 
20. If you received an item useful to you in your practice such as an educational 
monograph, product information, patient samples, note pads or pens, from a 
pharmaceutical representative, how likely would you be to see that 
pharmaceutical representative again? 
 
   Not Very Likely        Very Likely 
     
  1  2  3  4   
 
 
Carefully read the statements below and indicate your strength of agreement or 
disagreement by circling the corresponding number 
 
Strongly agree                              Strongly Disagree 
1         2       3      4    
 
21. Pharmaceutical representatives provide useful information   1 2 3 4 
 about pharmaceutical products  
 
22. I would continue to meet with pharmaceutical representatives  
even if they no longer provided drug samples for my practice  1 2 3 4 
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23. Pharmaceutical companies provide an important education  1 2 3 4 
function 
 
24. Pharmaceutical representatives provide unbiased information  
about their products        1 2 3 4 
 
25. Pharmaceutical company sponsored educational programs   1 2 3 4 
do not affect my prescribing practices    
 
Please rate the following statement based upon your recollection of your initial NP 
education program. 
Strongly agree                      Strongly Disagree 
 
 1         2        3      4    
 
 
26.       During my nurse practitioner education program I was given adequate 
           information concerning how a nurse practitioner should interact 
     with pharmaceutical representatives so that I could make informed 
     prescribing decisions        
 
1   2   3   4   
 
Please complete the following demographic data by circling the most appropriate 
response 
 
27. Age   
 
  A.  20-30 B.  31-40 C.  41-50 D.  51-60 E.  61-70 F.  >70 
 
 
28. Gender 
A. Female   B. Male 
 
 
29. Highest degree obtained 
 
A.  Diploma  B.  Associate Degree   C.  Bachelors degree 
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D. Masters degree    E.  Doctorate   F.  Post-doctorate 
 
 
30. State in which you have your primary practice site (please select just one) : 
 
 A.  FL  B.  PA  C.  NY  D.   Other __________________ 
 
 
31.  Total number years of nursing experience (RN and NP) 
 
A.  1-5     B.  6-10 C.  11-15 D.  16-20 E.  21-25 F.  >25 
 
 
32.  Number of years of NP experience 
 
A.  1-5 B.  6-10 C.  11-15 D.  16-20 E.  21-25 F.  >25 
 
 
33. Where is your primary clinical practice site located?  (If more than one site, 
please select the site in which you see the most patients) 
 
B. Urban 
C. Suburban 
D. Rural 
 
34. Which national NP certification(s) do you hold? (Circle all that apply) 
 
A. FNP     E.  Adult Primary Care NP 
B. Acute NP     F.  Family Psychiatric Mental Health 
NP 
C. Women’s Health Care NP             G.  Adult Psychiatric Mental Health   
D.  PNP     H.  Neonatal 
E.  Geriatric NP    I.   Other__________________ 
   
 
35. In which type of practice do you spend most of your clinical time (i.e. 
what is your major patient population)? Please select only ONE
 
A. Adult Primary Care  I. Psychiatric Outpatient Pediatrics 
B. Pediatric Primary Care J. Psychiatric Inpatient Pediatrics 
     C.    Women’s Health Care  K. Adult Tertiary Care 
      D.   Geriatrics   L. Psychiatric Inpatient pediatric  
      E.  Family Practice   M. Psychiatric Inpatient Adult 
F. Pediatric Tertiary Care  N. Pediatric Specialty Practice (i.e.  
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G. Family Specialty Practice  dermatology, surgery, cardiology)  
(i.e. orthopedics, dermatology,  please specify  _________________ 
surgery, cardiology, etc.)     O. Adult Specialty Practice (i.e.  
please specify  ____________ dermatology, surgery, cardiology,  
H. Other please specify ________  please specify  _________________ 
         
 
 
Additional comments – Please feel free to use the other side of this, or any other page: 
 
Thank you for taking the time to complete this survey! 
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APPENDIX E: SURVEY 
 
 
 
 
The Influence of Pharmaceutical Company Sponsored Educational 
Programs, Promotions and Gifts on the Self-Reported Prescribing Beliefs 
and Practices of Certified Nurse Practitioners in Three States 
 
 
 
 
 
 
Please answer the following questions based on your experience as a 
Nurse Practitioner over the last five years, except where otherwise indicated.  
                    
• Please circle your responses on the survey 
 
• If you have not practiced and/or have not prescribed medications 
for patients during the last five years, please indicate so below and 
return the survey 
 
Again, thank you for your time! 
 
 
 
 
 
_______ I have not practiced as a nurse practitioner and/or have not 
prescribed medications for patients during the last five years 
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Nurse Practitioner Prescribing Practices Survey 
 
1. Do you believe your prescribing practices are influenced by pharmaceutical 
company sponsored gifts such as pens, note pads, textbooks; promotions such as 
drug samples for patients; or educational programs at conferences, dinners or your 
office? 
 
A. Yes   B. No  
 
2. Do you believe it is appropriate to accept promotional products, drug samples,     
educational information or programming, or gifts from pharmaceutical company  
representatives? 
 
Never      Always 
 1  2          3       4  
 
 
3. When selecting a prescription drug for your patients, how important are each of 
the following factors when choosing which drug to prescribe?   
 
                               Very                                                                       Not 
                            Important                                                           Important 
         1   2         3              4           
 
 
  3a.   Patient request for a specific drug    1  2  3   4 
 
  3b.  Samples available in the office     1  2  3  4   
 
 
4. Please rate your opinion of the appropriateness of accepting each of the following 
pharmaceutical promotional products, gifts and events related to your practice 
 
                            Very                       Very 
                             Appropriate                                        Inappropriate 
            1             2   3             4 
     
 
 
4a.   pens, notepads, coffee mugs, paperclips, small desk clocks     1  2  3  4   
 
4b.    dinner, lunch, snacks or other foods in your clinical       1  2  3  4   
practice site while listening to a presentation about  
pharmaceutical product information 
 
4c. antibiotic and other pocket guides, textbooks, calculators     1  2  3  4   
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4d. conference registration fees       1  2  3  4   
 
4e.        breakfast lunch or dinner educational meeting at a  
restaurant or  conference       1  2  3  4   
 
4f. sample drugs for your patients      1  2  3  4   
 
4g.        day trip or event such as theater, concert or sports 
event which includes an educational presentation  
which is paid for by a  pharmaceutical company       1  2  3  4   
 
4h. receipt of an honorarium for consultation or a speaking    1  2  3  4   
engagement supported by a pharmaceutical company  
(consultation or meeting presentation) 
 
4i. sample drugs for your personal use       1  2  3  4   
 
4j. patient education materials        1  2  3  4   
 
4k. sample drugs for use by your family members     1  2  3  4   
 
 
5. I have changed or modified my prescribing practice  
after  attending a pharmaceutical company sponsored  
educational program or presentation or after receiving   
promotional items. (if disagree, please skip to question 17)  
 
Agree               Disagree 
 
 
6. If you have ever changed or modified your prescribing practices after attending a  
pharmaceutical company sponsored event, which of the following factors affected 
your decision?    The drug was: 
   
  
8a.   More effective for the problem     Yes No 
 
8b. As effective had less side effects     Yes No 
 
8c. Product had associated patient education materials   Yes No 
 
8d. A new alternative for my patient (a combination drug Yes No 
a new class of drug, etc.)   
 
8e. Requested by the patient      Yes No 
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8f. Samples available in the office     Yes No 
 
8g. More palatable (taste) or a new route of  
administration available      Yes No 
 
 
7. Do you believe other Nurse Practitioners’ prescribing practices  are influenced by 
pharmaceutical company sponsored gifts such as pens, note pads, textbooks; 
promotions such as drug samples for patients; or educational programs at 
conferences, dinners or their offices? 
 
  A. Yes  B.  No 
 
8.      Have you ever received any of the following promotional gifts or products from   
  pharmaceutical representatives in you clinical practice site, at an educational dinner                      
or luncheon, grand rounds, local or national conferences or by mail?   
 
8a. pens, notepads, coffee mugs, paperclips, small desk clocks  Yes No 
 
8b. dinner, lunch, snacks or other foods in your clinical   Yes No 
practice site while listening to a presentation about  
pharmaceutical product information 
 
8c. antibiotic and other pocket guides, textbooks, calculators  Yes No 
 
8d. breakfast lunch or dinner educational meeting at a   Yes No 
restaurant or conference 
 
8e. sample drugs for your patients     Yes No 
 
8f. day trip or event such as theater, concert or sports event  Yes No 
which includes an educational presentation which is paid  
for by a pharmaceutical company 
 
8g. receipt of an honorarium for consultation or a speaking   
engagement supported by a pharmaceutical company  
(consultation or meeting presentation)   Yes No 
 
8h. sample drugs for your personal use     Yes No 
 
8i. patient education materials     Yes No 
 
8j. sample drugs for use by your family members   Yes No 
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9. If you received an item useful to you in your practice such as an educational 
monograph, product information, patient samples, note pads or pens, from a 
pharmaceutical representative, how likely would you be to see that 
pharmaceutical representative again? 
 
  Not Very Likely        Very Likely 
 
1  2  3  4   
 
 
10. Carefully read the statements below and indicate your strength of agreement or 
disagreement. 
 
Strongly agree                      Strongly Disagree 
 
 1         2       3      4    
 
10a. Pharmaceutical representatives provide useful  
information about pharmaceutical products     1 2 3 4 
 
10b. I would continue to meet with pharmaceutical  
representatives even if they no longer provided  
drug samples for my practice       1 2 3 4          
 
10c. Pharmaceutical companies provide an important education    
function        1 2 3 4  
 
10d. Pharmaceutical representatives provide unbiased information    
about their products       1 2 3 4 
 
10e. Pharmaceutical company sponsored educational programs   
 do not affect my prescribing practices     1 2 3 4 
   
II. Demographic Information 
a.. On average, how many times a month do you interact with pharmaceutical 
company representatives while attending: your clinical practice, at educational meetings, 
continuing education conferences, grand rounds or other events? Please select only ONE. 
 
1. 0 
2. 1-4 
3. 5-9 
4. 10-14 
5. more than 14 times per month 
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b. During the last year, on average, how many times a month have you had a patient 
request a specific drug because they have seen it advertised on television, 
billboards, magazines or other media sources or because a friend or relative has 
suggested it? 
 
1. 0          
2. 1-5     
3. 6-10     
4. 11-15   
5. 16-20  
6.  >20 
 
c. Please rate the following statement based upon your recollection of your 
initial NP education program:  
  
During my nurse practitioner education program I was given adequate      
information concerning how a nurse practitioner should interact with  
pharmaceutical representatives so that I could make informed prescribing 
decisions 
 
Strongly agree            Strongly Disagree 
 
  1         2        3      4  
 
d. Age   
 
1. 20-35  
2. 36-50  
3. 51-60    
4.  >60 
 
 
e. Gender 
 
1.  Female   2.  Male 
 
 
f. Highest degree obtained 
 
1.  Diploma  2.  Associate Degree    3.  Bachelors degree 
 
4.  Masters degree    5.  Doctorate   6.  Post-doctorate 
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g. State in which you have your primary practice site (please select just one) : 
 
 1.  FL  2.  PA  3.  NY  4.   Other __________________ 
 
 
h.  Total number years of nursing experience (RN and NP) 
 
1.   1-5     2.   6-10 3.   11-15 4.   16-20 5.   21-25  
 
6.   >25 
 
 
i.  Number of years of NP experience 
 
1.   1-5    2.   6-10 3.   11-15 4.   16-20 5.   21-25 6.  >25 
 
 
 
j. Where is your primary clinical practice site located?  (If more than one site, 
please select the site in which you see the most patients) 
 
1.  Urban 
2.  Suburban 
3.  Rural 
 
k. Which national NP certification(s) do you hold? (Circle all that apply) 
 
1.  FNP    6.   Adult Primary Care NP 
2.  Acute NP    7.  Family Psychiatric Mental Health NP 
3.  Women’s Health Care NP 8.   Adult Psychiatric Mental Health NP 
4.    PNP    9.   Neonatal 
5.    Geriatric NP   10.   Other__________________  
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L. In which type of practice do you spend most of your clinical time (i.e. what is 
your major  patient population)? Please select only ONE
 
1. Adult Primary Care  8. Psychiatric Outpatient Pediatrics 
2. Pediatric Primary Care 9. Psychiatric Inpatient Pediatrics 
      3.   Women’s Health Care 10. Adult Tertiary Care 
      4.   Geriatrics Psychiatric   11.       Inpatient pediatric  
5. Family Practice   12. Psychiatric Inpatient Adult 
      6. Pediatric Tertiary Care  13. Pediatric Specialty Practice (i.e.  
      7. Family Specialty Practice  dermatology, surgery, cardiology,  
(i.e. orthopedics, dermatology,  please specify_______________ 
surgery, cardiology, etc.) 14.  Adult Specialty Practice (i.e.    
please specify  ____________ dermatology, surgery, cardiology, etc.) 
please specify  ____________ 
      15. Other please specify  ____________ 
 
 
Additional comments – Please feel free to use the other side of this, or any other page: 
 
Thank you for taking the time to complete this survey! 
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Survey Comments Practice Type 
21 Perhaps guidelines are in order? Gero-psych 
22 It is probably more the decision of the surgeons of practice I work with that 
influence which drug reps I come in contact with.  i.e. many of them have large 
accounts with our facility and frequently provide us with educational materials, 
dinners, etc.  
I do feel this information is biased (naturally) and this is why I do not let it 
influence my prescribing.  
The 2 most important influences I take into account are drug cost to the patient 
and patient request. 
CT surgery 
27 Since starting to practice I have learned a great deal by attending drug company 
sponsored educational activity.  I have found this educational helps invaluable, 
but often feel expected to prescribe their drug 
Adult primary 
care 
29 I also volunteer at a clinic that relies heavily on samples and with limited 
resources available sample availability strongly affects what the patient is given 
(as does cost) 
Occupational 
Health 
36 We don’t accept samples.  Our organization does not accept sample meds.   
We do see reps occasionally for education/lectures but they tend to visit less 
often because we do not accept samples, because our population is 50% 
uninsured and many times we choose cheaper alternatives rather than newer 
drugs.  We have a 301b med program. 
Family practice 
39 Practices influenced because I am more aware of their products Cardiology 
41 Pharmaceutical decisions are base don current national guidelines, research 
studies and (unfortunately) insurance carriers 
Cardiology 
51 No samples available in the office 
As a practice solely treating HIV our meds are continuously changing and 
research trials are always in progress. Any studies go for 24-48 weeks and 
HIV practice 
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results can change.  Cocktails (drugs) and drug interventions can predict 
medication change.   
58 I work in the VA system we do not get samples of drugs Cardiology 
62 My patients are my primary concern; I do not prescribe medications to please 
the pharmaceutical representatives that visit me.   
However, I do feel the information that they provide very helpful.  Especially 
recent studies and data essential to my prescribing practice.   
Although I believe that pharmaceutical reps are discerning, I believe that 
pharmaceutical reps are helpful to provide information and samples for my 
patients, as I prefer to try a patient on samples before they spend their own 
money on a medication that they may not be able tolerate. 
Family practice 
63 Good luck with your research- 
Pleased to fill out the survey- 
Excellent insight 
Dermatology 
64 I am cautious about info given by sales representatives.  Most do not have 
medical or clinical background and parrot information they have been fed by 
marketing divisions.  I will consider experts in their fields who speak at 
meetings sponsored by companies/.   
Luncheons in the office are entertained mostly because the office staff enjoys 
the sponsored event.   
The trinkets (coffee mugs) could be forgotten in my opinion. 
Asthma and 
allergy 
65 Good luck with the doctorate.   
I am interested din finding out why NPs cannot/do not receive honorarium for 
work completed re: participation or lectures given re: this topic.  It seems as 
though MDs receive payment but we get $0.00 (just curious) 
GI/Nutrition 
70 I agree that money used for dinner programs/seminars can be high, however, this 
is the time slot where I am not seeing patients and am able to digest the 
information.  
Adult primary 
care 
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As a speaker, I feel that being compensated for my time is justified.  I spend a 
lot of time prepping and preparing for a presentation.   
Samples are sometimes the only way my patients have of receiving needed 
meds.  I feel fortunate that we can provide meds when our patients can’t afford 
them 
72 Great survey.  Well organized.   
Maybe you should ask would I go to a presentation that did not include dinner.  
Answer-maybe
Family practice 
73 Samples are important in a dermatology practice to evaluate effectiveness of 
topical Rx before patient spends a significant amount of $ on something that 
isn’t effective. 
Dermatology 
75 I may be the best source on this.  I work nights for a neurosurgery service and 
rarely see drug reps. Nice idea and good survey! 
Neurosurgery 
89 Interesting survey Cardiology 
92 Many times the rep ahs to see the “doctor” to show how many they have seen.  I 
write 95% of the scripts for the practice! 
Women’s health 
care 
95 Patients don’t request specific drugs-I work with an MA pt. population. 
Believe me, I work in an underprivileged area and look to use samples for my 
patients who can’t afford meds 
I give samples to patients who don’t even have medical assistance 
Reps are biased.  I make my own decisions 
Pediatric primary 
care 
106 I work in a federally designated rural health care center.  My prescribing 
practices are driven by the lowest process.  Also, many of my patients are 
enrolled in indigent programs from the drug companies, and they medications 
for free 
Family practice 
109 It is impossible to say that companies have no influence as the educational 
materials and product information can sway a provider to try a specific agent.  I 
believe efficacy of the drug and cost to the patient are, more influential over 
Psych outpatient 
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time. 
116 This appears to be an excellent topic for your doctorate degree.  My hypothesis 
is that NP behavior in prescribing does not differ that much from MDs as for 
interaction with pharmaceutical representatives is concerned.  Good luck 
Women’s health 
care 
130 Thanks for doing research.  I feel as NPs we tend to offer what is best for our 
patients.  Not always what is the newest 
Woman’s health 
care 
134 Most of my prescribing practices are dictated y strict protocols. 
There are products I would like to use but are not permitted.  I also must always 
keep cost in mind for my clients because many are uninsured 
Women’s health 
care 
135 Having drug samples to try a patient on to see 1st if they are going to tolerate the 
drug is much more cost effective for the patient.   
Patients actually appreciate the samples. 
Endocrinology 
142 Why did you change terminology and reverse order on rating scales…a bit 
confusing. 
I accept pens etc. and in the past have found most information useful but I keep 
in mind the source of the info 
Drug reps sponsored activities often provide venue for learning, CEU and 
networking.  There is a place for it. 
Women’s health 
care 
143 Cost effectives medication selection is important in the population of clients I 
see.  Therefore, if I know a drug is available at decreased cost to my patient or 
free and is safe and appropriate for the diagnosis it makes sense to select that 
med. 
Adult primary 
care 
147 Interesting survey Family practice 
151 Most of patients I see have no insurance. I rely on samples Family practice 
155 Good luck Women’s health 
care 
156 Although I do feel the pharmaceutical companies spend too much time on 
superficial giveaways they are the only ones who provide free, accessible 
ADULT 
OUTPATIETN 
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contact with experienced practitioners who are (almost always) very informed 
about their general topics and usually happy to be a source of information. 
PSYCH 
1175 It would be more helpful to make your scales more specific and perhaps have 5 
responses 
Family practice 
176 Sounds like a good study – can’t wait to get the results Women’s health 
care 
183 It’s very nice to get info from other NPs and what research they are doing 
I enjoy meeting with reps.   
Yes, I take their samples and goods, but I still prescribe according to supportive 
research studies of the products 
Example: there are 7 ARBs on the market.  I prescribe only 1-3 of that class of 
drug but I will meet with other reps to be informed of the other ARBs out there 
in case my patients do question me about them, but I will prescribe them it 
would be rare unless strong supportive data. 
Cardiology 
186 I run a free family practice clinic 1 day a week and depend on drug reps samples 
to give away 
Geriatric LTC 
187 Good luck Family practice 
190 Question #7 was difficult, near impossible to answer with a clear conscience.  
Certainly some are, but I also assume most go through the mental/ethical 
balancing act I do. 
As a rural practice, many of my patients fall into the “working poor”, uninsured 
group.  I use free samples to treat those who cannot afford or at least to reduce 
their financial burden. 
I use samples as a trial for side effects before pt’s purchase the full script.  I also 
get patient signed up for pharm company free med programs 
Thanks you for this survey 
Family practice 
192 Referring to question 11, I recently in the past year worked minimally due to 
having my child.  While working full time, the number of interactions with a 
Neurology 
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pharmaceutical rep was almost daily. 
196 I am not influenced by trinkets.  I am however influenced by data supported by 
research regarding the efficacy of pharmaceutical agents 
Cardiology 
197 The likert scale was difficult for some questions as it should have been 1-5 Cardiology 
200 Most NPs see large percentage of their practice with indigent or "working poor” 
populations.  If not for samples, many of these patients would not be able to start 
treatment due to expense. 
The sample allows the patient to start treatment immediately and if effective we 
are able to sign up patient for assistance but it may take up to 6 weeks to be 
approved. 
Adult outpt psych 
208 My practice is hospital based NICU – some of the questions were not applicable 
to my practice. 
Neonatal ICU 
209 I like to have birth control pill samples for instructions and demonstration to the 
patient, as many insurance policies do not cover contraception for patients.  I 
like having samples for them.  I enjoy the updates and articles the reps bring but 
I try to keep a level head and evaluate for myself.  I have to admit a free lunch 
brought to me on a busy day is nice sometimes 
Women’s health 
care 
 
210 I’d like to say that although some aspects of pharmaceutical marketing may 
seem improper (to health care providers) this industry is still entitled o conduct 
business (like any other business or corporation) with marketing, give aways, 
promotion items, etc. AND my patients appreciate the samples 
Gero and adult  
psych 
214 Question #1 is a wide variety of options.  
I would say I am not influenced by pens, notepads, dinners in the office, but I 
am influenced by what samples are available in the office. 
Question #2 I believe there is a big difference between receiving gifts from reps 
and getting samples for patients 
Women’s health 
217 Sometimes reps present a biased viewpoint pointing only to the positive 
studies/aspects of their drug.  
Family practice 
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Can be pushy. 
Being in family practice there are too many reps to see in a day.  Also, difficult 
to go out without spouse to dinners, education events 
221 Good luck, I look forward to receiving your results Family practice 
222 Samples are important tot our practice as many of out patients can’t afford the 
needed meds without the samples. 
If pharmaceutical companies spent less on marketing (pens, clocks, note pads, 
etc.) and lower the cost of the drugs, samples wouldn’t be as great a need.  Non-
medical items are left in the office but are not an influence on my prescribing 
practice. 
Urgent care 
225 We are not allowed to accept samples Pain and palliative
 care 
228 The drug reps often flash research studies that may or may not be valid as a way 
to persuade prescribe  
Psych 
230 I practice in an urban hospital.  My prescriptive practice is influenced by what is 
available on the hospital formulary, what drugs Medicaid will pay for. 
If the cost is prohibitive, my patients will not pay. 
If the pharm company is willing to offer their drugs to the hospital at a 
reasonable price and if the benefits of that drug is more effective and has less 
side effect than the ones currently on formulary, then perhaps they will get their 
drugs on formulary 
Women’s health  
care 
237 Strong emphasis should be placed on benefit of education, should provide CEUs 
to support the educational forum 
Neonatal 
245 I think pharmaceutical companies spend an excessive amount of money and 
marketing to both professionals and the public.  These budgets should be 
decreased and medications made more affordable to patients.  Like anything, if 
it works and can easily be obtained, it will be used. 
I enjoy interacting with most reps because they have the ability to answer 
Women’s health 
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specific questions or get the answer in an efficient manner.   
If I never see another Celebrx mug, I won’t care! 
246 Being in neonatal field, some of these questions are not applicable Neonatal 
247 Great survey. 
#13  - although at school they only touched briefly on the subject, I believe most 
RNs (especially in management) have been exposed to pharmaceutical reps in a 
less aggressive way. 
Good luck 
Oncology 
254 Pharmaceutical information is OK as long as it is given in relation to education.  
Gifts for the sake of gifts is not OK 
Transplant 
256 Best of luck with your research.  I am very interested in your results Neonatal inpatient
260 In the practices I have been affiliated with, money ahs the power (not unusual, I 
know).  The huge practices have physicians with reps begging for a nano-second 
audience.  I have typically found the NP/PA “Oh, you’re invited too” when there 
is an educational event.   
We will have an ? Increasing base in medicine.   
I am looking forward to the results of this survey.  Good or bad.  The companies 
will continue their practices although change is always important.   
Good luck in your endeavors! 
Family practice 
261 It’s a fine line Neonatology 
262 Pharm reps almost always never come to my office empty handed.  It may be a 
simple gift like pens or pads, or even candy or maybe an elegant dinner invite 
for my spouse and me. 
I have more male reps, where as the men docs see the female reps more often.  
All dressed to perfection and looking “vogue” 
Good luck 
Women’s health  
care 
263 Samples are great for the uninsured. 
I strongly oppose the undue influence of the pharm industry in research and 
Geriatric primary  
care 
        204                                                 
                                     
        
 
prescribing.  I feel it is highly unethical and biased and skews healthcare 
towards expensive medications. 
My patients however must have free samples until we wake up and provide 
universal health insurance. 
264 I find pharmaceutical reps very helpful and informative.  It helps keep me up my 
knowledge of new medications and changes to treatment guidelines. 
I don’t have a problem with gifts of less than $100.00. 
If the doctors can do it then it is appropriate for NPs too. 
Pulmonary 
266 I always make a conscious effort to prescribe what seems best for the client, no 
matter what the relationship with the drug reps. 
Psychiatry 
269 Samples are most useful in my prescribing practice when cost is an issue to my 
patient 
Family practice 
292 I could really care less about the JUNK that they (the pharmaceutical 
companies) give us.  Rarely do I find something useful.   
I like the dosing charts for antibiotics.  
I find it very helpful to talk to reps. They summarize information in the 
prescribing guide which I don’t always have time to read and inform me of new 
indications and new research for a drug.   
They should give away less junk and provide more educational seminars (I like 
nice dinners but that is not why I go), decrease advertising so they can offer a 
drug at a lower cost and have more patient assistance programs.   
Score tablets so we can them in half to save money!   
Always include NPs in their invitations.  If a company can convince me with the 
research that their drug is better or cheaper, I will use it.  The Junk never 
influences my decision.   
Cost and evidenced based research helps me decide what to prescribe.  Also, the 
co-payment on insurance is a big factor 
Family practice 
296 Samples provided for our clinic have truly been “life savers” for those oncology Ped heme/onc 
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patients with chronic pain (Vioxx samples) and nausea (Zofram) and no 
insurance coverage. 
So although drug reps may “push their product” we feel the samples for our 
children are worth a few minutes of hype! 
300 Since I am a neonatal NP, patient request for a drug and samples in the office 
are never factors 
Neonatal ICU 
310 Neonatal  ICU – samples and patient request are not an issue Neonatal ICU 
307 Drug reps do not visit NICUs very frequently.  We do tend to see formula reps 
more often (I consider these extremely similar) 
Neonatal ICU 
312 I think NPs  are smart enough to use reps stuff to better serve patient 
populations, staff, etc, etc. and not be influenced by their used car salesman 
tactics. 
In-house neonatal 
317 Educational programs at conferences and dinners – yes to influence at both.  The 
gifts have no bearing 
Drug samples for patients, educational programs at conferences – yes NP 
practices are influenced to some degree 
Don’t have much choice about seeing a rep again, they are in my face when I 
walk out of a patient’s room 
I work 2 times a week and see reps 16-21 times per month.  It would be > 21 if I 
worked full time 
The gifts such as pens, notepads, etc..Is not an influence.  However, the 
educational material and studies they provide with re to efficacy, etc…are 
important. 
Samples definitely help 
Adult primary care
320 Pharm reps do not routinely call on NPs in central Florida due to the fact 
prescribing practices are not tracked because we have no DEA#.  It is difficult to 
have a  rep meet with me/give me information about a drug – my collaborating 
MDs get the call because pharmacies track the MDs DEA on my prescriptions 
Geriatric long-term
care 
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I attend dinners for education and to hear cases of use, problem, success by other 
health care providers.  I like to think I have a “thoughtful practice”.  The 
information can only be helpful  -  how I use it is my choice.  I need to be 
convinced before ever prescribing for my geriatric patients. 
PS – this is a great topic – good luck! 
 
322 Pharmaceutical influences have been educational and unbiased in my opinion X 
2years to date 
Elizabeth – good luck with your survey.  I hope your results will show + 
education, - harm, + samples for needy patients – appropriate therapy, win/win, 
this ahs been my experience to date. 
Cardiology 
325 My clinical practice does not allow drug reps into the office so I have had 
limited interaction with same 
Geriatrics 
331 Good luck with your study Cardiology 
332 #1 – this question is loaded.  I do rx meds which are readily available as samples 
for some patients who would otherwise go without 
#3a – varies with reason for request 
#3b – again, loaded question 
#5 – again a loaded, poorly written question.  Changed prescribing after 
educational program – sometimes,  after receiving a gift – never 
#7 – don’t know, purely speculative, not valid 
Psych outpatient 
334 Great idea! 
I think the positive aspect of the drug companies is the free sample so patients 
without prescription coverage.  I find this to be very helpful 
Neurology 
336 Great idea! Adult specialty  
348 Thanks,  Good luck to you Neonatal ICU 
349 I appreciate the help of the pharmaceutical reps and drug companies, but would 
appreciate even more actions that would lower the cost of drugs to patients 
Woman’s health  
care 
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Good luck with your research 
351  I have been a paid speaker for 2 companies.  I would not  speak for a drug in 
which I do not strongly believe, or with which I did not have adequate 
experience.  I do believe drug reps play an important educational role, however, 
I do believe their that their information is obviously biased.  I take ample 
opportunity to read medical literature for non-biased review of drugs.  Even if 
the reps did not supply lunch, I would still take the time to briefly talk with them 
re: new indications, warning, etc.  regarding their drugs. 
 
In fact, I often speak with them briefly when they stop in the office.  I often 
throw their useless “junk” i.e clocks, etc. away.  They do not persuade me with 
trinkets 
Adult primary care
353 I believe samples and educational materials are extremely useful.  I strongly 
believe the money spent on dinners, trips shows, etc. should be put to better use.  
I find it somewhat unethical however I have been guilty on occasion attending 
dinners that were given to our entire practice. 
Women’ health  
care 
376 I look forward to reading the results of your study.   
I find in my practice that a patient’s insurance/ability to pay for meds is often 
the deciding factor in choosing a specific med among those within the same 
class.   
Samples have been very beneficial 
Also, I have stopped accepting pharm reps “perks” like game tickets, day trips, 
etc.  I see accepting them as a conflict of interest. 
Geriatrics 
394 Good luck! Women’s health 
398 Free samples for geriatric patients have been helpful in compliance with meds 
for those who are unable to afford the medications 
Geriatric  
outpatient 
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